(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 January 2018 (18.01.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/014001 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C12N 15/09* (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2017/042264

(22) International Filing Date:
14 July 2017 (14.07.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/362,397 14 July 2016 (14.07.2016) US
62/480,230 31 March 2017 (31.03.2017) US

(71) Applicant: **FRED HUTCHINSON CANCER RESEARCH CENTER** [US/US]; 1100 Fairview Avenue North, Seattle, Washington 98109 (US).

(72) Inventors: **MEHLIN, Christopher**; 1100 Fairview Avenue North, Seattle, Washington 98109 (US). **CORRENTI, Colin**; 1100 Fairview Avenue North, Seattle, Washington 98109 (US). **OLSON, James**; 1100 Fairview Avenue North, Seattle, Washington 98109 (US). **WALTER, Roland B.**; 1100 Fairview Avenue North, Seattle, Washington 98109 (US). **BANDARANAYAKE, Ashok**; 1100 Fairview Avenue North, Seattle, Washington 98109 (US). **LASZLO, George S.**; 1100 Fairview Avenue North, Seattle, Washington 98109 (US).

(74) Agent: **WINGER, C. Rachal** et al.; Lee & Hayes PLLC, 601 W. Riverside Ave., Suite 1400, Spokane, Washington 99201 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2018/014001 A1

(54) Title: MULTIPLE BI-SPECIFIC BINDING DOMAIN CONSTRUCTS WITH DIFFERENT EPITOPE BINDING TO TREAT CANCER

(57) Abstract: Groups of bi-specific binding domain constructs (BS-BDC) to treat cancer are described. Each BS-BDC in a group targets a cancer antigen epitope and an immune cell activating epitope that is different from the cancer antigen epitope and immune cell activating epitope targeted by another BS-BDC in the group. The different cancer antigen epitopes can be on the same cancer antigen.

MULTIPLE BI-SPECIFIC BINDING DOMAIN CONSTRUCTS WITH DIFFERENT EPITOPE BINDING TO TREAT CANCER

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to 62/362,397 filed on July 14, 2016 and 62/480,230 filed on March 31, 2017, each of which are incorporated herein by reference in their entirety as if fully set forth herein.

FIELD OF THE DISCLOSURE

[0002] The present disclosure provides multiple bi-specific binding domain constructs (BS-BDC) to treat cancer. Each BS-BDC within a group targets a cancer antigen epitope and an immune cell activating epitope that is different from the cancer antigen epitope and immune cell activating epitope targeted by another BS-BDC within the group. The different cancer antigen epitopes can be on the same cancer antigen.

BACKGROUND OF THE DISCLOSURE

[0003] Despite advances in cancer treatments, mortality associated with the disease remains too high. For example, despite improvements in outcome for many pediatric patients, cancer remains the leading cause of death past infancy among children in the United States. Thus, the need for effective new therapies for cancers, including childhood cancers is unquestioned.

[0004] Targeting cancer cells with antibodies raised high expectations as a potent means of eliminating tumor cells with limited non-specific toxicities. For many patients, however, use of single antibodies has not been effective.

[0005] Bispecific T-cell engaging antibodies bind both a cancer antigen on tumor cells and a T cell activating epitope, with the goal of bringing T cells to cancer cells to destroy the cancer cells. See, for example, US 2008/0145362. Current bispecific T-cell engaging antibody therapeutics include pairs of monospecific, antibody-derived binding domains. One member of the pair targets a cancer antigen epitope and the other member of the pair targets a T cell activating epitope. Some have explored use of such antibodies in combinations that target two different T cell activating epitopes (e.g., CD3 and CD28). Unfortunately, this approach similarly has not achieved the hoped for therapeutic efficacy. Thus, there remains a dire need in the art for more effective cancer therapies, especially for those with more refractory or difficult to treat cancer types.

[0006] Progress has been made in genetically engineering T cells of the immune system to target and kill unwanted cell types, such as cancer cells. For example, T cells have been genetically engineered to express molecules having extracellular components that bind particular target

antigens and intracellular components that direct actions of the T cell when the extracellular component has bound the target antigen. As an example, the extracellular component can be designed to bind target antigens found on cancer cells and, when bound, the intracellular component directs the T cell to destroy the bound cancer cell. Examples of such molecules include genetically engineered T cell receptors (TCR) and chimeric antigen receptors (CAR).

[0007] While TCR and/or CAR-modified T cells provide a major advantage in that they can create immune memory against cancer cells that can attack recurrent or progressive cancer cells as they emerge over time, this immune memory can lead to autoimmune toxicities when they recognize targets on normal tissue as abnormal or foreign.

SUMMARY OF THE DISCLOSURE

[0008] The present disclosure provides multiple bi-specific binding domain constructs (BS-BDC) to treat cancer. Each BS-BDC within a group binds a cancer antigen epitope and an immune cell activating epitope that is different from the cancer antigen epitope and immune cell activating epitope bound by another BS-BDC within the group. The different cancer antigen epitopes can be on the same cancer antigen, and in particular embodiments are non-overlapping different cancer antigen epitopes on the same cancer antigen. This advance provides several benefits. First, because BS-BDC within a group bind different cancer antigen epitopes, there is less competition for binding and reduced steric hindrance. Second, by binding different immune cell activating epitopes, immune cell co-stimulation signals are achieved. Because the binding domains recognizing the immune cell activating epitopes (e.g., a T-cell receptor and a co-stimulatory receptor), are located on different BS-BDC within a group, the group will induce T-cell activation only in the presence of cancer cells. This approach provides a versatile platform that can be utilized to target a large variety of cancers.

[0009] Use of the described groups of BS-BDC targeting at least two cancer antigen epitopes and at least two immune cell activating epitopes provided unexpected synergistic effects on T cell mediated killing of cancer cells. Moreover, use of the described groups of BS-BDC unexpectedly overcame cancer cell resistance to single bispecific T-cell engaging antibody constructs.

[0010] Additional benefits of the disclosed approach over many currently available therapies include that the disclosed BS-BDC can be provided as an “off-the-shelf” therapy that can be administered universally to patients with a particular cancer without the need for personalized genetic therapies, such as CAR-modified T-cell therapies that can lead to autoimmune toxicities. Further, individual patient responses to the therapy can be monitored and dosages correspondingly adjusted to avoid adverse treatment effects such as cytokine storms. The therapy

also activates T cells specifically at the site of a cancer, as opposed to infusing activated T cells into patients, relying on tumor homing of the infused pre-activated cells.

[0011] The disclosed BS-BDC can also be used in combinations that track the course of an individual patient's disease over time. For example, CD28 provides an immune cell activating epitope expressed on T cells. Following on-going T cell activation, however (as in the tumor microenvironment), T cells can down-regulate expression of CD28 over time resulting in reduced opportunities for T cell activation through this epitope. Accordingly, while a treatment may beneficially begin with a BS-BDC that binds CD28, over time this BS-BDC may be replaced with one that binds an epitope that reverses or blocks the activation an inhibitory T cell epitope (e.g., 4-1BB (CD 137), PD-1, TIM-3, LAG3, VISTA). Many such beneficial evolving combinations of BS-BDC groups are described herein.

[0012] For all of the foregoing reasons, the described groups of BS-BDC provide an important and significant advance in the on-going fight against cancer.

BRIEF DESCRIPTION OF THE FIGURES

[0013] FIGs. 1A and 1B. (1A) Depiction of Simultaneous Multiple Interaction T-cell Engaging BS-BDC engaged with a T-cell and a cancer cell. In this depicted embodiment, one BS-BDC in a group binds an epitope on ROR1 and CD3. A second BS-BDC in the group binds a different epitope on ROR1 and CD28 on the same T cell. (1B) An exemplary BS-BDC format.

[0014] FIG. 2. Cytotoxicity of cancer cell/T-cell BS-BDC upon T-cell co-stimulation.

[0015] FIGs. 3A and 3B. T-cell co-activation with CD28-directed BS-BDC is strictly dependent on presence of target antigen-positive cancer cells.

[0016] FIGs. 4A-4D. T-cell co-activation with CD28-directed BS-BDC augments ROR1/CD3 antibody-induced cytotoxicity.

[0017] FIG. 5. T-cell co-activation with CD28-directed BS-BDC targeting a second cancer cell antigen augments anti-cancer activity of a therapeutic bispecific T-cell engaging antibody.

[0018] FIGs. 6A-6C. PD-L1/CD28 antibody can overcome PD-L1-mediated resistance to bispecific antibodies.

[0019] FIG. 7. R11 and 2A2 bind different but overlapping ROR1 epitopes while R12 binds a different and non-overlapping ROR1 epitope, as measured using an NFkB reporter Jurkat line.

[0020] FIG. 8. Supporting sequences.

DETAILED DESCRIPTION

[0021] Despite advances in cancer treatments, mortality associated with the disease remains too high. For example, despite improvements in outcome for many pediatric patients, cancer remains

the leading cause of death past infancy among children in the United States. Thus, the need for effective new therapies for cancers, including childhood cancers is unquestioned.

[0022] Targeting cancer cells with antibodies raised high expectations as a potent means of eliminating tumor cells with limited non-specific toxicities. For many patients, however, use of single antibodies has not been effective.

[0023] Bispecific T-cell Engaging antibodies bind both a cancer antigen on tumor cells and a T cell activating epitope, with the goal of bringing T cells to cancer cells to destroy the cancer cells. See, for example, US 2008/0145362. Current bispecific T-cell engaging antibody therapeutics include pairs of monospecific, antibody-derived binding domains. One member of the pair targets a cancer antigen epitope and the other member of the pair targets a T cell activating epitope. Some have explored use of such antibodies in combinations that target two different T cell activating epitopes (e.g., CD3 and CD28). Unfortunately, this approach similarly has not achieved the hoped for therapeutic efficacy. Thus, there remains a dire need in the art for more effective cancer therapies, especially for those with more refractory or difficult to treat cancer types.

[0024] The present disclosure provides multiple bi-specific binding domain constructs (BS-BDC; e.g., bi-specific antibodies) to treat cancer. Each BS-BDC in a group binds a cancer antigen epitope and an immune cell activating epitope that is different from the cancer antigen epitope and immune cell activating epitope bound by another BS-BDC in the group. The different cancer antigen epitopes can be on the same cancer antigen, and in particular embodiments are non-repetitive different cancer antigen epitopes on the same cancer antigen. This advance provides several benefits. First, because each BS-BDC in a group binds a different cancer antigen epitope, there is less competition for binding and reduced steric hindrance. Second, by binding different immune cell activating epitopes, co-stimulation signaling is achieved. Because binding domains recognizing the T-cell receptor and the co-stimulatory receptor are located on different BS-BDC, the BS-BDC group will induce T-cell activation only in the presence of cancer cells. This approach provides a versatile platform that can be utilized to target a large variety of cancers.

[0025] Use of the described groups of BS-BDC targeting at least two cancer antigen epitopes and at least two immune cell activating epitopes provided unexpected synergistic effects on T cell mediated killing of cancer cells. Moreover, use of the described groups of BS-BDC unexpectedly overcame cancer cell resistance to single bispecific T-cell engaging antibody constructs.

[0026] Additional benefits of the disclosed approach over many currently available therapies include that the disclosed BS-BDC can be provided as an “off-the-shelf” therapy that can be administered universally to patients with a particular cancer without the need for personalized genetic therapies, such as CAR-modified T-cell therapies. Further, individual patient responses

to the therapy can be monitored and dosages correspondingly adjusted to avoid adverse treatment effects such as cytokine storms. The therapy also activates T cells specifically at the site of a cancer, as opposed to infusing activated T cells into patients, relying on tumor homing of the infused pre-activated cells.

[0001] The disclosed BS-BDC can also be used in combinations that track the course of an individual patient's disease over time. In particular embodiments, the administered BS-BDC can change over the course of a treatment regimen based on immune system status (e.g., stage of activation), stage of response to treatment, and/or change in cancer antigens expressed by cancer cells. The change between BS-BDC can occur at least 1 hour following administration of a first BS-BDC or up to several days, weeks, or months following administration of a first BS-BDC. In particular embodiments, changes in administered in BS-BDC are based on on-going subject monitoring, by for example, feedback from subject samples (e.g., blood tests). In particular embodiments, changes in administered in BS-BDC can be pre-programmed based on predictable changes in immune status and/or cancer cycle or expected responses to treatment. In particular embodiments, changes in administered in BS-BDC can be pre-programmed and automatically made based on, for example, use of a programmable pump. Changes in administered BS-BDC can occur acutely or can shift gradually.

[0027] In particular embodiments, a patient can be monitored for changes in immune activation, and the BS-BDCs administered can be changed to BS-BDCs that target a different immune activating epitope. As one example, CD28 provides an immune cell activating epitope expressed on T cells. Following on-going T cell activation, however (as in the tumor microenvironment), T cells can down-regulate expression of CD28 over time resulting in reduced opportunities for T cell activation through this epitope. Accordingly, while a treatment may beneficially begin with a BS-BDC that binds CD28, over time this BS-BDC may be replaced with one that binds an epitope that reverses or blocks the activation an inhibitory T cell epitope (e.g., 4-1BB (CD 137), PD-1, TIM-3, LAG3, VISTA). Many such beneficial evolving combinations of BS-BDC groups are described herein.

[0028] In particular embodiments, a patient can be monitored for changes in cancer antigen expression, and the BS-BDCs administered can be switched to BS-BDCs that target a different cancer antigen. Cancer antigen expression often changes during the course of cancer. As one example, Her-2, the molecular target of the cancer drug trastuzumab, can become down-regulated during treatment, leading to treatment resistance (Shi et al. Breast Cancer Research 2014 16: R33). In particular embodiment, a patient being treated with BS-BDCs that target Her-2 can be monitored for Her-2 downregulation, and if their cancer loses or reduces Her-2 expression,

they can be treated with BS-BDCs that target a different cancer antigen. EGFR is another example of a cancer antigen that becomes down-regulated during the course of treatment.

[0029] During the course of treatment, administered BS-BDC groups can evolve to change targeted cancer antigens, targeted immune activating epitopes, or both. Changes can reflect addition of a targeted cancer antigen and/or immune cell activating epitope; removal of a targeted cancer antigen and/or immune cell activating epitope; and/or replacement of a targeted cancer antigen and/or immune cell activating epitope.

[0030] For all of the foregoing reasons, the described groups of BS-BDC provide an important and significant advance in the on-going fight against cancer.

[0031] As indicated, "different from" means that the targeted epitopes are distinct from one another in sequence and/or structure. In particular embodiments, in addition to being different, targeted epitopes are also non-overlapping. "Non-overlapping" means that the binding of one BS-BDC in a group to an epitope is not decreased to a statistically-significant degree in a competitive binding assay by the presence of at least one other BS-BDC in the group. Non-overlapping epitopes may be epitopes on different molecules (e.g., ROR1 and CD33; CD3 and CD28) or may be non-overlapping epitopes located on the same molecule (e.g., non-overlapping ROR1 epitopes; non-overlapping CD3 epitopes). Non-repetitive different epitopes on the same antigen exclude epitopes that are physically distinct in space from one another yet repetitive in sequence to each other. For example, MUC1 has a repetitive sequence, and the repeats within the sequence are not non-repetitive and different, as defined herein.

[0032] "Co-stimulation" of T cells means that a more robust T cell response is observed in the presence of members of a BS-BDC group than in the presence of one member of the BS-BDC group alone.

[0033] In particular embodiments, the BS-BDC groups disclosed herein can be referred to as SMITE groups. SMITE stands for "Simultaneous Multiple Interaction T-Cell Engaging" binding domain constructs (e.g., antibodies, scFv). This terminology reflects the fact that the disclosed BS-BDC group will engage two different immune cell activating epitopes when bound to two different cancer antigen epitopes. Engagement of the immune cell activating epitopes will overlap in time, causing robust T cell activation at the site of cancer cells.

[0034] Groups of BS-BDC can include two, three, or four BS-BDC. If a group includes two BS-BDC (a pair), each member of the pair will bind a different cancer antigen epitope and a different immune cell activating epitope. If a group includes three BS-BDC, each member of the group can bind a different cancer antigen epitope and a different immune cell activating epitope (targeting three cancer antigen epitopes and three immune cell activating epitopes), or two members of a

three member group may target the same cancer antigen epitope and two members of the three member group may target the same immune cell activating epitope. The same principle applies to four member groups. That is, if a group includes four BS-BDC, each member of the group can bind a different cancer antigen epitope and a different immune cell activating epitope (targeting four cancer antigen epitopes and four immune cell activating epitopes). Alternatively, a subset of members of the group can target a common cancer antigen epitope and/or immune cell activating epitope. No matter the number of members, each grouping will target at least two different cancer antigen epitopes and, in particular embodiments, at least two different immune cell activating epitopes. In particular embodiments, each grouping will target at least two different cancer antigen epitopes and a common immune cell activating epitope (e.g., CD3 or CD28).

[0035] The disclosed groups of BS-BDC provide a versatile platform that can be utilized to target a large variety of cancers, such as adrenal cancers, bladder cancers, blood cancers, bone cancers, brain cancers, breast cancers, carcinoma, cervical cancers, colon cancers, colorectal cancers, corpus uterine cancers, ear, nose and throat (ENT) cancers, endometrial cancers, esophageal cancers, gastrointestinal cancers, head and neck cancers, Hodgkin's disease, intestinal cancers, kidney cancers, larynx cancers, leukemias, liver cancers, lymph node cancers, lymphomas, lung cancers, melanomas, mesothelioma, myelomas, nasopharynx cancers, neuroblastomas, non-Hodgkin's lymphoma, oral cancers, ovarian cancers, pancreatic cancers, penile cancers, pharynx cancers, prostate cancers, rectal cancers, sarcoma, seminomas, skin cancers, stomach cancers, teratomas, testicular cancers, thyroid cancers, uterine cancers, vaginal cancers, vascular tumors, and metastases thereof.

[0036] Aspects of the disclosure are now described in more detail.

[0037] BS-BDC Formats. BS-BDC formats include a protein with a first binding domain that binds a cancer antigen epitope and a second binding domain that binds an immune cell activating epitope. Exemplary bispecific antibody formats are described in, e.g., WO2009/080251, WO2009/080252, WO2009/080253, WO2009/080254, WO2010/112193, WO2010/115589, WO2010/136172, WO2010/145792, and WO2010/145793.

[0038] Different binding domains can be derived from multiple sources such as antibodies, fibronectin, affibodies, natural ligands (e.g., CD80 and CD86 for CD28), etc. In particular embodiments, binding domains can be derived from whole antibodies or binding fragments of an antibody, e.g., Fv, Fab, Fab', $F(ab')_2$, Fc, and single chain Fv fragments (scFvs) or any biologically effective fragments of an immunoglobulin that bind specifically to a cancer antigen epitope or immune cell activating epitope (e.g., T cell receptor). Antibodies or antigen binding fragments include all or a portion of polyclonal antibodies, monoclonal antibodies, human antibodies,

humanized antibodies, synthetic antibodies, chimeric antibodies, bispecific antibodies, mini bodies, and linear antibodies.

[0039] BS-BDC including binding domains from human origin or humanized antibodies have lowered immunogenicity in humans and have a lower number of non-immunogenic epitopes compared to non-human antibodies. Binding domains will generally be selected to have reduced antigenicity in human subjects. Binding domains can particularly include any peptide that specifically binds a selected cancer antigen epitope or immune cell activating epitope. Sources of binding domains include antibody variable regions from various species (which can be in the form of antibodies, sFvs, scFvs, Fabs, scFv-based grababody, or soluble VH domain or domain antibodies). These antibodies can form antigen-binding regions using only a heavy chain variable region, *i.e.*, these functional antibodies are homodimers of heavy chains only (referred to as "heavy chain antibodies") (Jespers *et al.*, *Nat. Biotechnol. 22*:1161, 2004; Cortez-Retamozo *et al.*, *Cancer Res. 64*:2853, 2004; Baral *et al.*, *Nature Med. 12*:580, 2006; and Barthelemy *et al.*, *J. Biol. Chem. 283*:3639, 2008).

[0040] Phage display libraries of partially or fully synthetic antibodies are available and can be screened for an antibody or fragment thereof that can bind a selected epitope. For example, binding domains may be identified by screening a Fab phage library for Fab fragments that specifically bind to a target of interest (*see* Hoet *et al.*, *Nat. Biotechnol. 23*:344, 2005). Phage display libraries of human antibodies are also available. Additionally, traditional strategies for hybridoma development using a target of interest as an immunogen in convenient systems (*e.g.*, mice, HuMAb mouse®, TC mouse™, KM-mouse®, llamas, chicken, rats, hamsters, rabbits, *etc.*) can be used to develop binding domains. In particular embodiments, binding domains specifically bind to selected epitopes expressed by targeted cancer cells and/or T cells and do not cross react with nonspecific components or unrelated targets. Once identified, the amino acid sequence or polynucleotide sequence coding for the CDR within a binding domain can be isolated and/or determined.

[0041] An alternative source of binding domains includes sequences that encode random peptide libraries or sequences that encode an engineered diversity of amino acids in loop regions of alternative non-antibody scaffolds, such as scTCR (*see, e.g.*, Lake *et al.*, *Int. Immunol.*11:745, 1999; Maynard *et al.*, *J. Immunol. Methods 306*:51, 2005; U.S. Patent No. 8,361,794), mAb^2 or Fcab™ (*see*, *e.g.*, PCT Patent Application Publication Nos. WO 2007/098934; WO 2006/072620), affibodies, avimers, fynomers, cytotoxic T-lymphocyte associated protein-4 (Weidle *et al.*, *Cancer Gen. Proteo. 10*:155, 2013), and the like (Nord *et al.*, *Protein Eng. 8*:601, 1995; Nord *et al.*, *Nat. Biotechnol. 15*:772, 1997; Nord *et al.*, *Euro. J. Biochem. 268*:4269, 2001; Binz *et al.*, *Nat.*

Biotechnol. 23:1257, 2005; Boersma and Plückthun, *Curr. Opin. Biotechnol. 22*:849, 2011).

[0042] In particular embodiments, an antibody fragment is used as one or more binding domains in a BS-BDC. An "antibody fragment" denotes a portion of a complete or full length antibody that retains the ability to bind to an epitope. Examples of antibody fragments include Fv, scFv, Fab, Fab', Fab'-SH, $F(ab')_2$; diabodies; and linear antibodies.

[0043] A single chain variable fragment (scFv) is a fusion protein of the variable regions of the heavy and light chains of immunoglobulins connected with a short linker peptide. Fv fragments include the VL and VH domains of a single arm of an antibody. Although the two domains of the Fv fragment, VL and VH, are coded by separate genes, they can be joined, using, for example, recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (single chain Fv (scFv)). For additional information regarding Fv and scFv, see e.g., Bird, et al., Science 242 (1988) 423-426; Huston, et al., Proc. Natl. Acad. Sci. USA 85 (1988) 5879-5883; Plueckthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore (eds.), Springer-Verlag, New York), (1994) 269-315; WO1993/16185; US Patent 5,571,894; and US Patent 5,587,458.

[0044] A Fab fragment is a monovalent antibody fragment including VL, VH, CL and CH1 domains. A $F(ab')_2$ fragment is a bivalent fragment including two Fab fragments linked by a disulfide bridge at the hinge region. For discussion of Fab and $F(ab')_2$ fragments having increased *in vivo* half-life, see U.S. Patent 5,869,046. Diabodies include two epitope-binding sites that may be bivalent. See, for example, EP 0404097; WO1993/01161; and Holliger, et al., Proc. Natl. Acad. Sci. USA 90 (1993) 6444-6448. Dual affinity retargeting antibodies (DART™; based on the diabody format but featuring a C-terminal disulfide bridge for additional stabilization (Moore et al., Blood 117, 4542-51 (2011))) can also be used. Antibody fragments can also include isolated CDRs. For a review of antibody fragments, see Hudson, et al., Nat. Med. 9 (2003) 129-134.

[0045] Antibody fragments can be made by various techniques, including proteolytic digestion of an intact antibody as well as production by recombinant host-cells (e.g. human suspension cell lines, E. coli or phage), as described herein. Antibody fragments can be screened for their binding properties in the same manner as intact antibodies.

[0046] In particular embodiments, BS-BDC can also include a natural receptor or ligand for an epitope as a binding domain. For example, if a target for binding includes PD-L1, the binding domains can include PD-1 (including, e.g., a PD-1/antiCD3 fusion). One example of a receptor fusion for binding is Enbrel® (Amgen). Natural receptors or ligands can also be modified to enhance binding. For example, betalacept is a modified version of abatacept. In particular embodiments, the BS-BDC can include a natural receptor or ligand that induces phagocytosis.

Calreticulin (UniProt ID No. P27797) is a protein that is localized to the endoplasmic reticulum of healthy cells, but in dying cells it translocates to the cell surface and induces phagocytosis by immune cells such as macrophages. In particular embodiments, the binding domains can include calreticulin or a portion of calreticulin that is capable of inducing phagocytosis.

[0047] Binding can also be enhanced through increasing avidity which arises from multimerizaiton of the binding domain. Any screening method known in the art can be used to identify increased avidity to an antigen epitope.

[0048] In particular embodiments, the BS-BDC format can be based on blinatumomab with binding domains selected for particularly targeted cancer antigens and immune cell activating epitopes. In particular embodiments, the BS-BDC format can be based on AMG330 with binding domains selected for particularly targeted cancer antigens and immune cell activating epitopes.

[0049] In particular embodiments, the BS-BDC formats can include a single chain antibody attached to the C-terminus of a light chain (see, e.g., Oncoimmunology. 2017; 6(3): e1267891). This format can be useful because the presence of the Fc region can help preserve the protein half-life. The presence of the Fc region can also be useful because Fc interacts with several receptors and can contribute to the immune response. Antibody-scFv fusions can also be useful because the antibody portion binds to its epitope in a dimeric fashion, which enhances avidity and the scFv portion binds its epitope in a monomeric fashion, which can be useful, for example, for binding T-cell epitopes and only allowing multimerization in the presence of a target (e.g., cancer cell). These embodiments can be “tri-specific”.

[0050] For a review of additional BS-BDC formats that can be used, see Brinkmann & Kontermann, mAbs, 2017. 9:2, 182-212, DOI: 10.1080/19420862.2016.1268307.

[0051] An “epitope” includes any determinant capable of being bound by an antigen-binding protein, such as an antibody or a T-cell receptor. An epitope is a region of an antigen that is bound by an antigen binding protein that targets that antigen, and when that antigen is a protein, includes specific residues that directly contact the antigen binding protein. In particular embodiments, an “epitope” denotes the binding site on a protein target bound by a corresponding binding domain. The binding domain either binds to a linear epitope, (e.g., an epitope including a stretch of 5 to 12 consecutive amino acids), or the binding domain binds to a three-dimensional structure formed by the spatial arrangement of several short stretches of the protein target. Three-dimensional epitopes recognized by a binding domain, e.g. by the epitope recognition site or paratope of an antibody or antibody fragment, can be thought of as three-dimensional surface features of an epitope molecule. These features fit precisely (in)to the corresponding binding site of the binding domain and thereby binding between the binding domain and its target protein is facilitated. In

particular embodiments, an epitope can be considered to have two levels: (i) the “covered patch” which can be thought of as the shadow an antibody or binding domain would cast; and (ii) the individual participating side chains and backbone residues. Binding is then due to the aggregate of ionic interactions, hydrogen bonds, and hydrophobic interactions.

[0052] "Bind" means that the binding domain associates with its target epitope with a dissociation constant (1(D) of 10^{-8} M or less, in particular embodiments of from 10^{-5} M to 10^{-13} M, in particular embodiments of from 10^{-5} M to 10^{-10} M, in particular embodiments of from 10^{-5} M to 10^{-7} M, in particular embodiments of from 10^{-8} M to 10^{-13} M, or in particular embodiments of from 10^{-9} M to 10^{-13} M. The term can be further used to indicate that the binding domain does not bind to other biomolecules present, (e.g., it binds to other biomolecules with a dissociation constant (KD) of 10^{-4} M or more, in particular embodiments of from 10^{-4} M to 1 M). A targeted epitope is one that will be bound by its corresponding BS-BDC binding domain under relevant *in vitro* conditions and in *in vivo* conditions as described herein. In particular embodiments, relevant *in vitro* conditions for binding can include a buffered salt solution approximating physiological pH (7.4) at room temperature or 37°C.

[0053] Targeted Cancer Antigen Epitopes. Cancer cell antigens are expressed by cancer cells. One of the significant features of the current disclosure is that the cancer antigen need not be preferentially expressed by cancer cells. This is because meaningful SMITE-induced immune cell activation occurs only in the presence of cancer cells. As one example, PD-L1 is expressed by cancer cells and non-cancer cells.

[0054] In particular embodiments, cancer cell antigens are preferentially expressed by cancer cells. “Preferentially expressed” means that a cancer cell antigen is found at higher levels on cancer cells as compared to other cell types. In some instances, a cancer antigen is only expressed by the targeted cancer cell type. In other instances, the cancer antigen is expressed on the targeted cancer cell type at least 25%, 35%, 45%, 55%, 65%, 75%, 85%, 95%, 96%, 97%, 98%, 99%, or 100% more than on non-targeted cells.

[0055] The following table provides examples of particular cancers and cancer antigens that can be targeted with BS-BDC.

Targeted Cancer	Cancer Antigens
Leukemia/Lymphoma	CD19, CD20, CD22, ROR1, CD33, WT-1, CD123
Multiple Myeloma	B-cell maturation antigen (BCMA)
Prostate Cancer	PSMA, WT1, Prostate Stem Cell antigen (PSCA), SV40 T
Breast Cancer	HER2, ERBB2, ROR1
Stem Cell Cancer	CD133
Ovarian Cancer	L1-CAM, extracellular domain of MUC16 (MUC-CD), folate binding protein (folate receptor), Lewis Y, ROR1, mesothelin, WT-1

Mesothelioma	mesothelin
Renal Cell Carcinoma	carboxy-anhydrase-IX (CAIX);
Melanoma	GD2
Pancreatic Cancer	mesothelin, CEA, CD24, ROR1
Lung Cancer	ROR1

[0056] In more particular examples, cancer cell antigens include:

Cancer Antigen	Sequence
PSMA	KSSNEATNITPKHNMKAFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQ SQWKEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFNTSLFEPPPPGY ENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVIAR YGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVKSYPDGWNLPGGGVQ RGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYYDAQKLLE KMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNV IGTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGW RPRRTILFASWDAEEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTL RVDCTPLMYSLVHNLTKELKSPDEGFEGKSLYESWTKKSPSPEFSGMPRISK LGSGNDFEVFFQRLGIASGRARYTKNWETNKFSGYPLYHSVYETYELVEKFY DPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDYAVVLRKYADKIYSISMKH PQEMKTYSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIVLRMMNDQLMF LERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVDPSKA WGEVKRQIYVAAFTVQAAAETLSEVA (SEQ ID NO: 1)
PSCA	MKAVLLALLMAGLALQPGTALLCYSCKAQVSNEDCLQVENCTQLGEQCWTA RIRAVGLLTVISKGCSLNCVDDSQDYYVGKKNITCCDTDLCNASGAHALQPA AAILALLPALGLLLWGPGQL (SEQ ID NO: 2)
Mesothelin	MALPTARPLLGSCGTPALGSLLFLLFSLGWVQPSRTLAGETGQEAAPLDGVL ANPPNISSLSPRQLLGFPCAEVSGLSTERVRELAVALAQKNVKLSTEQLRCLA HRLSEPPEDLDALPLDLLLFLNPDAFSGPQACTHFFSRITKANVDLLPRGAPE RQRLLPAALACWGVRGSLLSEADVRALGGLACDLPGRFVAESAEVLLPRLVS CPGPLDQDQQEAARAALQGGGPPYGPPSTWSVSTMDALRGLLPVLGQPIIR SIPQGIVAAWRQRSSRDPSWRQPERTILRPRFRREVEKTACPSGKKAREIDE SLIFYKKWELEACVDAALLATQMDRVNAIPFTYEQLDVLKHKLDELYPQGYPE SVIQHLGYLFLKMSPEDIRKWNVTSLETLKALLEVNKGHEMSPQVATLIDRFV KGRGQLDKDTLDTLTAFYPGYLCSLSPEELSSVPPSSIWAVRPQDLDTCDPR QLDVLYPKARLAFQNMNGSEYFVKIQSFLGGAPTEDLKALSQQNVSMDLATF MKLRTDAVLPLTVAEVQKLLGPHVEGLKAEERHRPVRDWILRQRQDDLDTL GLGLQGGIPNGYLVLDLSVQEALSGTPCLLGPGPVLTVLALLLASTLA (SEQ ID NO: 3)
CD19	MPPPRLLFFLLFLTPMEVRPEEPLVVKVEEGDNAVLQCLKGTSDGPTQQLTW SRESPLKPFLKLSLGLPGLGIHMRPLASWLFIFNVSQQMGGFYLCQPGPPSE KAWQPGWTVNVEGSGELFRWNVSDLGGLGCGLKNRSSEGPSSPSGKLMS PKLYVWAKDRPEIWEGEPPCVPPRDSLNQSLSQDLTMAPGSTLWLSCGVPP DSVSRGPLSWTHVHPKGPKSLLSLELKDDRPARDMWVMETGLLLPRATAQD AGKYYCHRGNLTMSFHLEITARPVLWHWLLRTGGWKVSAVTLAYLIFCLCSL VGILHLQRALVLRRKRKRMTDPTRRFFKVTPPPGSGPQNQYGNVLSLPTPTS GLGRAQRWAAGLGGTAPSYGNPSSDVQADGALGSRSPPGVGPEEEEGEG YEEPDSEEDSEFYENDSNLGQDQLSQDGSGYENPEDEPLGPEDEDSFSNA ESYENEDEELTQPVARTMDFLSPHGSAWDPSREATSLGSQSYEDMRGILYA

	APQLRSIRGQPGPNHEEDADSYENMDNPDGPDPAWGGGGRMGTWSTR (SEQ ID NO: 4)
CD20	MTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRRMSSLVGPTQSFFMRESKT LGAVQIMNGLFHIALGGLLMIPAGIYAPICVTVWYPLWGGIMYIISGSLLAATEK NSRKCLVKGKMIMNSLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPYI NIYNCEPANPSEKNSPSTQYCYSIQSLFLGILSVMLIFAFFQELVIAGIVENEWK RTCSRPKSNIVLLSAEEKKEQTIEIKEEVVGLTETSSQPKNEEDIEIIPIQEEEEE ETETNFPEPPQDQESSPIENDSSP (SEQ ID NO: 5)
CD33 (full length)	MPLLLLLPLLWAGALAMDPNFWLQVQESVTVQEGLCVLVPCTFFHPIPYYDK NSPVHGYWFREGAIISRDSPVATNKLDQEVQEETQGRFRLLGDPSRNNCSL SIVDARRRDNGSYFFRMERGSTKYSYKSPQLSVHVTDLTHRPKILIPGTLEPG HSKNLTCSVSWACEQGTPPIFSWLSAAPTSLGPRTTHSSVLIITPRPQDHGT NLTCQVKFAGAGVTTERTIQLNVTYVPQNPTTGIFPGDGSGKQETRAGVVHG AIGGAGVTALLALCLCLIFFIVKTHRRKAARTAVGRNDTHPTTGSASPKHQKK SKLHGPTETSSCSGAAPTVEMDEELHYASLNFHGMNPSKDTSTEYSEVRTQ (SEQ ID NO: 6)
CD33 (DeltaE2 variant)	MPLLLLLPLLWADLTHRPKILIPGTLEPGHSKNLTCSVSWACEQGTPPIFSWL SAAPTSLGPRTTHSSVLIITPRPQDHGTNLTCQVKFAGAGVTTERTIQLNVTY VPQNPTTGIFPGDGSGKQETRAGVVHGAIGGAGVTALLALCLCLIFFIVKTHR RKAARTAVGRNDTHPTTGSASPKHQKKSKLHGPTETSSCSGAAPTVEMDEE LHYASLNFHGMNPSKDTSTEYSEVRTQ (SEQ ID NO: 7)
CD33 (with C-terminal truncation)	MPLLLLLPLLWAGALAMDPNFWLQVQESVTVQEGLCVLVPCTFFHPIPYYDK NSPVHGYWFREGAIISRDSPVATNKLDQEVQEETQGRFRLLGDPSRNNCSL SIVDARRRDNGSYFFRMERGSTKYSYKSPQLSVHVTDLTHRPKILIPGTLEPG HSKNLTCSVSWACEQGTPPIFSWLSAAPTSLGPRTTHSSVLIITPRPQDHGT NLTCQVKFAGAGVTTERTIQLNVTYVPQNPTTGIFPGDGSGKQETRAGVVHG AIGGAGVTALLALCLCLIFFIVKTHRRKAARTAVGRNDTHPTTGSASPVR (SEQ ID NO: 8)
ROR1	MHRPRRRGTRPPLLALLAALLLAARGAAAQETELSVSAELVPTSSWNISSEL NKDSYLTLDEPMNNITTSLGQTAELHCKVSGNPPPTIRWFKNDAPVVQEPRR LSFRSTIYGSRLRIRNLDTTDTGYFQCVATNGKEVVSSTGVLFVKFGPPPTAS PGYSDEYEEDGFCQPYRGIACARFIGNRTVYMESLHMQGEIENQITAAFTMI GTSSHLSDKCSQFAIPSLCHYAFPYCDETSSVPKPRDLCRDECEILENVLCQT EYIFARSNPMILMRLKLPNCEDLPQPESPEAANCIRIGIPMADPINKNHKCYNS TGVDYRGTVSVTKSGRQCQPWNSQYPHTHTFTALRFPELNGGHSYCRNPG NQKEAPWCFTLDENFKSDLCDIPACDSKDSKEKNKMEILYILVPSVAIPLAIAL LFFFICVCRNNQKSSSAPVQRQPKHVRGQNVEMSMLNAYKPKSKAKELPLS AVRFMEELGECAFGKIYKGHLYLPGMDHAQLVAIKTLKDYNNPQQWTEFQQ EASLMAELHHPNIVCLLGAVTQEQPVCMLFEYINQGDLHEFLIMRSPHSDVG CSSDEDGTVKSSLDHGDFLHIAIQIAAGMEYLSSHFFVHKDLAARNILIGEQLH VKISDLGLSREIYSADYYRVQSKSLLPIRWMPPEAIMYGKFSSDSDIWSFGVV LWEIFSFGLQPYYGFSNQEVIEMVRKRQLLPCSEDCPPRMYSLMTECWNEIP SRRPRFKDIHVRLRSWEGLSSHTSSTTPSGGNATTQTTSLSASPVSNLSNPR YPNYMFPSQGITPQGQIAGFIGPPIPQNQRFIPINGYPIPPGYAAFPAAHYQPT GPPRVIQHCPPPKSRSPSSASGSTSTGHVTSLPSSGSNQEANIPLLPHMSIP NHPGGMGITVFGNKSQKPYKIDSKQASLLGDANIHGHTESMISAEL (SEQ ID NO: 9)
WT1	IEGRHMRRVPGVAPTLVRSASETSEKRPFMCAYPGCNKRYFKLSHLQMHSR KHTGEKPYQCDFKDCERRFFRSDQLKRHQRRHTGVKPFQCKTCQRKFSRS DHLKTHTRTHTGEKPFSCRWPSCQKKFARSDELVRHHNMHQRNMTKLQLA

	L (SEQ ID NO: 10)
CD123	MVLLWLTLLLIALPCLLQTKEDPNPPITNLRMKAKAQQLTWDLNRNVTDIECV KDADYSMPAVNNSYCQFGAISLCEVTNYTVRVANPPFSTWILFPENSGKPW AGAENLTCWIHDVDFLSCSWAVGPGAPADVQYDLYLNVANRRQQYECLHY KTDAQGTRIGCRFDDISRLSSGSQSSHILVRGRSAAFGIPCTDKFVVFSQIEIL TPPNMTAKCNKTHSFMHWKMRSHFNRKFRYELQIQKRMQPVITEQVRDRTS FQLLNPGTYTVQIRARERVYEFLSAWSTPQRFECDQEEGANTRAWRTSLLIA LGTLLALVCVFVICRRYLVMQRLFPRIPHMKDPIGDSFQNDKLVVWEAGKAG LEECLVTEVQVVQKT (SEQ ID NO: 11)

[0057] As will be understood by one of ordinary skill in the art, targeted antigens can lack signal peptides, such as the underlined segments of representative CD33 antigens, SEQ ID NOs: 6-8. Further, and as will be understood, “same cancer antigen” allows, does not require that both targeted epitopes be on the same cancer antigen molecule. That is, and for example, when two different epitopes of ROR1 are targeted, one BS-BDC in a group could bind to the first epitope on a first ROR1 molecule and the second BS-BDC in the group could bind the second epitope on a different ROR1 molecule. Similarly, the first and second epitope could be bound by the first and second BS-BDC on the same ROR1 molecule.

[0058] In particular embodiments, the cancer antigen epitope binding domains present within a BS-BDC group each target a different RORI epitope (e.g., ROR1-A and ROR1-B).

[0059] In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable light chain including a CDRL1 sequence including ASGFDFSAYYM (SEQ ID NO: 12), a CDRL2 sequence including TIYPSSG (SEQ ID NO: 13), and a CDRL3 sequence including ADRATYFCA (SEQ ID NO: 14). In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable heavy chain including a CDRH1 sequence including DTIDWY (SEQ ID NO: 15), a CDRH2 sequence including VQSDGSYTKRPGVPDR (SEQ ID NO: 16), and a CDRH3 sequence including YIGGYVFG (SEQ ID NO: 17).

[0060] In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable light chain including a CDRL1 sequence including QASQSIDSNLA (SEQ ID NO: 18), a CDRL2 sequence including RASNLAS (SEQ ID NO: 19), and a CDRL3 sequence including LGGVGNVSYRTS (SEQ ID NO: 20). In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable heavy chain including a CDRH1 sequence including DYPIS (SEQ ID NO: 21), a CDRH2 sequence including FINSGGSTWYASWVKG (SEQ ID NO: 22), and a CDRH3 sequence including GYSTYYCDFNI (SEQ ID NO: 23). These reflect CDR sequences of the R11

antibody.

[0061] In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable light chain including a CDRL1 sequence including TLSSAHKTDTID (SEQ ID NO: 24), a CDRL2 sequence including GSYTKRP (SEQ ID NO: 25), and a CDRL3 sequence including GADYIGGYV (SEQ ID NO: 26). In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable heavy chain including a CDRH1 sequence including AYYMS (SEQ ID NO: 27), a CDRH2 sequence including TIYPSSGKTYYATWVNG (SEQ ID NO: 28), and a CDRH3 sequence including DSYADDGALFNI (SEQ ID NO: 29). These reflect CDR sequences of the R12 antibody.

[0062] In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable light chain including a CDRL1 sequence including KASQNVDAAVA (SEQ ID NO: 30), a CDRL2 sequence including SASNRYT (SEQ ID NO: 31), and a CDRL3 sequence including QQYDIYPYT (SEQ ID NO: 32). In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable heavy chain including a CDRH1 sequence including DYEMH (SEQ ID NO: 33), a CDRH2 sequence including AIDPETGGTAYNQKFKG (SEQ ID NO: 34), and a CDRH3 sequence including YYDYDSFTY (SEQ ID NO: 35). These reflect CDR sequences of the 2A2 antibody.

[0063] In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable light chain including a CDRL1 sequence including QASQSIGSYLA (SEQ ID NO: 36), a CDRL2 sequence including YASNLAS (SEQ ID NO: 37), and a CDRL3 sequence including LGSLSNSDNV (SEQ ID NO: 38). In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable heavy chain including a CDRH1 sequence including SHWMS (SEQ ID NO: 39), a CDRH2 sequence including IIAASGSTYYANWAKG (SEQ ID NO: 40), and a CDRH3 sequence including DYGDYRLVTFNI (SEQ ID NO: 41). These reflect CDR sequences of the Y31 antibody.

[0064] A number of additional antibodies specific for RORI are known to those of skill in the art and can be readily characterized for sequence, epitope binding, and affinity. See, for example, WO2008076868, WO/2008103849, WO201008069, WO2010124188, WO2011079902, WO2011054007, WO2011159847, WO2012076066, WO2012076727, WO 2012045085, and WO2012097313.

[0065] In particular embodiments, the cancer antigen epitope binding domains present within a BS-BDC group each target a different CD19 epitope. In particular embodiments, cancer antigen epitope binding domain of at least one BS-BDC in a group includes a binding domain (e.g., scFv) that include VH and VL regions specific for CD19. In particular embodiments, the V_H and V_L regions are human. Exemplary V_H and V_L regions include the segments of anti-CD19 specific monoclonal antibody FMC63. In particular embodiments, the binding domain (e.g., scFV) is human or humanized and including a variable light chain including a CDRL1 sequence including RASQDISKYLN (SEQ ID NO: 42), a CDRL2 sequence including SRLHSGV (SEQ ID NO: 43), and a CDRL3 sequence including GNTLPYTFG (SEQ ID NO: 44). In particular embodiments, the binding domain (e.g., scFV) is human or humanized and includes a variable heavy chain including a CDRH1 sequence including DYGVS (SEQ ID NO: 45), a CDRH2 sequence including VTWGSETTYYNSALKS (SEQ ID NO: 46), and a CDRH3 sequence including YAMDYWG (SEQ ID NO: 47). Other CD19-targeting antibodies such as SJ25C1 and HD37 are known. (SJ25C1: Bejcek et al. Cancer Res 2005, PMID 7538901; HD37: Pezutto et al. JI 1987, PMID 2437199).

[0066] In particular embodiments, the cancer antigen epitope binding domains present within a BS-BDC group each target a different PSMA epitope. A number of antibodies specific for PSMA are known to those of skill in the art and can be readily characterized for sequence, epitope binding, and affinity. Binding domains can also include anti-Mesothelin ligands (associated with treating ovarian cancer, pancreatic cancer, and mesothelioma). As will be understood by one of ordinary skill in the art, the different cancer antigen epitope binding domains can bind any number of different epitopes on the cancer antigens disclosed herein (among others). As previously indicated, in particular embodiments, the different epitopes are on the same cancer antigen. In particular embodiments, the different epitopes are on different cancer antigens.

[0067] In particular embodiments, the cancer antigen epitope binding domains present within a BS-BDC group each target a different CD20 epitope. Rituxan (Rituximab, Genentech) targets CD20 for CD20-positive non-Hodgkin's lymphoma and Arzerra (Ofatumumab, Novartis), targets a different epitope of CD20.

[0068] In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFV) including a variable light chain including a CDRL1 sequence including RASSSVSYIH (SEQ ID NO: 48), a CDRL2 sequence including ATSNLAS (SEQ ID NO: 49), and a CDRL3 sequence including QQWTSNPPT (SEQ ID NO: 50). In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable heavy chain including a CDRH1 sequence including SYNMH (SEQ ID NO: 51), a CDRH2

sequence including AIYPGNGDTSYNQKFKG (SEQ ID NO: 52), and a CDRH3 sequence including STYYGGDWYFNV (SEQ ID NO: 53). These reflect CDR sequences of the 2B8 antibody.

[0069] In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable light chain including a CDRL1 sequence including RASQDVNTAVAW (SEQ ID NO: 54), a CDRL2 sequence including YSASFLES (SEQ ID NO: 55), and a CDRL3 sequence including QQHYTTPT (SEQ ID NO: 56). In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable heavy chain including a CDRH1 sequence including SGFNTKDTYIHW (SEQ ID NO: 57), a CDRH2 sequence including RIYPTNGYTRYADSVKGR (SEQ ID NO: 58), and a CDRH3 sequence including WGGDGFYAMDV (SEQ ID NO: 59). These reflect CDR sequences of the 4D5 antibody.

[0070] In particular embodiments, the cancer antigen epitope binding domains present within a BS-BDC group each target a different CD33 epitope.

[0071] In particular embodiments, the BS-BDC binds only full length CD33 ($CD33^{FL}$), only the splice variant of CD33 that lacks exon 2 ($CD33^{\Delta E2}$); or (iii) CD33 regardless of whether it is $CD33^{FL}$ or $CD33^{\Delta E2}$. Groups of BS-BDC targeting different CD33 isoforms can target a higher percentage of CD33-expressing cells because they can target cells expressing $CD33^{FL}$ and $CD33^{\Delta E2}$. Further, BS-BDC binding $CD33^{\Delta E2}$ provides therapeutic targeting for cells that express the $CD33^{\Delta E2}$ variant, but that do not express the $CD33^{FL}$ protein.

[0072] Referring to FIG. 8, the following variable light (V_L) and variable heavy (V_H) chains are provided for BS-BDC with the following specificities:

Antibody Name	Specific For	Chain	SEQ ID NO:
5D12	$CD33^{FL}$	V_L	60
		V_H	61
8F5	$CD33^{FL}$	V_L	62
		V_H	63
12B12	$CD33^{\Delta E2}$	V_L	64
		V_H	65
4H10	$CD33^{\Delta E2}$	V_L	66
		V_H	67
11D5	$CD33^{\Delta E2}$	V_L	68

		V_H	69
13E11	$CD33^{\Delta E2}$	V_L	70
		V_H	71
1H7	$CD33^{FL}$ and $CD33^{\Delta E2}$	V_L	72
		V_H	73
11D11	$CD33^{\Delta E2}$	V_L	74
		V_H	75

[0073] Definitive delineation of a CDR and identification of residues including the binding site of an antibody can be accomplished by solving the structure of the antibody and/or solving the structure of the antibody-epitope complex. In particular embodiments, this can be accomplished by methods such as X-ray crystallography.

[0074] In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized CD33 binding domain (e.g., scFv) including a variable light chain including a CDRL1 sequence including RASEVDNYGISFMN (SEQ ID NO: 76), a CDRL2 sequence including AASNQGS (SEQ ID NO: 77), and a CDRL3 sequence including QQSKEVPW (SEQ ID NO: 78). In particular embodiments, In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized CD33 binding domain (e.g., scFv) including a variable heavy chain including a CDRH1 sequence including DYNMH (SEQ ID NO: 79), a CDRH2 sequence including YIYPYNGGTGYNQKFKS (SEQ ID NO: 80), and a CDRH3 sequence including GRPAMDY (SEQ ID NO: 81). These reflect CDR sequences of the M195 or the HuM195 antibody.

[0075] In particular embodiments, the CD33 binding domain includes a variable light chain including a CDRL1 sequence including (SEQ ID NO: 253), a sequence including (SEQ ID NO: 254), and a CDRL3 sequence including (SEQ ID NO: 255). In particular embodiments, the CD33 binding domain includes a variable heavy chain including a CDRH1 sequence including (SEQ ID NO: 256), a CDRH2 sequence including (SEQ ID NO: 257), and a CDRH3 sequence including (SEQ ID NO: 258). These reflect the CDR sequences of the 1H7 antibody.

[0076] In particular embodiments, the cancer antigen epitope binding domains present within a BS-BDC group each target a different PD-L1 epitope. In particular embodiments, the PD-L1 binding domain includes a variable light chain including a CDRL1 sequence including RASQDVSTAVA (SEQ ID NO: 267), a CDRL2 sequence including SASFLYS (SEQ ID NO: 268), and a CDRL3 sequence including QQYLYHPAT (SEQ ID NO: 269). In particular embodiments, the PD-L1 binding domain includes a variable heavy chain including a CDRH1 sequence including

SGFTFSDSWIH (SEQ ID NO: 270), a CDRH2 sequence including WISPYGGSTYYADSVKG (SEQ ID NO: 271), and a CDRH3 sequence including RHWPGGFDY (SEQ ID NO: 272).

[0077] In particular embodiments, the PD-L1 binding domain includes a variable light chain including a CDRL1 sequence including TGTSSDVGGYNYVS (SEQ ID NO: 273), a CDRL2 sequence including DVSNRPS (SEQ ID NO: 274), and a CDRL3 sequence including SSYTSSSTRV (SEQ ID NO: 275). In particular embodiments, the PD-L1 binding domain includes a variable heavy chain including a CDRH1 sequence including SGFTFSSYIMM (SEQ ID NO: 276), a CDRH2 sequence including SIYPSGGITFYADTVKG (SEQ ID NO: 277), and a CDRH3 sequence including IKLGTVTTVDY (SEQ ID NO: 259).

[0078] In particular embodiments, the PD-L1 binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable light chain including a CDRL1 sequence including RASQSVSSYL (SEQ ID NO: 82), a CDRL2 sequence including DASNRAT (SEQ ID NO: 83), and a CDRL3 sequence including QQRSNWPRT (SEQ ID NO: 84). In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable heavy chain including a CDRH1 sequence including DYGFS (SEQ ID NO: 85), a CDRH2 sequence including WITAYNGNTNYAQKLQG (SEQ ID NO: 86), and a CDRH3 sequence including DYFYGMDY (SEQ ID NO: 87). These reflect CDR sequences of the 3G10 antibody. Numerous additional sequences that bind PD-L1 are described in, for example, US 2016/0222117.

[0079] In particular embodiments, the cancer antigen epitope binding domains present within a BS-BDC group each target a different CD123 epitope. In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including the CDRs of the anti-CD123 7G3 antibody. In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable light chain including a CDRL1 sequence including RASESVDNYGNTFMH (SEQ ID NO: 88), a CDRL2 sequence including RASNLES (SEQ ID NO: 89), and a CDRL3 sequence including QQSNEDPPT (SEQ ID NO: 90). In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable heavy chain including a CDRH1 sequence including NYGMN (SEQ ID NO: 91), a CDRH2 sequence including WINTYTGESTYSADFKG (SEQ ID NO: 92), and a CDRH3 sequence including SGGYDPMDY (SEQ ID NO: 93). These reflect CDR sequences of antibody 32716 described in US Patent Number 8,163,279.

[0080] In particular embodiments, the cancer antigen epitope binding domain of at least one BS-

BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable light chain including a CDRL1 sequence including RSNKSLLHSNGNTYLY (SEQ ID NO: 94), a CDRL2 sequence including RMSNLAS (SEQ ID NO: 95), and a CDRL3 sequence including MQHLEYPYT (SEQ ID NO: 96). In particular embodiments, the cancer antigen epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable heavy chain including a CDRH1 sequence including NYWMN (SEQ ID NO: 97), a CDRH2 sequence including RIDPSDSESHYNQKFKD (SEQ ID NO: 98), and a CDRH3 sequence including YDYDDTMDY (SEQ ID NO: 99). These reflect CDR sequences of antibody 32703 described in US Patent Number 8,163,279.

[0081] Immune Cell Activating Epitopes. Immune cells that can be targeted for localized activation by SMITEs of the current disclosure include, for example, T cells, natural killer (NK) cells, and macrophages.

[0082] T-cell activation can be mediated by two distinct signals: those that initiate antigen-dependent primary activation and provide a T-cell receptor like signal (primary cytoplasmic signaling sequences) and those that act in an antigen- independent manner to provide a secondary or co-stimulatory signal (secondary cytoplasmic signaling sequences). BS-BDC groups disclosed herein can target any combination of T cell activating epitopes that upon binding induce T-cell activation. Examples of such T cell activating epitopes are on T cell markers including CD2, CD3, CD7, CD27, CD28, CD30, CD40, CD83, 4-1BB (CD 137), OX40, lymphocyte function-associated antigen-1 (LFA-1), LIGHT, NKG2C, and B7-H3. T cell suppressive receptors that can be blocked include 4-1BB, PD-1, LAG3, TIM-3, BTLA, CTLA-4, and CD200.

[0083] CD3 is a primary signal transduction element of T cell receptors. CD3 is composed of a group of invariant proteins called gamma (γ), delta (Δ), epsilon (Σ), zeta (Z) and eta (H) chains. The γ, Δ, and Σ chains are structurally-related, each containing an Ig-like extracellular constant domain followed by a transmembrane region and a cytoplasmic domain of more than 40 amino acids. The Z and H chains have a distinctly different structure: both have a very short extracellular region of only 9 amino acids, a transmembrane region and a long cytoplasmic tail including 113 and 115 amino acids in the Z and H chains, respectively. The invariant protein chains in the CD3 complex associate to form noncovalent heterodimers of the Σ chain with a γ chain (Σγ) or with a Δ chain (ΣΔ) or of the Z and H chain (ZH), or a disulfide-linked homodimer of two Z chains (ZZ). 90% of the CD3 complex incorporate the ZZ homodimer.

[0084] The cytoplasmic regions of the CD3 chains include a motif designated the immunoreceptor tyrosine-based activation motif (ITAM). This motif is found in a number of other receptors including the Ig-α/Ig-β heterodimer of the B-cell receptor complex and Fc receptors for IgE and IgG. The

ITAM sites associate with cytoplasmic tyrosine kinases and participate in signal transduction following TCR-mediated triggering. In CD3, the γ, Δ and Σ chains each contain a single copy of ITAM, whereas the Z and H chains harbor three ITAMs in their long cytoplasmic regions. Indeed, the Z and H chains have been ascribed a major role in T cell activation signal transduction pathways.

[0085] CD3 is expressed on all mature T cells. In particular embodiments, the CD3 binding domain (e.g., scFv) is derived from the OKT3 antibody (the same as the one utilized in blinatumomab). The OKT3 antibody is described in detail in U.S. Patent No. 5,929,212. It includes a variable light chain including a CDRL1 sequence including SASSSVSYMN (SEQ ID NO: 100), a CDRL2 sequence including RWIYDTSKLAS (SEQ ID NO: 101), and a CDRL3 sequence including QQWSSNPFT (SEQ ID NO: 102). In particular embodiments, the CD3 T cell activating epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable heavy chain including a CDRH1 sequence including KASGYTFTRYTMH (SEQ ID NO: 103), a CDRH2 sequence including INPSRGYTNYNQKFKD (SEQ ID NO: 104), and a CDRH3 sequence including YYDDHYCLDY (SEQ ID NO: 105).

[0086] The following sequence is an scFv derived from OKT3 which retains the capacity to bind CD3: QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGY TNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS SGGGGSGGGGSGGGGSQIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKR WIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEINR (SEQ ID NO: 106). It may also be used as a CD3 binding domain.

[0087] In particular embodiments, the CD3 T cell activating epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable light chain including a CDRL1 sequence including QSLVHNNGNTY (SEQ ID NO: 107), a CDRL2 sequence including KVS, and a CDRL3 sequence including GQGTQYPFT (SEQ ID NO: 109). In particular embodiments, the CD3 T cell activating epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable heavy chain including a CDRH1 sequence including GFTFTKAW (SEQ ID NO: 110), a CDRH2 sequence including IKDKSNSYAT (SEQ ID NO: 111), and a CDRH3 sequence including RGVYYALSPFDY (SEQ ID NO: 112). These reflect CDR sequences of the 20G6-F3 antibody.

[0088] In particular embodiments, the CD3 T cell activating epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable light chain including a CDRL1 sequence including QSLVHDNGNTY (SEQ ID NO: 113), a CDRL2 sequence including KVS, and a CDRL3 sequence including GQGTQYPFT (SEQ ID NO: 115). In

particular embodiments, the CD3 T cell activating epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable heavy chain including a CDRH1 sequence including GFTFSNAW (SEQ ID NO: 116), a CDRH2 sequence including IKARSNNYAT (SEQ ID NO: 117), and a CDRH3 sequence including RGTYYASKPFDY (SEQ ID NO: 118). These reflect CDR sequences of the 4B4-D7antibody.

[0089] In particular embodiments, the CD3 T cell activating epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable light chain including a CDRL1 sequence including QSLEHNNGNTY (SEQ ID NO: 119), a CDRL2 sequence including KVS, and a CDRL3 sequence including GQGTQYPFT (SEQ ID NO: 121). In particular embodiments, the CD3 T cell activating epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable heavy chain including a CDRH1 sequence including GFTFSNAW (SEQ ID NO: 122), a CDRH2 sequence including IKDKSNNYAT (SEQ ID NO: 123), and a CDRH3 sequence including RYVHYGIGYAMDA (SEQ ID NO: 124). These reflect CDR sequences of the 4E7-C9 antibody.

[0090] In particular embodiments, the CD3 T cell activating epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable light chain including a CDRL1 sequence including QSLVHTNGNTY (SEQ ID NO: 125), a CDRL2 sequence including KVS, and a CDRL3 sequence including GQGTHYPFT (SEQ ID NO: 127). In particular embodiments, the CD3 T cell activating epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable heavy chain including a CDRH1 sequence including GFTFTNAW (SEQ ID NO: 128), a CDRH2 sequence including KDKSNNYAT (SEQ ID NO: 129), and a CDRH3 sequence including RYVHYRFAYALDA (SEQ ID NO: 130). These reflect CDR sequences of the 18F5-H10 antibody.

[0091] Additional examples of anti-CD3 antibodies, binding domains, and CDRs can be found in WO2016/116626. TR66 may also be used.

[0092] CD28 is a surface glycoprotein present on 80% of peripheral T cells in humans, and is present on both resting and activated T cells. CD28 binds to B7-1 (CD80) and B7-2 (CD86) and is the most potent of the known co-stimulatory molecules (June et al., Immunol. Today 15:321 (1994); Linsley et al., Ann. Rev. Immunol. 11:191 (1993)). In particular embodiments, the CD28 binding domain (e.g., scFv) is derived from CD80, CD86 or the 9D7 antibody. Additional antibodies that bind CD28 include 9.3, KOLT-2, 15E8, 248.23.2, and EX5.3D10. Further, 1YJD provides a crystal structure of human CD28 in complex with the Fab fragment of a mitogenic antibody (5.11A1). In particular embodiments, antibodies that do not compete with 9D7 are selected.

[0093] In particular embodiments at least one BS-BDC within a group binds an epitope of CD28. In particular embodiments, the CD28 binding domain includes the CDRs of the TGN1412 antibody. In particular embodiments, the CD28 binding domain including a variable light chain including a CDRL1 sequence including HASQNIYVWLN (SEQ ID NO: 131), a CDRL2 sequence including KASNLHT (SEQ ID NO: 132), and a CDRL3 sequence including QQGQTYPYT (SEQ ID NO: 133). In particular embodiments, the CD28 binding domain including a variable heavy chain including a CDRH1 sequence including SYYIH (SEQ ID NO: 134), a CDRH2 sequence including CIYPGNVNTNYNEKFKD (SEQ ID NO: 135), and a CDRH3 sequence including SHYGLDWNFDV (SEQ ID NO: 136).

[0002] In particular embodiments at least one BS-BDC within a group binds an epitope of CD80/CD86. CD80 (also called B7-1, UniProt ID No. P33681, SEQ ID NO: 137) and CD86 (also called B7-2, UniProt ID No. P42081, SEQ ID NO: 138) both provide costimulatory signals for T-cell activation and survival. In particular embodiments a CD80/CD86 binding domain (e.g., scFv) is derived from one or more monoclonal antibodies described in U.S. Patent No. 7,531,175. In particular embodiments, the CD80/CD86 binding domain includes a variable light chain including a CDRL1 sequence including SVSSSISSSNLH (SEQ ID NO: 139), a CDRL2 sequence including GTSNLAS (SEQ ID NO: 140), and a CDRL3 sequence including QQWSSYPLT (SEQ ID NO: 141). In particular embodiments, the CD80/CD86 binding domain includes a variable heavy chain including a CDRH1 sequence including DYYMH (SEQ ID NO: 142), a CDRH2 sequence including WIDPENGNTLYDPKFQG (SEQ ID NO: 143), and a CDRH3 sequence including EGLFFAY (SEQ ID NO: 144).

[0094] Activated T-cells express 4-1BB (CD137). T-cells can further be classified into helper cells (CD4+ T-cells) and cytotoxic T-cells (CTLs, CD8+ T-cells), which include cytolytic T-cells. T helper cells assist other white blood cells in immunologic processes, including maturation of B cells into plasma cells and activation of cytotoxic T-cells and macrophages, among other functions. These cells are also known as CD4+ T-cells because they express the CD4 protein on their surface. Helper T-cells become activated when they are presented with peptide antigens by MHC class II molecules that are expressed on the surface of antigen presenting cells (APCs). Once activated, they divide rapidly and secrete small proteins called cytokines that regulate or assist in the active immune response.

[0095] Particular embodiments can include activating CD4 T cells by binding CD3, TLR2 or CD28 and/or by blocking the suppression of CD4 T cells by binding 4-1BB, PD-1, LAG3, TIM-3, BTLA, CTLA-4, CD200, and/or VISTA.

[0096] TLR2 (UniProt ID No. O60603, SEQ ID NO: 145) is involved in the innate immune

response to bacterial lipoproteins and other microbial cell wall components. In particular embodiments, the TLR2 binding domain is derived from an anti-TLR2 antibody. Commercially available anti-TLR2 antibodies include anti-hTLR2-IgA and mAb-hTLR2 (both available from Invivogen)

[0097] In particular embodiments at least one BS-BDC within a group binds an epitope of co-stimulatory receptor 4-1BB. 4-1BB, also called CD137 or TNFSF9 (UniProt ID No. Q07011, SEQ ID NO: 146) is a T-cell co-stimulatory receptor. In particular embodiments a 4-1BB binding domain (e.g., scFv) is derived from a monoclonal antibody described in U.S. Patent Number 9,382,328B2 In particular embodiments, the 4-1BB binding domain includes a variable light chain including a CDRL1 sequence including RASQSVS (SEQ ID NO: 147), a CDRL2 sequence including ASNRAT (SEQ ID NO: 148), and a CDRL3 sequence including QRSNWPPALT (SEQ ID NO: 149). In particular embodiments, the 4-1BB binding domain includes a variable heavy chain including a CDRH1 sequence including YYWS (SEQ ID NO: 150), a CDRH2 sequence including INH, and a CDRH3 sequence including YGPGNYDWYFDL (SEQ ID NO: 152).

[0098] In particular embodiments, the 4-1BB binding domain includes a variable light chain including a CDRL1 sequence including SGDNIGDQYAH (SEQ ID NO: 261), a CDRL2 sequence including QDKNRPS (SEQ ID NO: 262), and a CDRL3 sequence including ATYTGFGSLAV (SEQ ID NO: 263). In particular embodiments, the 4-1BB binding domain includes a variable heavy chain including a CDRH1 sequence including GYSFSTYWIS (SEQ ID NO: 264), a CDRH2 sequence including KIYPGDSYTNYSPS (SEQ ID NO: 265), and a CDRH3 sequence including GYGIFDY (SEQ ID NO: 266).

[0099] In particular embodiments at least one BS-BDC within a group binds an epitope of programmed cell death protein 1 (PD-1). PD-1, also called CD279 (UniProt ID No. Q15116, SEQ ID NO: 153) is an inhibitory cell surface receptor involved in regulating the T-cell immune response. In particular embodiments a PD-1 binding domain (e.g., scFv) is derived from a monoclonal antibody described in U.S. Patent Publication 2011/0271358. In particular embodiments, the PD-1 binding domain includes a variable light chain including a CDRL1 sequence including RASQSVSTSGYSYMH (SEQ ID NO: 154), a CDRL2 sequence including FGSNLES (SEQ ID NO: 155), and a CDRL3 sequence including QHSWEIPYT (SEQ ID NO: 156). In particular embodiments, the PD-1 binding domain includes a variable heavy chain including a CDRH1 sequence including SSWIH (SEQ ID NO: 157), a CDRH2 sequence including YIYPSTGFTEYNQKFKD (SEQ ID NO: 158), and a CDRH3 sequence including WRDSSGYHAMDY (SEQ ID NO: 159).

[00100] In particular embodiments, a PD-1 binding domain (e.g., scFv) is derived from a

monoclonal antibody described in U.S. Patent Application 20090217401A1. In particular embodiments, the PD-1 binding domain includes a variable light chain including a CDRL1 sequence including RASQSVSSYLA (SEQ ID NO: 160), a CDRL2 sequence including DASNRAT (SEQ ID NO: 161), and a CDRL3 sequence including QQSSNWPRT (SEQ ID NO: 162). In particular embodiments, the PD-1 binding domain includes a variable heavy chain including a CDRH1 sequence including NSGMH (SEQ ID NO: 163), a CDRH2 sequence including VLWYDGSKRYYADSVKG (SEQ ID NO: 164), and a CDRH3 sequence including NDDY (SEQ ID NO: 165).

[00101] In particular embodiments at least one BS-BDC within a group binds an epitope of lymphocyte activation gene 3 protein (LAG3). LAG3, also called CD223 (UniProt ID No. P18627, SEQ ID NO: 166) binds to HLA classs-II antigens and is involved in activation of lymphocytes. In particular embodiments a LAG3 binding domain (e.g., scFv) is derived from a monoclonal antibody described in PCT Patent Publication WO/2014/008218. In particular embodiments, the LAG3 binding domain includes a variable light chain including a CDRL1 sequence including RASQSISSYLA (SEQ ID NO: 167), a CDRL2 sequence including of DASNRAT (SEQ ID NO: 168), and a CDRL3 sequence including QQRSNWPLT (SEQ ID NO: 169). In particular embodiments, the LAG3 binding domain includes a variable heavy chain including a CDRH1 sequence including DYYWN (SEQ ID NO: 170), a CDRH2 sequence including EINHRGSTNSNPSLKS (SEQ ID NO: 171), and a CDRH3 sequence including GYSDYEYNWFDP (SEQ ID NO: 172).

[00102] In particular embodiments at least one BS-BDC within a group binds an epitope of T-cell immunoglobulin mucin receptor 3 (TIM-3). TIM-3, also known as HAVcr-2 or TIMD-3 (UniProt ID No. Q9TDQ0; SEQ ID NO: 173) is a cell surface receptor that plays an inhibitory role in innate and adaptive immune responses. In particular embodiments a TIM-3 binding domain (e.g., scFv) is derived from a monoclonal antibody described in U.S. Patent Publication 2015/0218274. In particular embodiments, the TIM-3 binding domain includes a variable light chain including a a CDRL1 sequence including SESVEYYGTSL (SEQ ID NO: 174), a CDRL2 sequence including AAS, and a CDRL3 sequence including SRKDPS (SEQ ID NO: 176). In particular embodiments, the TIM-3 binding domain includes a variable heavy chain including a CDRH1 sequence including GYTFTSY (SEQ ID NO: 177), a CDRH2 sequence including YPGNGD (SEQ ID NO: 178), and a CDRH3 sequence including VGGAFPMDY (SEQ ID NO: 179).

[0100] In particular embodiments at least one BS-BDC within a group binds an epitope of B- and T-lymphocyte attenuator (BTLA). BTLA, also known as CD272 (UniProt ID No. Q7Z6A9, SEQ ID NO: 180), is an inhibitory receptor that inhibits the immune response of lymphocytes. In particular

embodiments a BTLA binding domain (e.g., scFv) is derived from one or more monoclonal antibodies described in U.S. Patent Publication 2012/0288500. In particular embodiments, the BTLA binding domain includes a variable light chain including a CDRL1 sequence including RASQSVSSSYLA (SEQ ID NO: 181), a CDRL2 sequence including GASSRAT (SEQ ID NO: 182), and a CDRL3 sequence including QQYGSSIT (SEQ ID NO: 183). In particular embodiments, the BTLA binding domain includes a variable heavy chain including a CDRH1 sequence including TIGVGVN (SEQ ID NO: 184), a CDRH2 sequence including LIYWDDDKRYSPSLKR (SEQ ID NO: 185), and a CDRH3 sequence including SGITEVRGVIIHYYGMDV (SEQ ID NO: 186).

[0101] In particular embodiments, the BTLA binding domain includes a variable light chain including a CDRL1 sequence including RASQSVSSSYLA (SEQ ID NO: 187), a CDRL2 sequence including of GASSRAT (SEQ ID NO: 188), and a CDRL3 sequence including QQYGSSPPIT (SEQ ID NO: 189). In particular embodiments, the BTLA binding domain includes a variable heavy chain including a CDRH1 sequence including TSGMCVS (SEQ ID NO: 190), a CDRH2 sequence including LIDWDDVKYYSSSLKT (SEQ ID NO: 191), and a CDRH3 sequence including IRFTMFRGVYYYYYGLDV (SEQ ID NO: 192).

[0102] In particular embodiments at least one BS-BDC within a group binds an epitope of cytotoxic T-lymphocyte protein 5 (CTLA-4). CTLA-4, also known as CD152 (UniProt ID No. P16410, SEQ ID NO: 193), is an inhibitory receptor that is a major negative regulator of the T-cell response. In particular embodiments a CTLA-4 binding domain (e.g., scFv) is derived from a monoclonal antibody described in U.S. Patent No. 6,984,720. In particular embodiments, the CTLA-4 binding domain includes the CDRs of the Hu26B antibody. In particular embodiments, the CTLA-4 binding domain includes a variable light chain including a CDRL1 sequence including RASQSVGSSYLA (SEQ ID NO: 194), a CDRL2 sequence including GAFSRAT (SEQ ID NO: 195), and a CDRL3 sequence including QQYGSSPWT (SEQ ID NO: 196). In particular embodiments, the CTLA-4 binding domain includes a variable heavy chain including a CDRH1 sequence including SYTMH (SEQ ID NO: 197), a CDRH2 sequence including FISYDGNNKYYADSVKG (SEQ ID NO: 198), and a CDRH3 sequence including TGWLGPFDY (SEQ ID NO: 199).

[0103] In particular embodiments, the CTLA-4 binding domain includes a variable light chain including a CDRL1 sequence including RASQGISSWLA (SEQ ID NO: 200), a CDRL2 sequence including AASSLQS (SEQ ID NO: 201), and a CDRL3 sequence including QQYNSYPPT (SEQ ID NO: 202). In particular embodiments, the CTLA-4 binding domain includes a variable heavy chain including a CDRH1 sequence including SYGMH (SEQ ID NO: 203), a CDRH2 sequence

including VIWYDGSNKYYADSVKG (SEQ ID NO: 204), and a CDRH3 sequence including APNYIGAFDV (SEQ ID NO: 205).

[0104] In particular embodiments, the CTLA-4 binding domain includes a variable light chain including a CDRL1 sequence including SATSSITYMS (SEQ ID NO: 206), a CDRL2 sequence including DTSNLAS (SEQ ID NO: 207), and a CDRL3 sequence including QQWSSYPLT (SEQ ID NO: 208). In particular embodiments, the CTLA-4 binding domain includes a variable heavy chain including a CDRH1 sequence including SYGVY (SEQ ID NO: 209), a CDRH2 sequence including VIWAGGTTNYNSALMS (SEQ ID NO: 210), and a CDRH3 sequence including GPPHAMMKRGYAMDY (SEQ ID NO: 211). These reflect CDRs sequences described in US Patent Application US20020039581A1.

[0105] In particular embodiments at least one BS-BDC within a group binds an epitope of CD200. CD200 (also known as ox-2 membrane glycoprotein, UniProt ID No. P41217, SEQ ID NO: 212) is a protein that can deliver inhibitory signals to immune cells. In particular embodiments a CD200 binding domain (e.g., scFv) is derived from one or more monoclonal antibodies described in U.S. Patent Publication 2013/0189258. In particular embodiments, the CD200 binding domain includes a variable light chain including a CDRL1 sequence including RASESVDSYGNSFMH (SEQ ID NO: 213), a CDRL2 sequence including RASNLES (SEQ ID NO: 214), and a CDRL3 sequence including QQSNEDPRT (SEQ ID NO: 215). In particular embodiments, the CD200 binding domain includes a variable heavy chain including a CDRH1 sequence including GFTFSGFAMS (SEQ ID NO: 216), a CDRH2 sequence including SISSGGTTYYLDSVKG (SEQ ID NO: 217), and a CDRH3 sequence including GNYYSGTSYDY (SEQ ID NO: 218).

[0106] In particular embodiments at least one BS-BDC within a group binds an epitope of V-type immunoglobulin domain-containing suppressor of T-cell activation precursor (VISTA; NP_071436.1; SEQ ID NO: 219). Binding domains for VISTA can be derived from antibodies available from, for example, R&D Systems, LifeSpan Biosciences, Invitrogen, BioLegend, BD Biosciences, and Abcam. In particular embodiments a VISTA binding domain (e.g., scFv) is derived from one or more monoclonal antibodies described in U.S. Patent Application 2017/0051061 or International Patent Publication WO2015097536A2. In particular embodiments, a VISTA binding domain (e.g., scFv) is derived from the antibody JNJ-61610588, which binds to and inhibits VISTA signaling. In particular embodiments, the VISTA binding domain includes a variable light chain including a CDRL1 sequence including GGTFSSY (SEQ ID NO: 220), a CDRL2 sequence including IIPIFGT (SEQ ID NO: 221), and a CDRL3 sequence including ARSSYGW (SEQ ID NO: 222). In particular embodiments, the VISTA binding domain includes a variable heavy chain including a CDRH1 sequence including QSIDTR (SEQ ID NO: 223), a

CDRH2 sequence including SAS, and a CDRH3 sequence including QQSAYNP (SEQ ID NO: 225).

[0107] Cytotoxic T-cells destroy tumor cells. These cells are also known as CD8+ T-cells because they express the CD8 glycoprotein at their surface. These cells recognize their targets by binding to antigen associated with MHC class I, which is present on the surface of nearly every cell of the body. Particular embodiments can include activating CD8 T cells by binding CD3, CD28, or 4-1BB and/or by blocking the suppression of CD8 T cells by binding PD-1, LAG3, TIM-3, or VISTA.

[0108] Particular embodiments disclosed herein including binding domains that bind epitopes on CD8. In particular embodiments, the CD8 binding domain (e.g., scFv) is derived from the OKT8 antibody. For example, in particular embodiments, the CD8 T cell activating epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable light chain including a CDRL1 sequence including RTSRSISQYLA (SEQ ID NO: 226), a CDRL2 sequence including SGSTLQS (SEQ ID NO: 227), and a CDRL3 sequence including QQHNENPLT (SEQ ID NO: 228). In particular embodiments, the CD8 T cell activating epitope binding domain of at least one BS-BDC in a group is a human or humanized binding domain (e.g., scFv) including a variable heavy chain including a CDRH1 sequence including GFNIKD (SEQ ID NO: 229), a CDRH2 sequence including RIDPANDNT (SEQ ID NO: 230), and a CDRH3 sequence including GYGYYVFDH (SEQ ID NO: 231). These reflect CDR sequences of the OKT8 antibody.

[0109] In particular embodiments, a binding domain is a single chain T-cell receptor (scTCR) including $V_{\alpha/\beta}$ and $C_{\alpha/\beta}$ chains (*e.g.*, V_α-C_α, V_β-C_β, V_α-V_β) or including V_α-C_α, V_β-C_β, V_α-V_β pair specific for a target epitope of interest. In particular embodiments, T cell activating epitope binding domains can be derived from or based on a V_α, V_β, C_α, or C_β of a known TCR (*e.g.*, a high-affinity TCR).

[0110] In particular embodiments, T cell activating epitope binding domains include one or more (*e.g.*, 2, 3, 4, 5, 6, 7, 8, 9, 10) insertions, one or more (*e.g.*, 2, 3, 4, 5, 6, 7, 8, 9, 10) deletions, one or more (*e.g.*, 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions (*e.g.*, conservative amino acid substitutions or non-conservative amino acid substitutions), or a combination of the above-noted changes, when compared with the V_α, V_β, C_α, or C_β of a known TCR. An insertion, deletion or substitution may be anywhere in a V_α, V_β, C_α, or C_β region, including at the amino- or carboxy-terminus or both ends of these regions, provided that each CDR includes zero changes or at most one, two, or three changes and provided a binding domain including a modified V_α, V_β, C_α, or C_β region can still specifically bind its target with an affinity similar to wild type.

[0111] In particular embodiments natural killer cells (also known as NK cells, K cells, and killer

cells) are targeted for localized activation by SMITEs. NK cells can induce apoptosis or cell lysis by releasing granules that disrupt cellular membranes, and can secrete cytokines to recruit other immune cells.

[0112] Examples of activating proteins expressed on the surface of NK cells include NKG2D, CD8, CD16, KIR2DL4, KIR2DS1, KIR2DS2, KIR3DS1, NKG2C, NKG2E, NKG2D, and several members of the natural cytotoxicity receptor (NCR) family. Examples of NCRs that activate NK cells upon ligand binding include NKp30, NKp44, NKp46, NKp80, and DNAM-1.

[0113] Examples of commercially available antibodies that bind to an NK cell receptor and induce and/or enhance activation of NK cells include: 5C6 and 1D11, which bind and activate NKG2D (available from BioLegend® San Diego, CA); mAb 33, which binds and activates KIR2DL4 (available from BioLegend®); P44-8, which binds and activates NKp44 (available from BioLegend®); SK1, which binds and activates CD8; and 3G8 which binds and activates CD16.

[0114] In particular embodiments, the BS-BDCs can bind to and block an NK cell inhibitory receptor to enhance NK cell activation. Examples of NK cell inhibitory receptors that can be bound and blocked include KIR2DL1, KIR2DL2/3, KIR3DL1, NKG2A, and KLRG1. In particular embodiments, a binding domain that binds and blocks the NK cell inhibitory receptors KIR2DL1 and KIR2DL2/3 includes a variable light chain region of the sequence EIVLTQSPVTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSG SGSGTDFTLTISSLEPEDFAVYYCQQRSNWMYTFGQGTKLEIKRT (SEQ ID NO: 232) and a variable heavy chain region of the sequence QVQLVQSGAEVKKPGSSVKVSCKA SGGTFSFYAISWVRQAPGQGLEWMGGFIPIFGAANYAQKFQGRVTITADESTSTAYMELSSLR SDDTAVYYCARIPSGSYYYDYDMDVWGQGTTVTVSS (SEQ ID NO: 233).

[0115] Additional NK cell activating antibodies are described in WO/2005/0003172 and US Patent No. 9,415,104.

[0116] In particular embodiments macrophages are targeted for localized activation by SMITEs. Macrophages are a type of leukocyte (or white blood cell) that can engulf and digest cells, cellular debris, and/or foreign substances in a process known as phagocytosis.

[0117] The BS-BDC groups can be designed to bind to a protein expressed on the surface of macrophages. Examples of activating proteins expressed on the surface of macrophages (and their precursors, monocytes) include CD11b, CD11c, CD64, CD68, CD119, CD163, CD206, CD209, F4/80, IFGR2 Toll-like receptors (TLRs) 1-9, IL-4Rα, and MARCO. Commercially available antibodies that bind to proteins expressed on the surface of macrophages include M1/70, which binds and activates CD11b (available from BioLegend®); KP1, which binds and activates CD68 (available from ABCAM®, Cambridge, United Kingdom); and ab87099, which

binds and activates CD163 (available from ABCAM®).

[003]In particular embodiments at least one BS-BDC within a group binds an epitope of CD40. CD40 (or Tumor necrosis factor receptor superfamily member 5, UniProt ID No. P25942, SEQ ID NO: 234) is a receptor that can transduce activating signals in macrophages. In particular embodiments, the CD40 binding domain is derived from the CD40-activating antibody CP-870,893.

[004]In particular embodiments, examples of inhibitory proteins expressed by macrophages (and their precursors, monocytes) include programmed cell death ligands 1 and 2 (PD-L1 and PD-L2) and galectin 9 (Gal-9).

[0118] In particular embodiments at least one BS-BDC within a group binds to and inhibits PD-L1. PD-L1 (also known as CD274 or B7-H1, UniProt ID No. Q9NZQ7, SEQ ID NO: 235) can inhibit T-cell proliferation and cytokine production. In particular embodiments, the PD-L1 binding domain can be derived from an anti-PD-L1 antibody. An example of a commercially available antibody that blocks PD-L1 is Nivolumab. An example of a neutralizing antibody that binds to and neutralizes PD-L1 is the monoclonal antibody 71213 (available from BPS Bioscience).

[0119] In particular embodiments at least one BS-BDC within a group binds an epitope of PD-L2. PD-L2 (also known as CD273, UniProt ID No. Q9WUL5, SEQ ID NO: 236) can interact with TIM-3 and induce proliferation of regulatory T-cells, and induce apoptosis of cytotoxic T-cells. In particular embodiments, the PD-L2 binding domain is derived from an anti-PD-L2 antibody. An example of a commercially available PD-L2 antibody includes TY25 (ab21107, available from Abcam).

[0120] In particular embodiments at least one BS-BDC within a group binds an epitope of Gal-9 (UniProt ID No. O00182, SEQ ID NO: 237) In particular embodiments, the Gal-9 binding domain can be derived from an anti-Gal-9 antibody that blocks binding to TIM-3. An example of a commercially available anti-Gal-9 antibody that blocks TIM-3 binding is 9M1-3 (available from Biolegend).

[0121] In particular embodiments, SMITEs can target a pathogen recognition receptor (PRR). PRRs are proteins or protein complexes that recognize a danger signal and activate and/or enhance the innate immune response. Examples of PRRs include the TLR4/MD-2 complex, which recognizes gram negative bacteria; Dectin-1 and Dectin-2, which recognize mannose moieties on fungus and other pathogens; TLR2/TLR6 or TLR2/TLR1 heterodimers, which recognize gram positive bacteria; TLR5, which recognizes flagellin; and TLR9 (CD289), which recognizes CpG motifs in DNA. In particular embodiments, BS-BDCs can bind and activate TLR4/MD-2, Dectin-1, Dectin-2, TRL2/TLR6, TLR2/TLR1, TLR5, and/or TLR9.

[0122] In particular embodiments, SMITEs can target the complement system. The complement system refers to an immune pathway that is induced by antigen-bound antibodies and involves signaling of complement proteins, resulting in immune recognition and clearance of the antibody-coated antigens. In particular embodiments, the BS-BDCs can bind complement-activating antibodies.

[0123] As indicated, in particular embodiments, a binding domain V_H region of the present disclosure can be derived from or based on a V_H of a known monoclonal antibody and can include one or more (*e.g.*, 2, 3, 4, 5, 6, 7, 8, 9, 10) insertions, one or more (*e.g.*, 2, 3, 4, 5, 6, 7, 8, 9, 10) deletions, one or more (*e.g.*, 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions (*e.g.*, conservative amino acid substitutions or non-conservative amino acid substitutions), or a combination of the above-noted changes, when compared with the V_H of a known monoclonal antibody. An insertion, deletion or substitution may be anywhere in the V_H region, including at the amino- or carboxy-terminus or both ends of this region, provided that each CDR includes zero changes or at most one, two, or three changes and provided a binding domain including the modified V_H region can still specifically bind its target with an affinity similar to the wild type binding domain.

[0124] In particular embodiments, a V_L region in a binding domain of the present disclosure is derived from or based on a V_L of a known monoclonal antibody and includes one or more (*e.g.*, 2, 3, 4, 5, 6, 7, 8, 9, 10) insertions, one or more (*e.g.*, 2, 3, 4, 5, 6, 7, 8, 9, 10) deletions, one or more (*e.g.*, 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions (*e.g.*, conservative amino acid substitutions), or a combination of the above-noted changes, when compared with the V_L of the known monoclonal antibody. An insertion, deletion or substitution may be anywhere in the V_L region, including at the amino- or carboxy-terminus or both ends of this region, provided that each CDR includes zero changes or at most one, two, or three changes and provided a binding domain including the modified V_L region can still specifically bind its target with an affinity similar to the wild type binding domain.

[0125] In particular embodiments, a binding domain includes or is a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% identical to a known amino acid sequence of a light chain variable region (V_L) or to a heavy chain variable region (V_H), or both, wherein each CDR includes zero changes or at most one, two, or three changes, from a monoclonal antibody or fragment or derivative thereof that specifically binds to target of interest.

[0126] Particular embodiments include BS-BDC groups that bind: two different cancer antigen epitopes and CD3 and CD28. Particular embodiments include BS-BDC groups that bind: different cancer antigen epitopes and CD3, CD28, and CD137 (4-1BB). Particular embodiments include

BS-BDC groups that bind: different cancer antigen epitopes and (i) two different epitopes on CD3 and (ii) CD28. Particular embodiments include BS-BDC groups that bind: different cancer antigen epitopes and (i) two different epitopes on CD28 and (ii) CD3.

[0127] Particular embodiments include BS-BDC that bind: ROR1/CD3; ROR1/CD28; CD33/CD3; CD19/CD3; CD123/CD3; CD33/CTLA-4; CD33/CD28; CD123/CD28; and PD-L1/CD28. Particular embodiments may utilize cancer antigen epitopes in combination with T cell activating epitopes as shown in the following Table 1:

Table 1. Exemplary Targeted Cancer Antigen Epitope/T Cell Activating Epitope Combinations

	CD3	CD28	CD8
ROR1-A	ROR1-A/CD3	ROR1-A/CD28	ROR1-A/CD8
ROR1-a	ROR1-a/CD3	ROR1-a/CD28	ROR1-a/CD8
ROR1-B	ROR1-B/CD3	ROR1-B/CD28	ROR1-B/CD8

In this table and elsewhere herein, ROR1-A can be interpreted synonymously with R11; ROR1-B can be interpreted synonymously with 2A2; and ROR1-a can be can be interpreted synonymously with R12. The R12 antibody targets an epitope that is different from and non-overlapping with the epitopes bound by R11 and 2A2. R11 and 2A2 target epitopes that are different and non-competing, so these two can bind ROR-1 simultaneously.

[0128] ROR1 epitopes in the preceding table may be replaced with epitopes from other cancer antigens disclosed herein (e.g., CD19, CD33, PSMA, mesothelin, CD123, PD-L1). Particular embodiments include ROR1/CD3 and ROR1/CD28 BS-BDC within a BS-BDC group. Particular embodiments include ROR1/CD28 and CD33/CD3 BS-BDC within a BS-BDC group. Particular embodiments include CD33/CD3 and PD-L1/CD28 BS-BDC within a BS-BDC group. Particular embodiments include CD19/CD3 and PD-L1/CD28 BS-BDC within a BS-BDC group. Particular embodiments include CD123/CD28 and CD123/CD3 BS-BDC within a BS-BDC group. Particular embodiments include CD33/CD3 and CD123/CD28 BS-BDC within a BS-BDC group.

[0129] In particular embodiments, each group of BS-BDC will target at least two different epitopes on the same cancer antigen. If additional epitopes are targeted, the additional epitopes can be on the same cancer antigen or can be on a different cancer antigen.

[0130] Particular examples of bispecific T-cell engaging antibodies that can be used within BS-BDC groups described herein include MDT000098 (SEQ ID NO: 238; bAb_2A2-CD28-His); MDT000099 (SEQ ID NO: 239; bAb_2A2-CD8-His); MDT000100 (SEQ ID NO: 240; bAb_R11-CD3-Myc-His); MDT000327 (SEQ ID NO: 241; bAb_R11-CD3-His (Version 2 of MDT000100)); MDT000346 (SEQ ID NO: 242; bAb_R11-CD28-His); MDT000320 (SEQ ID NO: 243; bAb_R12-CD3-His); MDT000347 (SEQ ID NO: 244; _bAb_R12-CD28-His); MDT000319 (SEQ ID NO: 245; _bAb_2A2-CD3-His); MDT000359 (SEQ ID NO: 246; _bAb_PDL1-CD28-His); MDT000479 (SEQ

ID NO: 247; _scFv_CD28_TGN1412-His); MDT000480 (SEQ ID NO: 248; _scFv_PDL1_Tecentriq-His); MDT000244 (SEQ ID NO: 249; _bAb_Blincyto-His); MDT000245 (SEQ ID NO: 250; bAb_AMG330-His); MDT000470 (SEQ ID NO: 251; _bAb_Blincyto-CD28-His); a BS-BDC targeting ROR1 and 4-1BB (SEQ ID NO: 252; bAb_R12-CD137-His); ROR1/CD3 bispecific antibodies described in WO2014/167022; the CD19/CD3 antibody (Blinatumomab); the CD19/CD3 antibodies described in US 2016/0208001; and/or the Her2/CD3 antibodies described in US 2014/0302037 and US 2014/0308285, among others.

[0131] As indicated, binding domains of a BS-BDC may be joined through a linker. A linker is an amino acid sequence which can provide flexibility and room for conformational movement between the binding domains of a BS-BDC. Any appropriate linker may be used. Examples of linkers can be found in Chen et al., Adv Drug Deliv Rev. 2013 Oct 15; 65(10): 1357–1369. Linkers can be flexible, rigid, or semi-rigid, depending on the desired functional domain presentation to a target. Commonly used flexible linkers include Gly-Ser linkers such as GGSGGGSGGSG (SEQ ID NO: 120), GGSGGGSGSG (SEQ ID NO: 151) and GGSGGGSG (SEQ ID NO: 175). Additional examples include: GGGGSGGGGS (SEQ ID NO: 224); GGGSGGGS (SEQ ID NO: 108); and GGSGGS (SEQ ID NO: 114). Linkers that include one or more antibody hinge regions and/or immunoglobulin heavy chain constant regions, such as CH3 alone or a CH2CH3 sequence can also be used.

[0132] In some situations, flexible linkers may be incapable of maintaining a distance or positioning of binding domains needed for a particular use. In these instances, rigid or semi-rigid linkers may be useful. Examples of rigid or semi-rigid linkers include proline-rich linkers. In particular embodiments, a proline-rich linker is a peptide sequence having more proline residues than would be expected based on chance alone. In particular embodiments, a proline-rich linker is one having at least 30%, at least 35%, at least 36%, at least 39%, at least 40%, at least 48%, at least 50%, or at least 51% proline residues. Particular examples of proline-rich linkers include fragments of proline-rich salivary proteins (PRPs).

[0133] In particular embodiments, BS-BDC disclosed herein are formed using the Daedalus expression system as described in Pechman et al., Am J Physiol 294: R1234-R1239, 2008. The Daedalus system utilizes inclusion of minimized ubiquitous chromatin opening elements in transduction vectors to reduce or prevent genomic silencing and to help maintain the stability of decigram levels of expression. This system can bypass tedious and time-consuming steps of other protein production methods by employing the secretion pathway of serum-free adapted human suspension cell lines, such as 293 Freestyle. Using optimized lentiviral vectors, yields of 20-100 mg/l of correctly folded and post-translationally modified, endotoxin-free protein of up to

70 kDa in size, can be achieved in conventional, small-scale (100 ml) culture. At these yields, most proteins can be purified using a single size-exclusion chromatography step, immediately appropriate for use in structural, biophysical or therapeutic applications. Bandaranayake et al., Nucleic Acids Res., 2011 (Nov); 39(21). In some instances, purification by chromatography may not be needed due to the purity of manufacture according the methods described herein.

[0134] Particular embodiments utilize DNA constructs (e.g., chimeric genes, expression cassettes, expression vectors, recombination vectors, etc.) including a nucleic acid sequence encoding the protein or proteins of interest operatively linked to appropriate regulatory sequences. Such DNA constructs are not naturally-occurring DNA molecules and are useful for introducing DNA into host-cells to express selected proteins of interest.

[0135] Operatively linked refers to the linking of DNA sequences (including the order of the sequences, the orientation of the sequences, and the relative spacing of the various sequences) in such a manner that the encoded protein is expressed. Methods of operatively linking expression control sequences to coding sequences are well known in the art. See, e.g., Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, N. Y., 1982; and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, N. Y., 1989.

[0136] Expression control sequences are DNA sequences involved in any way in the control of transcription or translation. Suitable expression control sequences and methods of making and using them are well known in the art. Expression control sequences generally include a promoter. The promoter may be inducible or constitutive. It may be naturally-occurring, may be composed of portions of various naturally-occurring promoters, or may be partially or totally synthetic. Guidance for the design of promoters is provided by studies of promoter structure, such as that of Harley and Reynolds, Nucleic Acids Res., 15, 2343-2361, 1987. Also, the location of the promoter relative to the transcription start may be optimized. See, e.g., Roberts et al., Proc. Natl. Acad. Sci. USA, 76:760-764, 1979.

[0137] The promoter may include, or be modified to include, one or more enhancer elements. In particular embodiments, the promoter will include a plurality of enhancer elements. Promoters including enhancer elements can provide for higher levels of transcription as compared to promoters that do not include them.

[0138] For efficient expression, the coding sequences can be operatively linked to a 3' untranslated sequence. In particular embodiments, the 3' untranslated sequence can include a transcription termination sequence and a polyadenylation sequence. The 3' untranslated region can be obtained, for example, from the flanking regions of genes.

[0139] In particular embodiments, a 5' untranslated leader sequence can also be employed. The

5' untranslated leader sequence is the portion of an mRNA that extends from the 5' CAP site to the translation initiation codon.

[0140] In particular embodiments, a “hisavi” tag can be added to the N-terminus or C-terminus of a gene by the addition of nucleotides coding for the Avitag amino acid sequence, “GLNDIFEAQKIEWHE” (SEQ ID NO: 126), as well as the 6xhistidine tag coding sequence “HHHHHH (SEQ ID NO: 260)”. The Avitag avidity tag can be biotinylated by a biotin ligase to allow for biotin-avidin or biotin-streptavidin based interactions for protein purification, as well as for immunobiology (such as immunoblotting or immunofluorescence) using anti-biotin antibodies. The 6xhistidine tag allows for protein purification using Ni-2+ affinity chromatography.

[0141] Nucleic acid sequences encoding proteins disclosed herein can be derived by those of ordinary skill in the art. Nucleic acid sequences can also include one or more of various sequence polymorphisms, mutations, and/or sequence variants. In particular embodiments, the sequence polymorphisms, mutations, and/or sequence variants do not affect the function of the encoded protein. The sequences can also include degenerate codons of a native sequence or sequences that may be introduced to provide codon preference.

[0142] In some aspects, the DNA constructs can be introduced by transfection, a technique that involves introduction of foreign DNA into the nucleus of eukaryotic cells. In some aspects, the proteins can be synthesized by transient transfection (DNA does not integrate with the genome of the eukaryotic cells, but the genes are expressed for 24-96 hours). Various methods can be used to introduce the foreign DNA into the host-cells, and transfection can be achieved by chemical-based means including by the calcium phosphate, by dendrimers, by liposomes, and by the use of cationic polymers. Non-chemical methods of transfection include electroporation, sono-poration, optical transfection, protoplast fusion, impalefection, and hydrodynamic delivery. In some embodiments, transfection can be achieved by particle-based methods including gene gun where the DNA construct is coupled to a nanoparticle of an inert solid which is then "shot" directly into the target-cell's nucleus. Other particle-based transfection methods include magnet assisted transfection and impalefection.

[0143] In particular embodiments, the BS-BDC can be modified to produce an administration benefit. In particular embodiments, modified BS-BDC include those wherein one or more amino acids have been replaced with a non-amino acid component, or where the amino acid has been conjugated to a functional group or a functional group has been otherwise associated with an amino acid. The modified amino acid may be, e.g., a glycosylated amino acid, a PEGylated amino acid, a farnesylated amino acid, an acetylated amino acid, a biotinylated amino acid, an amino acid conjugated to a lipid moiety, or an amino acid conjugated to an organic derivatizing agent.

Amino acid(s) can be modified, for example, co-translationally or post-translationally during recombinant production (e.g., N-linked glycosylation at N-X-S/T motifs during expression in mammalian cells) or modified by synthetic means. The modified amino acid can be within the sequence or at the terminal end of a sequence. Modifications also include nitrited constructs.

[0144] PEGylation particularly is a process by which polyethylene glycol (PEG) polymer chains are covalently conjugated to other molecules such as proteins. Several methods of PEGylating proteins have been reported in the literature. For example, N-hydroxy succinimide (NHS)-PEG was used to PEGylate the free amine groups of lysine residues and N-terminus of proteins; PEGs bearing aldehyde groups have been used to PEGylate the amino-termini of proteins in the presence of a reducing reagent; PEGs with maleimide functional groups have been used for selectively PEGylating the free thiol groups of cysteine residues in proteins; and site-specific PEGylation of acetyl-phenylalanine residues can be performed.

[0145] Covalent attachment of proteins to PEG has proven to be a useful method to increase the half-lives of proteins in the body (Abuchowski, A. et al., Cancer Biochem. Biophys.,1984, 7:175-186; Hershfield, M. S. et al., N. Engl. J. Medicine, 1987, 316:589-596; and Meyers, F. J. et al., Clin. Pharmacol. Ther., 1991, 49:307-313). The attachment of PEG to proteins not only protects the molecules against enzymatic degradation, but also reduces their clearance rate from the body. The size of PEG attached to a protein has significant impact on the half-life of the protein. The ability of PEGylation to decrease clearance is generally not a function of how many PEG groups are attached to the protein, but the overall molecular weight of the altered protein. Usually the larger the PEG is, the longer the *in vivo* half-life of the attached protein. In addition, PEGylation can also decrease protein aggregation (Suzuki et al., Biochem. Bioph. Acta vol. 788, pg. 248 (1984)), alter protein immunogenicity (Abuchowski et al.; J. Biol. Chem. vol. 252 pg. 3582 (1977)), and increase protein solubility as described, for example, in PCT Publication No. WO 92/16221).

[0146] Several sizes of PEGs are commercially available (Nektar Advanced PEGylation Catalog 2005-2006; and NOF DDS Catalogue Ver 7.1), which are suitable for producing proteins with targeted circulating half-lives. A variety of active PEGs have been used including mPEG succinimidyl succinate, mPEG succinimidyl carbonate, and PEG aldehydes, such as mPEG-propionaldehyde.

[0147] Sequence information provided by public databases can be used to identify additional gene and protein sequences that can be used with the systems and methods disclosed herein.

[0148] As indicated previously in relation to the discussion of binding domain sequences and encoding gene sequences, variants of the sequences disclosed and referenced herein are also

included. Variants of proteins can include those having one or more conservative amino acid substitutions or one or more non-conservative substitutions that do not adversely affect the function of the protein in a measure described in for example, FIGs. 4-6. A "conservative substitution" involves a substitution found in one of the following conservative substitutions groups: Group 1: Alanine (Ala), Glycine (Gly), Serine (Ser), Threonine (Thr); Group 2: Aspartic acid (Asp), Glutamic acid (Glu); Group 3: Asparagine (Asn), Glutamine (Gln); Group 4: Arginine (Arg), Lysine (Lys), Histidine (His); Group 5: Isoleucine (Ile), Leucine (Leu), Methionine (Met), Valine (Val); and Group 6: Phenylalanine (Phe), Tyrosine (Tyr), Tryptophan (Trp).

[0149] Additionally, amino acids can be grouped into conservative substitution groups by similar function or chemical structure or composition (e.g., acidic, basic, aliphatic, aromatic, sulfur-containing). For example, an aliphatic grouping may include, for purposes of substitution, Gly, Ala, Val, Leu, and Ile. Other groups containing amino acids that are considered conservative substitutions for one another include: sulfur-containing: Met and Cysteine (Cys); acidic: Asp, Glu, Asn, and Gln; small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr, Pro, and Gly; polar, negatively charged residues and their amides: Asp, Asn, Glu, and Gln; polar, positively charged residues: His, Arg, and Lys; large aliphatic, nonpolar residues: Met, Leu, Ile, Val, and Cys; and large aromatic residues: Phe, Tyr, and Trp. Additional information is found in Creighton (1984) Proteins, W.H. Freeman and Company.

[0150] As indicated elsewhere, variants of gene sequences can include codon optimized variants, sequence polymorphisms, splice variants, and/or mutations that do not affect the function of an encoded product to a statistically-significant degree.

[0151] Variants of the protein and nucleic acid sequences disclosed herein also include sequences with at least 70% sequence identity, 80% sequence identity, 85% sequence, 90% sequence identity, 95% sequence identity, 96% sequence identity, 97% sequence identity, 98% sequence identity, or 99% sequence identity to the protein and nucleic acid sequences described or disclosed herein.

[0152] "% sequence identity" refers to a relationship between two or more sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between protein and nucleic acid sequences as determined by the match between strings of such sequences. "Identity" (often referred to as "similarity") can be readily calculated by known methods, including (but not limited to) those described in: Computational Molecular Biology (Lesk, A. M., ed.) Oxford University Press, NY (1988); Biocomputing: Informatics and Genome Projects (Smith, D. W., ed.) Academic Press, NY (1994); Computer Analysis of Sequence Data, Part I (Griffin, A. M., and Griffin, H. G., eds.) Humana Press, NJ (1994); Sequence Analysis in

Molecular Biology (Von Heijne, G., ed.) Academic Press (1987); and Sequence Analysis Primer (Gribskov, M. and Devereux, J., eds.) Oxford University Press, NY (1992). Preferred methods to determine identity are designed to give the best match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Sequence alignments and percent identity calculations may be performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR, Inc., Madison, Wisconsin). Multiple alignment of the sequences can also be performed using the Clustal method of alignment (Higgins and Sharp CABIOS, 5, 151-153 (1989) with default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Relevant programs also include the GCG suite of programs (Wisconsin Package Version 9.0, Genetics Computer Group (GCG), Madison, Wisconsin); BLASTP, BLASTN, BLASTX (Altschul, et al., J. Mol. Biol. 215:403-410 (1990); DNASTAR (DNASTAR, Inc., Madison, Wisconsin); and the FASTA program incorporating the Smith-Waterman algorithm (Pearson, Comput. Methods Genome Res., [Proc. Int. Symp.] (1994), Meeting Date 1992, 111-20. Editor(s): Suhai, Sandor. Publisher: Plenum, New York, N.Y.. Within the context of this disclosure it will be understood that where sequence analysis software is used for analysis, the results of the analysis are based on the "default values" of the program referenced. "Default values" will mean any set of values or parameters, which originally load with the software when first initialized.

[0153] BS-BDC can be formulated alone or in combination into compositions for administration to subjects. In particular embodiments, compositions include at least two BS-BDC disclosed herein formulated with a pharmaceutically acceptable carrier.

[0154] Salts and/or pro-drugs of BS-BDC can also be used.

[0155] A pharmaceutically acceptable salt includes any salt that retains the activity of the BS-BDC and is acceptable for pharmaceutical use. A pharmaceutically acceptable salt also refers to any salt which may form in vivo as a result of administration of an acid, another salt, or a prodrug which is converted into an acid or salt.

[0156] Suitable pharmaceutically acceptable acid addition salts can be prepared from an inorganic acid or an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids can be selected from aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids.

[0157] Suitable pharmaceutically acceptable base addition salts include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'-dibenzylethylene-diamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-

methylglucamine, lysine, arginine and procaine.

[0158] A prodrug includes an active ingredient which is converted to a therapeutically active compound after administration, such as by cleavage of a BS-BDC or by hydrolysis of a biologically labile group.

[0159] In particular embodiments, the compositions include BS-BDC of at least 0.1% w/v or w/w of the composition; at least 1% w/v or w/w of composition; at least 10% w/v or w/w of composition; at least 20% w/v or w/w of composition; at least 30% w/v or w/w of composition; at least 40% w/v or w/w of composition; at least 50% w/v or w/w of composition; at least 60% w/v or w/w of composition; at least 70% w/v or w/w of composition; at least 80% w/v or w/w of composition; at least 90% w/v or w/w of composition; at least 95% w/v or w/w of composition; or at least 99% w/v or w/w of composition.

[0160] Exemplary generally used pharmaceutically acceptable carriers include any and all absorption delaying agents, antioxidants, binders, buffering agents, bulking agents or fillers, chelating agents, coatings, disintegration agents, dispersion media, gels, isotonic agents, lubricants, preservatives, salts, solvents or co-solvents, stabilizers, surfactants, and/or delivery vehicles.

[0161] Exemplary antioxidants include ascorbic acid, methionine, and vitamin E.

[0162] Exemplary buffering agents include citrate buffers, succinate buffers, tartrate buffers, fumarate buffers, gluconate buffers, oxalate buffers, lactate buffers, acetate buffers, phosphate buffers, histidine buffers, and/or trimethylamine salts.

[0163] An exemplary chelating agent is EDTA.

[0164] Exemplary isotonic agents include polyhydric sugar alcohols including trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol, or mannitol.

[0165] Exemplary preservatives include phenol, benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, octadecyldimethylbenzyl ammonium chloride, benzalkonium halides, hexamethonium chloride, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, and 3-pentanol.

[0166] Stabilizers refer to a broad category of excipients which can range in function from a bulking agent to an additive which solubilizes the BS-BDC or helps to prevent denaturation or adherence to the container wall. Typical stabilizers can include polyhydric sugar alcohols; amino acids, such as arginine, lysine, glycine, glutamine, asparagine, histidine, alanine, ornithine, L-leucine, 2-phenylalanine, glutamic acid, and threonine; organic sugars or sugar alcohols, such as lactose, trehalose, stachyose, mannitol, sorbitol, xylitol, ribitol, myoinisitol, galactitol, glycerol, and cyclitols, such as inositol; PEG; amino acid polymers; sulfur-containing reducing agents, such as

urea, glutathione, thioctic acid, sodium thioglycolate, thioglycerol, alpha-monothioglycerol, and sodium thiosulfate; low molecular weight polypeptides (i.e., <10 residues); proteins such as human serum albumin, bovine serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; monosaccharides such as xylose, mannose, fructose and glucose; disaccharides such as lactose, maltose and sucrose; trisaccharides such as raffinose, and polysaccharides such as dextran. Stabilizers are typically present in the range of from 0.1 to 10,000 parts by weight based on therapeutic weight.

[0167] The compositions disclosed herein can be formulated for administration by, for example, injection, inhalation, infusion, perfusion, lavage, or ingestion. The compositions disclosed herein can further be formulated for intravenous, intradermal, intraarterial, intranodal, intralymphatic, intraperitoneal, intralesional, intraprostatic, intravaginal, intrarectal, topical, intrathecal, intratumoral, intramuscular, intravesicular, oral and/or subcutaneous administration and more particularly by intravenous, intradermal, intraarterial, intranodal, intralymphatic, intraperitoneal, intralesional, intraprostatic, intravaginal, intrarectal, intrathecal, intratumoral, intramuscular, intravesicular, and/or subcutaneous injection.

[0168] For injection, compositions can be formulated as aqueous solutions, such as in buffers including Hanks' solution, Ringer's solution, or physiological saline. The aqueous solutions can include formulatory agents such as suspending, stabilizing, and/or dispersing agents. Alternatively, the formulation can be in lyophilized and/or powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

[0169] For oral administration, the compositions can be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like. For oral solid formulations such as powders, capsules and tablets, suitable excipients include binders (gum tragacanth, acacia, cornstarch, gelatin), fillers such as sugars, e.g. lactose, sucrose, mannitol and sorbitol; dicalcium phosphate, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate; cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxy- methylcellulose, and/or polyvinylpyrrolidone (PVP); granulating agents; and binding agents. If desired, disintegrating agents can be added, such as corn starch, potato starch, alginic acid, cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. If desired, solid dosage forms can be sugar-coated or enteric-coated using standard techniques. Flavoring agents, such as peppermint, oil of wintergreen, cherry flavoring, orange flavoring, etc. can also be used.

[0170] Compositions can be formulated as an aerosol. In particular embodiments, the aerosol is

provided as part of an anhydrous, liquid or dry powder inhaler. Aerosol sprays from pressurized packs or nebulizers can also be used with a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, a dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of gelatin for use in an inhaler or insufflator may also be formulated including a powder mix of BS-BDC and a suitable powder base such as lactose or starch.

[0171] Compositions can also be formulated as depot preparations. Depot preparations can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salts.

[0172] Additionally, compositions can be formulated as sustained-release systems utilizing semipermeable matrices of solid polymers including at least one BS-BDC group. Various sustained-release materials have been established and are well known by those of ordinary skill in the art. Sustained-release systems may, depending on their chemical nature, release BS-BDC following administration for a few weeks up to over 100 days. Depot preparations can be administered by injection; parenteral injection; instillation; or implantation into soft tissues, a body cavity, or occasionally into a blood vessel with injection through fine needles.

[0173] Depot formulations can include a variety of bioerodible polymers including poly(lactide), poly(glycolide), poly(caprolactone) and poly(lactide)-co(glycolide) (PLG) of desirable lactide:glycolide ratios, average molecular weights, polydispersities, and terminal group chemistries. Blending different polymer types in different ratios using various grades can result in characteristics that borrow from each of the contributing polymers.

[0174] The use of different solvents (for example, dichloromethane, chloroform, ethyl acetate, triacetin, N-methyl pyrrolidone, tetrahydrofuran, phenol, or combinations thereof) can alter microparticle size and structure in order to modulate release characteristics. Other useful solvents include water, ethanol, dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP), acetone, methanol, isopropyl alcohol (IPA), ethyl benzoate, and benzyl benzoate.

[0175] Exemplary release modifiers can include surfactants, detergents, internal phase viscosity enhancers, complexing agents, surface active molecules, co-solvents, chelators, stabilizers, derivatives of cellulose, (hydroxypropyl)methyl cellulose (HPMC), HPMC acetate, cellulose acetate, pluronics (e.g., F68/F127), polysorbates, Span® (Croda Americas, Wilmington, Delaware), poly(vinyl alcohol) (PVA), Brij® (Croda Americas, Wilmington, Delaware), sucrose acetate isobutyrate (SAIB), salts, and buffers.

[0176] Excipients that partition into the external phase boundary of microparticles such as surfactants including polysorbates, dioctylsulfosuccinates, poloxamers, PVA, can also alter properties including particle stability and erosion rates, hydration and channel structure, interfacial transport, and kinetics in a favorable manner.

[0177] Additional processing of the disclosed sustained release depot formulations can utilize stabilizing excipients including mannitol, sucrose, trehalose, and glycine with other components such as polysorbates, PVAs, and dioctylsulfosuccinates in buffers such as Tris, citrate, or histidine. A freeze-dry cycle can also be used to produce very low moisture powders that reconstitute to similar size and performance characteristics of the original suspension.

[0178] Any composition disclosed herein can advantageously include any other pharmaceutically acceptable carriers which include those that do not produce significantly adverse, allergic, or other untoward reactions that outweigh the benefit of administration. Exemplary pharmaceutically acceptable carriers and formulations are disclosed in Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990. Moreover, formulations can be prepared to meet sterility, pyrogenicity, general safety, and purity standards as required by U.S. FDA Office of Biological Standards and/or other relevant foreign regulatory agencies.

[0179] In particular embodiments, BS-BDC compositions include immunogenic compositions. An immunogenic composition refers to a composition that stimulates an immune response in a subject. The immune response can be, for example, a T-cell response. A T-cell response can be detected, for example, by measuring production of cytokines, such as IL-2.

[0180] In particular embodiments, BS-BDC compositions include therapeutic compositions. A therapeutic composition refers to a composition that treats a subject. A treatment can be detected by a reduction in a subject's disease or symptoms as described elsewhere herein.

[0181] Kits. Also disclosed herein are kits including one or more containers including one or more of the BS-BDC and/or compositions described herein. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use, or sale for human administration. In particular embodiments, BS-BDC groups within kits are chosen based on assessment of a particular subject's anticipated disease course. In particular embodiments, BS-BDC within kits are updated for a particular subject based on on-going assessments of the subject's current disease status.

[0182] Methods disclosed herein include treating subjects (humans, veterinary animals (dogs, cats, reptiles, birds, etc.) livestock (horses, cattle, goats, pigs, chickens, etc.) and research animals (monkeys, rats, mice, fish, etc.) with compositions disclosed herein. Treating subjects

includes delivering therapeutically effective amounts. Therapeutically effective amounts include those that provide effective amounts, prophylactic treatments and/or therapeutic treatments.

[0183] An "effective amount" is the amount of a composition necessary to result in a desired physiological change in the subject. For example, an effective amount can provide an immunogenic effect. Effective amounts are often administered for research purposes. Effective amounts disclosed herein can cause a statistically-significant effect in an animal model or in vitro assay relevant to the assessment of a cancer's development or progression. An immunogenic composition can be provided in an effective amount, wherein the effective amount stimulates an immune response.

[0184] A "prophylactic treatment" includes a treatment administered to a subject who does not display signs or symptoms of a cancer or displays only early signs or symptoms of a cancer such that treatment is administered for the purpose of diminishing or decreasing the risk of developing the cancer further. Thus, a prophylactic treatment functions as a preventative treatment against a cancer. In particular embodiments, prophylactic treatments reduce, delay, or prevent metastasis from a primary a cancer tumor site from occurring.

[0185] A "therapeutic treatment" includes a treatment administered to a subject who displays symptoms or signs of a cancer and is administered to the subject for the purpose of diminishing or eliminating those signs or symptoms of the cancer. The therapeutic treatment can reduce, control, or eliminate the presence or activity of the cancer and/or reduce control or eliminate side effects of the cancer.

[0186] Function as an effective amount, prophylactic treatment or therapeutic treatment are not mutually exclusive, and in particular embodiments, administered dosages may accomplish more than one treatment type.

[0187] In particular embodiments, therapeutically effective amounts provide anti-cancer effects. Anti-cancer effects include a decrease in the number of cancer cells, decrease in the number of metastases, a decrease in tumor volume, an increase in life expectancy, induced chemo- or radiosensitivity in cancer cells, inhibited angiogenesis near cancer cells, inhibited cancer cell proliferation, inhibited tumor growth, prevented or reduced metastases, prolonged subject life, reduced cancer-associated pain, and/or reduced relapse or re-occurrence of cancer following treatment.

[0188] A "tumor" is a swelling or lesion formed by an abnormal growth of cells (called neoplastic cells or tumor cells). A "tumor cell" is an abnormal cell that grows by a rapid, uncontrolled cellular proliferation and continues to grow after the stimuli that initiated the new growth cease. Tumors show partial or complete lack of structural organization and functional coordination with the normal

tissue, and usually form a distinct mass of tissue, which may be benign, pre-malignant or malignant.

[0189] For administration, therapeutically effective amounts (also referred to herein as doses) can be initially estimated based on results from in vitro assays and/or animal model studies. Such information can be used to more accurately determine useful doses in subjects of interest. The actual dose amount administered to a particular subject can be determined by a physician, veterinarian or researcher taking into account parameters such as physical and physiological factors including target, body weight, severity of condition, type of cancer, stage of cancer, previous or concurrent therapeutic interventions, idiopathy of the subject and route of administration.

[0190] Useful doses can range from 0.1 to 5 μg/kg or from 0.5 to 1 μg /kg. In other non-limiting examples, a dose can include 1 μg /kg, 15 μg /kg, 30 μg /kg, 50 μg/kg, 55 μg/kg, 70 μg/kg, 90 μg/kg, 150 μg/kg, 350 μg/kg, 500 μg/kg, 750 μg/kg, 1000 μg/kg, 0.1 to 5 mg/kg or from 0.5 to 1 mg/kg. In other non-limiting examples, a dose can include 1 mg/kg, 10 mg/kg, 30 mg/kg, 50 mg/kg, 70 mg/kg, 100 mg/kg, 300 mg/kg, 500 mg/kg, 700 mg/kg, 1000 mg/kg or more.

[0191] Therapeutically effective amounts can be achieved by administering single or multiple doses during the course of a treatment regimen (e.g., daily, every other day, every 3 days, every 4 days, every 5 days, every 6 days, weekly, every 2 weeks, every 3 weeks, monthly, every 2 months, every 3 months, every 4 months, every 5 months, every 6 months, every 7 months, every 8 months, every 9 months, every 10 months, every 11 months or yearly).

[0192] In particular embodiments, BS-BDC can be administered through a pump such as a programmable pump (e.g., an insulin pump). In particular embodiments, staged administration of different BS-BDC can be achieved using, for example, a programmed pump.

[0193] In particular embodments, BS-BDC have a short half-life (e.g., short in vivo half-life) such that the BS-BDC are administered using continuous infusion with a pump. In particular embodiments, any BS-BDC with an in vivo half-life of less than 5 hours can be administered through continuous infusion. In contrast, antibodies can have in vivo half-lives of several weeks due to their larger size and Fc portion, and bi-specific formats that contain an Fc portion can similarly have extended in vivo half-lives.

[0194] In particular embodiments, therapeutically effective amounts are administered at a time interval to reduce or eliminate cancer recurrence without causing autoimmune toxicity.

[0195] The pharmaceutical compositions described herein can be administered by, without limitation, injection, inhalation, infusion, perfusion, lavage or ingestion. Routes of administration can include intravenous, intradermal, intraarterial, intraparenteral, intranasal, intranodal,

intralymphatic, intraperitoneal, intralesional, intraprostatic, intravaginal, intrarectal, topical, intrathecal, intratumoral, intramuscular, intravesicular, oral, subcutaneous, and/or sublingual administration and more particularly by intravenous, intradermal, intraarterial, intraparenteral, intranasal, intranodal, intralymphatic, intraperitoneal, intralesional, intraprostatic, intravaginal, intrarectal, topical, intrathecal, intratumoral, intramuscular, intravesicular, oral, subcutaneous, and/or sublingual injection.

[0196] As indicated, in particular embodiments, the administration of BS-BDC evolve over time during the course of a subject's treatment regimen. Groups of BS-BDC can combinatorically address many different types of cancer and be customized for individual subjects (e.g., A + B; A + C; A + F; B + F; etc). Likewise, there can be a very personalized aspect to the administration of BS-BDC groups in which subject samples (e.g., liquid biopsies, standard biopsies) are assessed using, for example, polymerase chain reaction (PCR), deep sequencing, flow cytometry, or immunohistochemistry (IHC) to identify emerging clones and to choose pairs of BS-BDC to specifically address an emerging clone. This "cassette" approach can involve monitoring the emergence of resistant clones and rapidly addressing them through new combinations of BS-BDC. "Emerging clone" can refer to a cancer cell or a clonal population of cancer cells with one or more alleles that are distinct from the dominant genotype of the population of cancer cells the clone was derived from. "Drug resistant clone" can refer to a cancer cell or a clonal population of cancer cells that have acquired a new allele that confers resistance to one or more cancer drugs. A patient's cancer can be monitored for the emergence of new cancer clones and/or treatment resistant clones, for example, by sequencing the DNA from a cancer sample derived from the patient.

[0197] In particular embodiments, a patient can be monitored for immune suppression in the tumor microenvironment and/or T-cell suppression. Immune suppression in the microenvironment and/or T-cell suppression can be monitored, for example, by measuring cytokine levels and/or the number of T-cells in a sample derived from the patient.

[0198] In particular embodiments, methods disclosed herein include activating immune cells in the tumor microenvironment. In particular embodiments, activating immune cells in the tumor microenvironment includes reducing or reversing T cell suppression in the tumor microenvironment. T cell suppression can refer to a block of or reduction in T cell activation, such as can be caused by regulatory T cells. Methods to measure T cell suppression can be found, for example in McMurchy & Levings, European Journal of Immunology 42(1): 27-34. Reducing or reversing T cell suppression in the tumor microenvironment can include replacing a CD28-binding BS-BDC with a BS-BDC that reduces the activity of an immune cell suppressor. This approach is

beneficial when T cells in the tumor microenvironment reduce expression of CD28 following on-going activation.

[0199] Exemplary Embodiments.

1. A group of bi-specific binding domain constructs (BS-BDC) wherein each BS-BDC in the group targets a cancer antigen epitope and an immune cell activating epitope that are different from the cancer antigen epitope and immune cell activating epitope targeted by another BS-BDC in the group, provided that at least two targeted cancer antigen epitopes are on the same cancer antigen.
2. A group of embodiment 1 wherein the different cancer antigen epitopes are non-overlapping and/or non-repetitive.
3. A group of embodiments 1 or 2 wherein all of the different targeted cancer antigen epitopes are on the same cancer antigen.
4. A group of embodiment 3 wherein the same cancer antigen is BCMA, CAIX, CD19, CD20, CD22, CD33, CD133, ERBB2, folate receptor, HER2, Lewis Y, L1-CAM, mesothelin, MUC-CD, PSCA, PSMA, ROR1, SV40 T, WT-1, PD-L1, or CD123.
5. A group of embodiment 3 wherein the same cancer antigen is ROR1 and the different and non-overlapping epitopes are targeted by ROR1-A and ROR1-B or are targeted by ROR1-a and ROR1-B.
6. A group of embodiments 1 or 2 wherein the BS-BDC group additionally targets different cancer antigen epitopes on different cancer antigens.
7. A group of embodiment 6 wherein the different cancer antigen epitopes are on:
   (i) ROR1 and CD33;
   (ii) CD33 and PD-L1;
   (iii) CD19 and PD-L1;
   (iv) CD123 and CD33;
   (v) two or more of CD19, CD20, CD22, ROR1, CD33, CD123, and WT-1;
   (vi) two or more of PSMA, WT1, PSCA, and SV40 T;
   (vii) two or more of HER2, ERBB2, and ROR1;
   (viii) two or more of L1-CAM, MUC-CD, folate receptor, Lewis Y, ROR1, mesothelin, and WT-1; or
   (ix) two or more of mesothelin, CEA, CD24, and ROR1.
8. A group of embodiment 6 wherein the different cancer antigen epitopes are on ROR1, CD33, CD19, CD123 and/or PD-L1.
9. A group of any of embodiments 1-8 wherein a BS-BDC in the group includes a CDR sequence

of R11, R12, 2A2, and/or Y31.

10. A group of any of embodiments 1-9 wherein a BS-BDC in the group includes a CDR sequence selected from SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; and SEQ ID NO: 17.

11. A group of any of embodiments 1- 10 wherein a BS-BDC in the group includes a CDR sequence selected from SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; and SEQ ID NO: 23.

12. A group of any of embodiments 1-11 wherein a BS-BDC in the group includes a CDR sequence selected from SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; and SEQ ID NO: 29.

13. A group of any of embodiments 1-12 wherein a BS-BDC in the group includes a CDR sequence selected from SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 32; SEQ ID NO: 33; SEQ ID NO: 34; and SEQ ID NO: 35.

14. A group of any of embodiments 1-13 wherein a BS-BDC in the group includes a CDR sequence selected from SEQ ID NO: 36; SEQ ID NO: 37; SEQ ID NO: 38; SEQ ID NO: 39; SEQ ID NO: 40; and SEQ ID NO: 41.

15. A group of any of embodiments 1-4 or 6-14 wherein a BS-BDC in the group includes CDR sequences of FMC63, SJ25C1, and/or HD37.

16. A group of any of embodiments 1-4 or 6-15 wherein a BS-BDC in the group includes a CDR sequence selected from SEQ ID NO: 42; SEQ ID NO: 43; SEQ ID NO: 44; SEQ ID NO: 45; SEQ ID NO: 46; and SEQ ID NO: 47.

17. A group of any of embodiments 1-4 or 6-16 wherein a BS-BDC in the group includes a CDR sequence selected from SEQ ID NO: 48; SEQ ID NO: 49; SEQ ID NO: 50; SEQ ID NO: 51; SEQ ID NO: 52; and SEQ ID NO: 53.

18. A group of any of embodiments 1-4 or 6-17 wherein a BS-BDC in the group includes a CDR sequence selected from SEQ ID NO: 54; SEQ ID NO: 55; SEQ ID NO: 56; SEQ ID NO: 57; SEQ ID NO: 58; and SEQ ID NO: 59.

19. A group of any of embodiments 1-4 or 6-18 wherein a BS-BDC in the group includes a CDR sequence of Rituximab, Ofatumumab, and/or Herceptin.

20. A group of any of embodiments 1-4 or 6-19 wherein a BS-BDC in the group includes a CDR sequence selected from SEQ ID NO: 76; SEQ ID NO: 77; SEQ ID NO: 78; SEQ ID NO: 79; SEQ ID NO: 80; and SEQ ID NO: 81.

21. A group of any of embodiments 1-4 or 6-20 wherein a BS-BDC in the group includes a CDR sequence selected from SEQ ID NO: 253; SEQ ID NO: 254; SEQ ID NO: 255; SEQ ID NO: 256;

SEQ ID NO: 257; and SEQ ID NO: 258.

22. A group of any of embodiments 1-4 or 6-21 wherein a BS-BDC in the group includes a CDR sequence selected from SEQ ID NO: 82; SEQ ID NO: 83; SEQ ID NO: 84; SEQ ID NO: 85; SEQ ID NO: 86; and SEQ ID NO: 87.

23. A group of any of embodiments 1-4 or 6-22 wherein a BS-BDC in the group includes a CDR sequence selected from SEQ ID NO: 88; SEQ ID NO: 89; SEQ ID NO: 90; SEQ ID NO: 91; SEQ ID NO: 92; and SEQ ID NO: 93.

24. A group of any of embodiments 1-4 or 6-23 wherein a BS-BDC in the group includes a CDR sequence selected from SEQ ID NO: 94; SEQ ID NO: 95; SEQ ID NO: 96; SEQ ID NO: 97; SEQ ID NO: 98; and SEQ ID NO: 99.

25. A group of any of embodiments 1-4 or 6-24 wherein a BS-BDC in the group includes CDR sequences (i) SEQ ID NO: 267; SEQ ID NO: 268; SEQ ID NO: 269; SEQ ID NO: 270; SEQ ID NO: 271; and SEQ ID NO: 272; or (ii) SEQ ID NO: 273; SEQ ID NO: 274; SEQ ID NO: 275; SEQ ID NO: 276; SEQ ID NO: 277; and SEQ ID NO: 259.

26. A group of any of embodiments 1-4 or 6-25 wherein a BS-BDC in the group targets full length CD33 ($CD33^{FL}$), only the splice variant of CD33 that lacks exon 2 ($CD33^{\Delta E2}$); or (iii) CD33 regardless of whether it is $CD33^{FL}$ or $CD33^{\Delta E2}$.

27. A group of embodiment 26 wherein a BS-BDC in the group includes a V_L and a V_H chain of 5D12, 85F, 12B12, 4H10, 11D5, 13E11, 1H7, or 11D11.

28. A group of embodiment 25 or 26 wherein a BS-BDC in the group includes CDR sequences from a V_L and a V_H chain of 5D12, 85F, 12B12, 4H10, 11D5, 13E11, 1H7, 11D11, or M195.

29. A group of any of embodiments 1-28 wherein the immune cell is a T cell, natural killer cell, or macrophage.

30. A group of any of embodiments 1-29 wherein the different immune cell activating epitopes are on the same immune cell activator.

31. A group of any of embodiments 1-29 wherein the different immune cell activating epitopes are on the different immune cell activators.

32. A group of any of embodiments 1-29 wherein the different immune cell activating epitopes are on the same immune cell activator and on different immune cell activators.

33. A group of any of embodiments 1-32 wherein an immune cell activating epitope is on a T cell.

34. A group of embodiment 32 wherein the same immune cell activator is CD3 and the different epitopes are on different invariant proteins including the T cell CD3 dimer.

35. A group of embodiment 31 or 32 wherein the different immune cell activating epitopes are on: CD3 and CD28; CD3 and CD8; or CD8 and CD28.

36. A group of embodiment 31 or 32 wherein the different immune cell activating epitopes are on CD3, CD8, and CD28.

37. A group of embodiment 31 or 32 wherein the different immune cell activating epitopes are on CD3, CD28, and CD137.

38. A group of embodiment 31 or 32 wherein the different immune cell activating epitopes are on (i) CD3, (ii) CD3, and (iii) CD28.

39. A group of embodiment 31 or 32 wherein the different immune cell activating epitopes are on (i) CD28, (ii) CD28, and (iii) CD3.

40. A group of any of embodiments 1-39 wherein the different immune cell activating epitopes are on one or more of CD2, CD3, CD7, CD27, CD28, CD30, CD40, CD83, CD137, OX40, LFA-1, LIGHT, NKG2C, and B7-H3.

41. A group of any of embodiments 1-40 wherein a BS-BDC in the group includes the CDR sequences of OKT3, OKT8, or 9D7.

42. A group of any of embodiments 1-41 wherein a BS-BDC in the group includes the CDR sequences of OKT3, 20G6-F3, 4B4-D7, 4E7-C9, and/or 18F5-H10.

43. A group of embodiment 42 wherein a BS-BDC in the group includes CDR sequences selected from SEQ ID NO: 100; SEQ ID NO: 101; SEQ ID NO: 102; SEQ ID NO: 103; SEQ ID NO: 104; and SEQ ID NO: 105.

44. A group of embodiment 42 or 43 wherein a BS-BDC in the group includes CDR sequences selected from SEQ ID NO: 107; KVS; SEQ ID NO: 109; SEQ ID NO: 110; SEQ ID NO: 111; and SEQ ID NO: 112.

45. A group of any of embodiments 42-44 wherein a BS-BDC in the group includes CDR sequences selected from SEQ ID NO: 113; KVS; SEQ ID NO: 115; SEQ ID NO: 116; SEQ ID NO: 117; and SEQ ID NO: 118.

46. A group of any of embodiments 42-45 wherein a BS-BDC in the group includes CDR sequences selected from SEQ ID NO: 119; KVS; SEQ ID NO: 121; SEQ ID NO: 122; SEQ ID NO: 123; and SEQ ID NO: 124.

47. A group of any of embodiments 42-46 wherein a BS-BDC in the group includes CDR sequences selected from SEQ ID NO: 125; KVS; SEQ ID NO: 127; SEQ ID NO: 128; SEQ ID NO: 129; and SEQ ID NO: 130.

48. A group of any of embodiments 1-47 wherein a BS-BDC in the group includes the CDR sequences of 9D7, 9.3, KOLT-2, 15E8, 248.23.2, EX5.3D10, 5.11A1 and/or TGN1412.

49. A group of embodiment 50 wherein a BS-BDC in the group includes CDR sequences selected from SEQ ID NO: 131; SEQ ID NO: 132; SEQ ID NO: 133; SEQ ID NO: 134; SEQ ID NO: 135;

and SEQ ID NO: 136.

50. A group of any of embodiments 1-49 wherein a BS-BDC in the group includes OKT8.

51. A group of embodiment 50 wherein a BS-BDC in the group includes CDR sequences selected from SEQ ID NO: 226; SEQ ID NO: 227; SEQ ID NO: 228; SEQ ID NO: 229; SEQ ID NO: 230; and SEQ ID NO: 231.

52. A group of any of embodiments 1-51 wherein an immune cell activating epitope is on a natural killer cell.

53. A group of embodiment 52 wherein a BS-BDC in the group includes a variable light chain region of SEQ ID NO: 232 and a variable heavy chain region of SEQ ID NO: 233.

54. A group of any of embodiments 1-53 wherein a BS-BDC in the group includes the CDR sequences of 5C6, 1D11, mAb 33, P44-8, SK1, and/or 3G8.

55. A group of any of embodiments 1-54 wherein an immune cell activating epitope is on a macrophage.

56. A group of embodiment 55 wherein a BS-BDC in the group includes the CDR sequences of M1/70, KP1, and/or ab87099.

57. A group of any of embodiments 1-56 wherein at least one of the immune cell activating epitopes is on an immune cell suppressor.

58. A group of embodiment 57 wherein the immune cell suppressor includes one or more of 4-1BB, PD-1, LAG3, TIM-3, BTLA, CTLA-4, CD200, and VISTA.

59. A group of embodiment 57 or 58 wherein a BS-BDC in the group includes CDR sequences (i) SEQ ID NO: 147; SEQ ID NO: 148; SEQ ID NO: 149; SEQ ID NO: 150; INH; and SEQ ID NO: 152; or (ii) SEQ ID NO: 261; SEQ ID NO: 262; SEQ ID NO: 263; SEQ ID NO: 264; SEQ ID NO: 265; and SEQ ID NO: 266.

60. A group of any of embodiments 57-59 wherein a BS-BDC in the group includes CDR sequences selected from SEQ ID NO: 154; SEQ ID NO: 155; SEQ ID NO: 156; SEQ ID NO: 157; SEQ ID NO: 158; and SEQ ID NO: 159.

61. A group of any of embodiments 57-60 wherein a BS-BDC in the group includes CDR sequences selected from SEQ ID NO: 160; SEQ ID NO: 161; SEQ ID NO: 162; SEQ ID NO: 163; SEQ ID NO: 164; and SEQ ID NO: 165.

62. A group of any of embodiments 57-61 wherein a BS-BDC in the group includes CDR sequences selected from SEQ ID NO: 167; SEQ ID NO: 168; SEQ ID NO: 169; SEQ ID NO: 170; SEQ ID NO: 171; and SEQ ID NO: 172.

63. A group of any of embodiments 57-62 wherein a BS-BDC in the group includes CDR sequences selected from SEQ ID NO: 174; AAS; SEQ ID NO: 176; SEQ ID NO: 177; SEQ ID NO:

178; and SEQ ID NO: 179.

64. A group of any of embodiments 57-63 wherein a BS-BDC in the group includes CDR sequences selected from SEQ ID NO: 181; SEQ ID NO: 182; SEQ ID NO: 183; SEQ ID NO: 184; SEQ ID NO: 185; and SEQ ID NO: 186.

65. A group of any of embodiments 57-64 wherein a BS-BDC in the group includes CDR sequences selected from SEQ ID NO: 187; SEQ ID NO: 188; SEQ ID NO: 189; SEQ ID NO: 190; SEQ ID NO: 191; and SEQ ID NO: 192.

66. A group of any of embodiments 57-65 wherein a BS-BDC in the group includes CDR sequences selected from SEQ ID NO: 194; SEQ ID NO: 195; SEQ ID NO: 196; SEQ ID NO: 197; SEQ ID NO: 198; and SEQ ID NO: 199.

67. A group of any of embodiments 57-66 wherein a BS-BDC in the group includes CDR sequences selected from SEQ ID NO: 200; SEQ ID NO: 201; SEQ ID NO: 202; SEQ ID NO: 203; SEQ ID NO: 204; and SEQ ID NO: 205.

68. A group of any of embodiments 57-67 wherein a BS-BDC in the group includes CDR sequences selected from SEQ ID NO: 206; SEQ ID NO: 207; SEQ ID NO: 208; SEQ ID NO: 209; SEQ ID NO: 210; and SEQ ID NO: 211.

69. A group of any of embodiments 57-68 wherein a BS-BDC in the group includes CDR sequences selected from SEQ ID NO: 213; SEQ ID NO: 214; SEQ ID NO: 215; SEQ ID NO: 216; SEQ ID NO: 217; and SEQ ID NO: 218.

70. A group of any of embodiments 57-69 wherein a BS-BDC in the group includes CDR sequences selected from SEQ ID NO: 220; SEQ ID NO: 221; SEQ ID NO: 222; SEQ ID NO: 223; SAS; and SEQ ID NO: 225.

71. A group of any of embodiments 1-70 wherein the group includes two, three, or four BS-BDC.

72. A group of bi-specific binding domain constructs (BS-BDC) wherein a BS-BDC in the group targets a first ROR1 epitope and CD3 and a second BS-BDC in the group targets a second ROR1 epitope and CD28.

73. A group of bi-specific binding domain constructs (BS-BDC) wherein a BS-BDC in the group targets a ROR1 epitope and CD28 and a second BS-BDC in the group targets CD33 epitope and CD3.

74. A group of bi-specific binding domain constructs (BS-BDC) wherein a BS-BDC in the group targets a ROR1 epitope and CD3 and a second BS-BDC in the group targets CD33 epitope and CD28.

75. A group of bi-specific binding domain constructs (BS-BDC) wherein a BS-BDC in the group targets a CD33 epitope and CD3 and a second BS-BDC in the group targets a PD-L1 epitope and

CD28.

76. A group of bi-specific binding domain constructs (BS-BDC) wherein a BS-BDC in the group targets a CD33 epitope and CD28 and a second BS-BDC in the group targets a PD-L1 epitope and CD3.

77. A group of bi-specific binding domain constructs (BS-BDC) wherein a BS-BDC in the group targets a CD19 epitope and CD3 and a second BS-BDC in the group targets a PD-L1 epitope and CD28.

78. A group of bi-specific binding domain constructs (BS-BDC) wherein a BS-BDC in the group targets a CD19 epitope and CD28 and a second BS-BDC in the group targets a PD-L1 epitope and CD3.

79. A group of bi-specific binding domain constructs (BS-BDC) wherein a BS-BDC in the group targets a CD123 epitope and a CD3 epitope and a second BS-BDC in the group targets a CD123 epitope and a CD28 epitope.

80. A group of bi-specific binding domain constructs (BS-BDC) wherein a BS-BDC in the group targets a CD33 epitope and a CD3 epitope and a second BS-BDC in the group targets a CD123 epitope and a CD28 epitope.

81. A group of any of embodiments 71-80 wherein a BS-BDC that targets CD28 is replaced with a BS-BDC that inhibits an immune cell suppressor epitope.

82. A group of embodiment 81 wherein the immune cell suppressor epitope is located on 4-1BB, PD-1, LAG3, TIM-3, BTLA, CTLA-4, CD200, and/or VISTA.

83. A group of embodiment 81 wherein administration of the group reduces or reverses immune cell suppression in the tumor microenvironment.

84. A group of embodiment 81 wherein administration of the group reduces or reverses T cell suppression in the tumor microenvironment.

85. A group of bi-specific binding domain constructs (BS-BDC) including at least two BS-BDC selected from SEQ ID NO: 238; SEQ ID NO: 239; SEQ ID NO: 240; SEQ ID NO: 241; SEQ ID NO: 242; SEQ ID NO: 243; SEQ ID NO: 244; SEQ ID NO: 245; SEQ ID NO: 246; SEQ ID NO: 247; SEQ ID NO: 248; SEQ ID NO: 249; SEQ ID NO: 250; SEQ ID NO: 251; and SEQ ID NO: 252.

86. A group of bi-specific binding domain constructs (BS-BDC) including three BS-BDC selected from SEQ ID NO: 238; SEQ ID NO: 239; SEQ ID NO: 240; SEQ ID NO: 241; SEQ ID NO: 242; SEQ ID NO: 243; SEQ ID NO: 244; SEQ ID NO: 245; SEQ ID NO: 246; SEQ ID NO: 247; SEQ ID NO: 248; SEQ ID NO: 249; SEQ ID NO: 250; SEQ ID NO: 251; and SEQ ID NO: 252.

87. A group of bi-specific binding domain constructs (BS-BDC) including four BS-BDC selected

from SEQ ID NO: 238; SEQ ID NO: 239; SEQ ID NO: 240; SEQ ID NO: 241; SEQ ID NO: 242; SEQ ID NO: 243; SEQ ID NO: 244; SEQ ID NO: 245; SEQ ID NO: 246; SEQ ID NO: 247; SEQ ID NO: 248; SEQ ID NO: 249; SEQ ID NO: 250; SEQ ID NO: 251; and SEQ ID NO: 252.

88. A group of any of embodiments 1-87 wherein the BS-BDC group includes scFv.

89. A group of any of embodiments 1-88 wherein the BS-BDC group includes bi-specific antibodies.

90. A composition including a group of any of embodiments 1-89.

91. A method of treating cancer in a subject in need thereof including administering a therapeutically amount of a composition of embodiment 90 to a subject, thereby treating the cancer in the subject in need thereof.

92. A method of embodiment 91 wherein the treating overcomes resistance of a cancer cell to a treatment.

93. A method of embodiment 91 or 92 including monitoring the subject for changes in the subject's cancer.

94. A method of any of embodiments 91-93 including administering a composition with a different group of BS-BDC.

95. A method of embodiment 94 wherein the administering the composition with a different group of BS-BDC is based on results of the monitoring.

96. A method of embodiment 95 wherein the results of the monitoring indicate emergence of a clone.

97. A method of embodiment 95 or 96 wherein the results of the monitoring indicate emergence of a treatment resistant clone.

98. A method of any of embodiments 95-97 wherein the results of the monitoring indicate immune suppression in the tumor microenvironment.

99. A method of any of embodiments 95-98 wherein the results of the monitoring indicate T cell suppression in the tumor microenvironment.

100. A use of a group, composition, or method of any of embodiments 1-99 to overcome the resistance of a cancer cell to a treatment.

101. A use of embodiment 100 wherein overcoming resistance is based on reducing or reversing immune suppression in the tumor microenvironment.

102. A use of embodiment 100 or 101 wherein overcoming resistance is based on reducing or reversing T cell suppression in the tumor microenvironment.

103. A use of a group or composition of any of the preceding embodiments to stimulate an immune response in a subject.

104. A method of stimulating an immune response in a subject in need thereof including administering a therapeutically amount of a composition of embodiment 90 to a subject in need thereof, thereby stimulating an immune response in the subject in need thereof.

[0200] Example 1. The Fred Hutchinson Cancer Research Center (FHCRC) Antibody Development Facility and the Molecular Design Therapeutics Core will be used to enable a rational, computational protein design approach for the development and humanization of novel "clinic ready" SMITE antibody therapeutics. A description of the human material used in this research is provided below.

[0201] Healthy donor T-cells: Unstimulated mononuclear cells will be collected from healthy adult volunteers via leukapheresis by the FHCRC Hematopoietic Cell Processing Core under IRB-approved research protocols as used in prior bispecific antibody studies. T-cells will be enriched through magnetic cell sorting, and then frozen in de-identified fashion in aliquots and stored in liquid nitrogen until use. Thawed cell aliquots will be labeled with CellBue Burgundy to allow separation from cancer cells.

[0202] T-cell co-stimulation is required for maximum activity of bispecific T-cell engaging antibodies: Acute leukemia cell lines and genetically engineered sublines were used to test the impact of inhibitory (PD-L1 and PD-L2) and activating (CD80 and CD86) T-cell ligands on the in vitro activity of the CD33/CD3 and CD19/CD3 antibodies, AMG330 and blinatubmomab. Next these experiments were repeated using specimens obtained from acute leukemia patients. The results demonstrated that expression of PD-L1 or PD-L2 reduced the cytolytic activity of bispecific T-cell engaging antibodies, whereas expression of CD80 or CD86 augmented their activity. Consistent with this, co-treatment with an activating antibody directed at the co-stimulatory T-cell receptor, CD28, significantly increased bispecific T-cell engaging antibody-induced cytotoxicity in acute leukemia cell lines. In 12 AML patient specimens, simultaneous activation of CD28 also increased the activity of AMG330 in primary leukemia cells (P=0.023). Together, these findings indicate that T-cell co-receptor activation is required for maximum activity of bispecific T-cell engaging antibodies and suggest that provision of a co-stimulatory signal to T-cells can overcome resistance to these agents. Previous studies from other investigators have indicated that CD3 x CD28 cross-reactive bispecific antibodies may provide a large therapeutic window where only tumor cell dependent T-cell activation is induced and systemic tumor cell independent T-cell activation is avoided.

[0203] In particular embodiments, the SMITE antibody approach requires the concomitant use of two bispecific T-cell engaging antibodies, one directed at CD3 (or CD8) and the other directed at CD28. To relay a maximal activation signal to T-cells, both antibodies need to bind ROR1 in a

time-overlapped fashion. For these studies, well validated, publicly available sequences from three ROR1 antibodies can be used. In the initial antibody set of interest, the ROR1-A antibody (clone: R11) and ROR1-a antibody (clone: 2A2) bind the same epitope and compete with each other for binding to ROR1. The ROR1-B antibody (clone: R12) binds a non-overlapping proximal epitope and can bind ROR1 simultaneously with either one of the other two antibodies. Using the scFvs of these three ROR1 antibodies, as well as scFvs of publicly available antibodies recognizing CD3 (clone: OKT3), CD8 (clone: OKT8) and CD28 (clone: 9D7), bispecific T-cell engaging antibodies will be generated as building blocks with swappable binding modules to form a flexible ROR1-directed SMITE antibody platform (see, e.g., Table 1). All antibodies will be generated as "hisavi" constructs including the 6xhistidine tag for purification and an avitag for specific biotinylation by Bir-A ligase.

[0204] Single-chain constructs targeting ROR1 from the ROR1-A, ROR1-a, and ROR1-B antibodies have been designed as expressed. As evidenced by surface plasmon resonance (SPR) analyses using Biacore chips, these single-chain constructs retain robust affinity for the ROR1 antigen. Using size-exclusion chromatography, single-chain constructs derived from ROR1-A and ROR1-B were then demonstrated to bind simultaneously to ROR1.Subsequently, two bispecific T-cell engaging antibody molecules were designed and successfully expressed. Using 2-liter preps, yields of 22.4mg and 14.4mg were obtained for the aROR1-a/aCD28 and the aROR1-B/aCD3 construct, respectively. In both productions, little aggregation, degradation, or misfolding was observed and the aROR1-B/aCD3 construct was confirmed to bind ROR1, demonstrating successful conversion of antibody sequences into high-quality bispecific T-cell engaging antibodies.

[0205] Experimental approach: Antibody generation: All antibodies will be generated using the customized Daedalus lentiviral transduction system as described previously. Briefly, each construct will be cloned with a cleavable C-terminal 6xHis-Avi tag into a parental expression plasmid (including an IRES-GFP) and co-transfected (along with psPAX2 and pMD2G) into 293T-cells stably expressing the BirA biotin ligase using polyethylenimine (PEI). The resulting lentivirus will be used to transduce suspension-adapted 293F cells, and protein expression will be monitored using GFP. Secreted antibodies will be harvested 2 weeks after transduction and then purified from conditioned media using conventional affinity chromatography. Size-exclusion chromatography and SDS-PAGE will then be used to determine the stability and aggregation tendency of individual molecules.

[0206] Binding of individual bispecific T-cell engaging antibodies to ROR1 captured on SPR biosensors will be quantified on a Biacore T100 instrument (GE Healthcare) as previously

described (see, e.g., Finton et al., Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10. PLoS Pathog. 2013;9(9):e1003639 and Finton et al., Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10. PLoS Pathog. 2014; 10(9):e1004403) and successfully performed on early ROR1 scFvs as summarized above. As reagents are currently not available to allow SPR interaction analyses between bispecific T-cell engaging antibodies and CD3, CD8, or CD28, appropriate target antigen positive/negative cell lines, together with anti-His antibodies, will be used to measure binding of antibody molecules to T-cells using flow cytometry-based assays.

[0207] Cytolytic properties of all bispecific T-cell engaging antibodies will be determined in comparative in vitro assays that have been successfully employed to characterize other bispecific T-cell engaging antibodies. ROR1+ primary tumor cells (JeKo) and transfected cells (K562/ROR1) are available for these studies, and ROR1 expression constructs that permit the generation of additional cell lines if necessary are also available. Appropriate ROR1- cells (e.g. parental K562 cells or MKN45 cells) will serve as negative controls. ROR1+ or ROR1- cell lines will be incubated in 96-well round bottom plates at 5-10,000 cells/well in 225 µL of appropriate culture medium including various concentrations of individual bispecific T-cell engaging antibodies in the presence or absence of healthy donor T-cells added at different E:T-cell ratios. After 48 hours, cell numbers and drug-induced cytotoxicity, using 4',6-diamidino-2-phenylindole (DAPI) to detect non-viable cells, will be determined using a LSRII cytometer. In experiments where healthy donor T-cells are added, cancer cells will be identified by forward/side scatter properties and negativity for CellVue Burgundy dye.

[0208] The generated BS-BDC group, in particular those directed at CD3, will have potent cytolytic properties when used alone. Based on the preliminary findings, however, it is anticipated that the efficacy of bispecific T-cell engaging antibodies can be augmented if they are used in groups such that they also activate T- cell co-stimulatory signaling. It is expected that a combination of CD3- and CD28-directed antibodies will provide the best response, but this modular system allows for determining empirically the best combination of antibodies without limiting the search to an a priori determined set of molecules. These bispecific T-cell engaging antibody groups will also be useful to show that simultaneous targeting of two non-overlapping ROR1 epitopes (while targeting one or two T-cell antigens) provides an advantage over targeting a single ROR1 epitope. Antibody groups with the most favorable biophysical and cytolytic properties will be identified. Next, the selected antibody groups will be humanized. Most antibodies in the clinic today are humanized versions of mouse antibodies. Although the murine

forms of the bispecific T-cell engaging molecules could have utility, immunogenicity can be a liability in clinical development. As humanization is an accepted technology to minimize the formation of neutralizing antibodies, this step is considered essential for their clinical development, and thus will be incorporated into the earliest possible stage of candidate molecule development.

[0209] Experimental approach: Groups of bispecific T-cell engaging antibodies were rationally selected based on specificities for T-cell antigens (e.g. CD3 and CD28 or CD8 and CD28) and non-overlapping ROR1 epitope recognition (e.g. ROR1- A and ROR1-B or ROR1-a and ROR1-B). Besides these groups of potential interest, a few groups that are predicted to be less suited as SMITE antibodies (e.g. ROR1-A and ROR1-a, or CD3 and CD8) will also be tested. Next, these antibody groups will be subjected to analyses of target antigen binding and determination of drug-induced cytotoxicity. Individual antibodies used alone will serve for comparative analyses. In addition, the ability of SMITE antibody constructs to elicit T-cell cytokine release in the presence of ROR1-expressing cells will be assessed in co-culture experiments by ELISA and intracellular flow cytometry. Antibody groups will then be ranked based on biophysical and cytolytic properties, and groups of highest interest will be subjected to antibody humanization, using labor-intensive standard methodologies routinely available in the FHCRC core facility. This approach will primarily be based on Complementary Determining Region (CDR) grafting with mutation of vernier zone residues back to murine as needed to retain binding, with a focus on surface residues, if it is determined that a large number of murine vernier zone residues are needed. The Molecular Therapeutic Core has a 24-well, robotic transduction and expression system well-suited for the generation of the large numbers of candidate molecules.

[0210] Groups of BS-BDC that have better cytolytic properties together than when used individually will be identified. However, it is conceivable that the simultaneous engagement of two bispecific T-cell engaging antibodies requires adjustment of the linker length of at least one of the BS-BDC. Use of a robotic expression facility will allow for several iterations of linker design if necessary.

[0211] Groups of humanized ROR1-directed antibodies will be generated to identify lead candidate molecules that can then be tested in more extensive preclinical studies (e.g. for toxicity properties in large animals) and, ultimately, be brought to the clinic.

[0212] Constructs of interest will be tested for their ability to mediate anti-tumor activity in NSG mice engrafted with human T- cells and firefly luciferase-expressing ROR1+ tumor cells (JeKo and MDA-MB231) that represent hematological (JeKo) and solid tumor (MDA-MB231) cell models. NSG mice will also be used for studies to determine serum half-lives of antibodies of

interest. In these studies, blood will be collected by cardiac puncture at euthanasia and analyzed by mass spectrometry or scintillation counting. These studies will identify lead candidate humanized antibody bispecific T-cell engaging molecule(s) that can be used for further testing.

[0213] Example 2. FIGs. 3A and 3B show that T-cell co-activation with CD28-directed bispecific antibodies is strictly dependent on presence of target antigen-positive cancer cells. In these experiments, ROR1-negative parental K562 cells or K562 cells expressing ROR1 were incubated in wells coated with CD3 antibody (clone OKT3) together with healthy donor T-cells at an E:T ratio of 1:1 with or without a monoclonal CD28 antibody or a ROR1/CD28 antibody as indicated. After 48 hours, T-cell activation was quantified by flow cytometry via determination of cell surface expression of CD69 and CD25. T- cell activation was almost exclusively seen when an activating CD3 antibody was present. In the presence of ROR1-negative cancer cells, T-cell co-activation was possible with an activating CD28 monoclonal antibody but not with ROR1/CD28 antibodies. On the other hand, in the presence of ROR1-positive cancer cells, T-cell co-activation was possible with both a monoclonal CD28 antibody as well as ROR1/CD28 antibodies. Together, these data are consistent with the notion of cancer cell target ("non-specific") T-cell activation when monoclonal CD28 antibodies were used, whereas T-cell co-activation with CD28-directed bispecific T-cell engaging antibodies was as efficient as that seen with a monoclonal CD28 antibody but strictly depended on the presence of target antigen-positive cancer cells.

[0214] FIGs. 4A-4D show that T-cell co-activation with CD28-directed bispecific antibody augments ROR1/CD3 antibody-induced cytotoxicity. K562 cells forced to express ROR1 (K562/ROR1) were incubated with healthy donor T-cells at an E:T ratio of 1:1 in the presence of the ROR1/CD3 antibody MDT319 (including variable domains from the ROR1 antibody, clone 2A2) (4A, 4B) or the ROR1/CD3 antibody MDT320 (including variable domains from the non-cross-reactive ROR1 antibody, clone R12) (4C, 4D) with or without various concentrations of either the ROR1/CD28 antibody MDT347 (including variable domains from the ROR1 antibody, clone R12) (4A, 4C) or a monoclonal CD28 antibody (clone CD28.2) (4B, 4D) as indicated. After 48 hours, cell numbers and drug-induced cytotoxicity were determined. Both ROR1/CD3 antibodies cause dose-dependent cytotoxicity in ROR1-transduced K562 cells. This cytotoxicity can be significantly augmented via co-treatment with either a monoclonal CD28 antibody or a ROR1/CD28 antibody. The magnitude of this augmenting effect is comparable between the monoclonal CD28 antibody and the ROR1/CD28 antibody.

[0215] FIG. 5 shows that T-cell co-activation with CD28-directed bispecific antibodies targeting a second cancer cell antigen can augment anti-cancer activity of therapeutic bispecific T-cell engaging antibody. $CD33^{dim+}$ K562 cells forced to express ROR1 (K562/ROR1) were incubated

with healthy donor T-cells at an E:T ratio of 1:1 in the presence of a CD33/CD3 antibody with or without various concentrations of a ROR1/CD28 antibody (MDT347) as indicated. After 48 hours, cell numbers and drug-induced cytotoxicity were determined. In these K562 cells that only express low levels of CD33, the CD33/CD3 antibody has limited single agent activity. Combination with a second antibody that targets ROR1 and co-activates CD28 synergizes in a dose-dependent fashion with the CD33/CD3 antibody and substantially increases drug-induced cytotoxicity.

[0216] FIGs. 6A-6C show that PD-L1/CD28 antibody can overcome PD-L1-mediated resistance to bispecific antibodies. Parental CD33+ TF-1 cells (6A), CD19+ RCV-ACV cells (6B), or CD19+ REH cells (6C) and corresponding sublines over-expressing PD-L1 were incubated with healthy donor T-cells at an E:T ratio of 1:1 in the presence of a CD33/CD3 or CD19/CD3 antibody as appropriate with or without a PD-L1/CD28 antibody (MDT359) as indicated. After 48 hours, cell numbers and drug-induced cytotoxicity were determined. As demonstrated previously (Laszlo et al, Blood Cancer J 2015), over-expression of PD-L1 leads to relative of resistance of leukemia cells to bispecific antibody-induced cytotoxicity. A PD-L1/CD28 antibody is able to fully overcome this resistance.

[0217] Once lead candidate antibodies have been identified, larger-scale production of clinical-grade antibodies for preclinical safety and initial human clinical trials will be initiated. It is important to note that the Biologics Production Facility at FHCRC, as a current Good Manufacturing Processes (cGMP) laboratory, can generate validated biologics for Phase 1/2 studies. For example, the scFv to CD3, derived from the OKT3 antibody, is the same as the one utilized in blinatumomab, whereas the CD28 antibody that is being derived from scFv sequences has been demonstrated to activate T-cells in vivo.

[0218] Statistical considerations: Predominantly, standard descriptive statistics for paired analyses will be used, which will be performed in consultation with a biostatistician.

[0219] As will be understood by one of ordinary skill in the art, each embodiment disclosed herein can comprise, consist essentially of or consist of its particular stated element, step, ingredient or component. Thus, the terms “include” or “including” should be interpreted to recite: “comprise, consist of, or consist essentially of.” The transition term “comprise” or “comprises” means includes, but is not limited to, and allows for the inclusion of unspecified elements, steps, ingredients, or components, even in major amounts. The transitional phrase “consisting of” excludes any element, step, ingredient or component not specified. The transition phrase “consisting essentially of” limits the scope of the embodiment to the specified elements, steps, ingredients or components and to those that do not materially affect the embodiment. A material

effect would cause a statistically-significant reduction in T cell activation following binding of a BS-BDC group to a cancer cell.

[0220] Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. When further clarity is required, the term "about" has the meaning reasonably ascribed to it by a person skilled in the art when used in conjunction with a stated numerical value or range, i.e. denoting somewhat more or somewhat less than the stated value or range, to within a range of ±20% of the stated value; ±19% of the stated value; ±18% of the stated value; ±17% of the stated value; ±16% of the stated value; ±15% of the stated value; ±14% of the stated value; ±13% of the stated value; ±12% of the stated value; ±11% of the stated value; ±10% of the stated value; ±9% of the stated value; ±8% of the stated value; ±7% of the stated value; ±6% of the stated value; ±5% of the stated value; ±4% of the stated value; ±3% of the stated value; ±2% of the stated value; or ±1% of the stated value.

[0221] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.

[0222] The terms "a," "an," "the" and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No

language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.

[0223] Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.

[0224] Certain embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

[0225] Furthermore, numerous references have been made to patents, printed publications, journal articles and other written text throughout this specification (referenced materials herein). Each of the referenced materials are individually incorporated herein by reference in their entirety for their referenced teaching.

[0226] In closing, it is to be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed are within the scope of the invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described.

[0227] The particulars shown herein are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of various embodiments of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for the fundamental understanding of the invention, the description taken with the drawings and/or examples making apparent to those skilled in the art how the several forms of the invention may

be embodied in practice.

[0228] Definitions and explanations used in the present disclosure are meant and intended to be controlling in any future construction unless clearly and unambiguously modified in the following examples or when application of the meaning renders any construction meaningless or essentially meaningless. In cases where the construction of the term would render it meaningless or essentially meaningless, the definition should be taken from Webster's Dictionary, 3rd Edition or a dictionary known to those of ordinary skill in the art, such as the Oxford Dictionary of Biochemistry and Molecular Biology (Ed. Anthony Smith, Oxford University Press, Oxford, 2004).

CLAIMS

What is claimed is:

1. A group of bi-specific binding domain constructs (BS-BDC) wherein each BS-BDC in the group targets

   (i) a cancer antigen epitope that is non-overlapping and non-repetitive with a cancer antigen epitope targeted by another BS-BDC within the group and

   (ii) an immune cell activating epitope that is non-overlapping and non-repetitive with an immune cell activating epitope targeted by another BS-BDC within the group,

   wherein two of the non-overlapping and non-repetitive cancer antigen epitopes are located on ROR1 and one of the non-overlapping and non-repetitive immune cell activating epitopes is located on CD3 and one of the non-overlapping and non-repetitive immune cell activating epitopes is located on CD28.
2. The group of claim 1 wherein at least one BS-BDC comprises a scFV comprising a CDRL1 CDRL2, CDRL3, CDRH1, CDRH2, and CDRH3 sequence of the R11 antibody.
3. The group of claim 1 wherein at least one BS-BDC comprises a scFV comprising a CDRL1 CDRL2, CDRL3, CDRH1, CDRH2, and CDRH3 sequence of the R12 antibody.
4. The group of claim 1 wherein at least one BS-BDC comprises a scFV comprising a CDRL1 CDRL2, CDRL3, CDRH1, CDRH2, and CDRH3 sequence of the 2A2 antibody.
5. The group of claim 1 wherein at least one BS-BDC comprises a scFV comprising a CDRL1 CDRL2, CDRL3, CDRH1, CDRH2, and CDRH3 sequence of the OKT3 antibody.
6. The group of claim 1 wherein at least one BS-BDC comprises a scFV comprising a CDRL1 CDRL2, CDRL3, CDRH1, CDRH2, and CDRH3 sequence of the 9D7 antibody.
7. The group of claim 1 wherein at least one BS-BDC comprises a scFV comprising a CDRL1 CDRL2, CDRL3, CDRH1, CDRH2, and CDRH3 sequence of the TGN1412 antibody.
8. The group of claim 1 comprising SEQ ID NO: 238.
9. The group of claim 1 comprising SEQ ID NO: 239.
10. The group of claim 1 comprising SEQ ID NO: 240.
11. The group of claim 1 comprising SEQ ID NO: 241.
12. The group of claim 1 comprising SEQ ID NO: 242.
13. The group of claim 1 comprising SEQ ID NO: 243.
14. The group of claim 1 comprising SEQ ID NO: 244.
15. A group of bi-specific binding domain constructs (BS-BDC) wherein each BS-BDC in the group targets a cancer antigen epitope and an immune cell activating epitope that is different from

the cancer antigen epitope and immune cell activating epitope targeted by another BS-BDC in the group, provided that at least two of the cancer antigen epitopes are on the same cancer antigen.

16. The group of claim 15 wherein the different cancer antigen epitopes are non-overlapping and/or non-repetitive.

17. The group of claim 15 wherein all of the different cancer antigen epitopes are on the same cancer antigen.

18. The group of claim 15 wherein the same cancer antigen is ROR1 and the different epitopes are targeted by ROR1-A and ROR1-B or are targeted by ROR1-a and ROR1-B.

19. The group of claim 15 wherein all of the different cancer antigen epitopes are not on the same cancer antigen.

20. The group of claim 15 wherein the BS-BDC group additionally targets different cancer antigen epitopes on different cancer antigens.

21. The group of claim 20 wherein the different cancer antigen epitopes comprise a cancer antigen epitope on a cancer antigen that is different from the cancer antigen with the at least two targeted epitopes.

22. The group of claim 20 wherein

(i) the cancer antigen with at least two targeted epitopes is ROR1 and the different cancer antigen is CD33;

(ii) the cancer antigen with at least two targeted epitopes is CD33 and the different cancer antigen is PD-L1;

(iii) the cancer antigen with at least two targeted epitopes is CD19 and the different cancer antigen is PD-L1; or

(iv) the cancer antigen with at least two targeted epitopes is CD123 and the different cancer antigen is CD33.

23. The group of claim 20 wherein the different cancer antigen epitopes are on:

(i) ROR1 and CD33;

(ii) CD33 and PD-L1;

(iii) CD19 and PD-L1;

(iv) CD123 and CD33;

(v) two or more of CD19, CD20, CD22, ROR1, CD33, CD123, and WT-1;

(vi) two or more of PSMA, WT1, PSCA, and SV40 T;

(vii) two or more of HER2, ERBB2, and ROR1;

(viii) two or more of L1-CAM, MUC-CD, folate receptor, Lewis Y, ROR1, mesothelin, and

WT-1; or

(ix) two or more of mesothelin, CEA, CD24, and ROR1.

24. The group of claim 15 wherein the same cancer antigen is BCMA, CAIX, CD19, CD20, CD22, CD33, CD123, CD133, ERBB2, folate receptor, HER2, Lewis Y, L1-CAM, mesothelin, MUC-CD, PD-L1, PSCA, PSMA, ROR1, SV40 T, or WT-1.

25. The group of claim 15 wherein a BS-BDC in the group comprises VH, VL, and/or the CDR sequences of R11, R12, 2A2, or Y31.

26. The group of claim 15 wherein a BS-BDC in the group comprises VH, VL, and/or the CDR sequences of 8F5, 12B12, 4H10, 11D5, 13E11, 1H7,11D11, or M195.

27. The group of claim 15 wherein the different immune cell activating epitopes are on different T cell activators.

28. The group of claim 27 wherein the different T cell activators are: CD3 and CD28; CD3 and CD8; or CD8 and CD28.

29. The group of claim 15 wherein a BS-BDC in the group comprises CDR sequences of OKT3, OKT8, or 9D7.

30. The group of claim 15 wherein the group comprises no more than four BS-BDC.

31. The group of claim 15 wherein the group comprises: a BS-BDC that targets a first ROR1 epitope and CD3; and a BS-BDC that targets a second ROR1 epitope and CD28.

32. The group of claim 15 wherein the group comprises: a BS-BDC that targets ROR1 and CD28; and a BS-BDC that targets CD33 and CD3.

33. The group of claim 15 wherein the group comprises: a BS-BDC that targets CD33 and CD3; and a BS-BDC that targets PD-L1 and CD28.

34. The group of claim 15 wherein the group comprises: a BS-BDC that targets CD19 and CD3; and a BS-BDC that targets PD-L1 and CD28.

35. The group of claim 15 wherein the group comprises: a BS-BDC that targets a first epitope of CD123 and CD3; and a BS-BDC that targets a second epitope of CD123 and CD28.

36. The group of claim 15 wherein the group comprises: a BS-BDC that targets CD33 and CD3; and a BS-BDC that targets CD123 and CD28.

37. The group of claim 15 wherein the different cancer antigen epitopes are on ROR1, CD33, CD19, PD-L1, and/or CD123.

38. The group of claim 15 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; and SEQ ID NO: 17.

39. The group of claim 15 wherein a BS-BDC in the group comprises CDR sequences selected

from SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; and SEQ ID NO: 23.

40. The group claim 15 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; and SEQ ID NO: 29.

41. The group of claim 15 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 32; SEQ ID NO: 33; SEQ ID NO: 34; and SEQ ID NO: 35.

42. The group of claim 15 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 36; SEQ ID NO: 37; SEQ ID NO: 38; SEQ ID NO: 39; SEQ ID NO: 40; and SEQ ID NO: 41.

43. The group of claim 15 wherein a BS-BDC in the group comprises CDR sequences of FMC63, SJ25C1, and/or HD37.

44. The group of claim 15 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 42; SEQ ID NO: 43; SEQ ID NO: 44; SEQ ID NO: 45; SEQ ID NO: 46; and SEQ ID NO: 47.

45. The group of claim 15 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 48; SEQ ID NO: 49; SEQ ID NO: 50; SEQ ID NO: 51; SEQ ID NO: 52; and SEQ ID NO: 53.

46. The group of claim 15 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 54; SEQ ID NO: 55; SEQ ID NO: 56; SEQ ID NO: 57; SEQ ID NO: 58; and SEQ ID NO: 59.

47. The group of claim 15 wherein a BS-BDC in the group comprises CDR sequences of Rituximab, Ofatumumab, and/or Herceptin.

48. The group of claim 15 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 82; SEQ ID NO: 83; SEQ ID NO: 84; SEQ ID NO: 85; SEQ ID NO: 86; and SEQ ID NO: 87.

49. The group of claim 15 wherein a BS-BDC in the group comprises CDR sequences (i) SEQ ID NO: 267; SEQ ID NO: 268; SEQ ID NO: 269; SEQ ID NO: 270; SEQ ID NO: 271; and SEQ ID NO: 272; or (ii) SEQ ID NO: 273; SEQ ID NO: 274; SEQ ID NO: 275; SEQ ID NO: 276; SEQ ID NO: 277; and SEQ ID NO: 259.

50. The group of claim 15 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 88; SEQ ID NO: 89; SEQ ID NO: 90; SEQ ID NO: 91; SEQ ID NO: 92; and SEQ ID NO: 93.

51. The group of claim 15 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 94; SEQ ID NO: 95; SEQ ID NO: 96; SEQ ID NO: 97; SEQ ID NO: 98; and SEQ ID NO: 99.

52. The group of claim 15 wherein a BS-BDC in the group targets CD33, wherein the CD33 is (i) full length CD33 ($CD33^{FL}$), (ii) only the splice variant of CD33 that lacks exon 2 ($CD33^{\Delta E2}$); or (iii) CD33 regardless of whether it is $CD33^{FL}$ or $CD33^{\Delta E2}$.

53. The group of claim 15 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 76; SEQ ID NO: 77; SEQ ID NO: 78; SEQ ID NO: 79; SEQ ID NO: 80; and SEQ ID NO: 81.

54. The group of claim 15 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 253; SEQ ID NO: 254; SEQ ID NO: 255; SEQ ID NO: 256; SEQ ID NO: 257; and SEQ ID NO: 258.

55. The group of claim 15 wherein a BS-BDC in the group comprises a V_L and a V_H chain of 5D12, 85F, 12B12, 4H10, 11D5, 13E11, 1H7, 11D11, or M195.

56. The group of claim 15 wherein a BS-BDC in the group comprises CDR sequences from a V_L and a V_H chain of 5D12, 85F, 12B12, 4H10, 11D5, 13E11, 1H7, 11D11, or M195.

57. A group of bi-specific binding domain constructs (BS-BDC) wherein each BS-BDC in the group targets

(i) a cancer antigen epitope that is non-overlapping and non-repetitive with a cancer antigen epitope targeted by another BS-BDC within the group and

(ii) an immune cell activating epitope that is non-overlapping and non-repetitive with an immune cell activating epitope targeted by another BS-BDC within the group,

wherein two of the non-overlapping and non-repetitive cancer antigen epitopes are located on CD33 and two of the non-overlapping and non-repetitive immune cell activating epitopes are located on CD3 and one or more of 4-1BB, PD-1, LAG3, TIM-3, BTLA, CTLA-4, CD200, or VISTA.

58. The group of claim 57 wherein the immune cell is a T cell, natural killer cell, or macrophage.

59. The group of claim 57 wherein the different immune cell activating epitopes are on the same immune cell activator.

60. The group of claim 57 wherein the different immune cell activating epitopes are on the different immune cell activators.

61. The group of claim 57 wherein the different immune cell activating epitopes are on the same immune cell activator and on different immune cell activators.

62. The group of claim 57 wherein at least one of the immune cell activating epitopes is on a T

cell.

63. The group of claim 61 wherein the same immune cell activator is CD3 and the different epitopes are on different invariant proteins comprising the T cell CD3 dimer.

64. The group of claim 57 wherein the different immune cell activating epitopes are on: CD3 and CD28; CD3 and CD8; or CD8 and CD28.

65. The group of claim 57 wherein the different immune cell activating epitopes are on CD3, CD8, and CD28.

66. The group of claim 57 wherein the different immune cell activating epitopes are on CD3, CD28, and CD137.

67. The group of claim 57 wherein the different immune cell activating epitopes are on (i) CD3, (ii) CD3, and (iii) CD28.

68. The group of claim 57 wherein the different immune cell activating epitopes are on (i) CD28, (ii) CD28, and (iii) CD3.

69. The group of claim 57 wherein the different immune cell activating epitopes are on one or more of CD2, CD3, CD7, CD27, CD28, CD30, CD40, CD83, CD137, OX40, LFA-1, LIGHT, NKG2C, and B7-H3.

70. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences of OKT3, OKT8, 9D7, or Hu26B.

71. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences of OKT3, 20G6-F3, 4B4-D7, 4E7-C9, and/or 18F5-H10.

72. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 100; SEQ ID NO: 101; SEQ ID NO: 102; SEQ ID NO: 103; SEQ ID NO: 104; and SEQ ID NO: 105.

73. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 107; KVS; SEQ ID NO: 109; SEQ ID NO: 110; SEQ ID NO: 111; and SEQ ID NO: 112.

74. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 113; KVS; SEQ ID NO: 115; SEQ ID NO: 116; SEQ ID NO: 117; and SEQ ID NO: 118.

75. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 119; KVS; SEQ ID NO: 121; SEQ ID NO: 122; SEQ ID NO: 123; and SEQ ID NO: 124.

76. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 125; KVS; SEQ ID NO: 127; SEQ ID NO: 128; SEQ ID NO: 129; and

SEQ ID NO: 130.

77. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences of 9D7, 9.3, KOLT-2, 15E8, 248.23.2, EX5.3D10, and/or 5.11A1.

78. The group of claim 57 wherein a BS-BDC in the group comprises OKT8.

79. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 226; SEQ ID NO: 227; SEQ ID NO: 228; SEQ ID NO: 229; SEQ ID NO: 230; and SEQ ID NO: 231.

80. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 261; SEQ ID NO: 262; SEQ ID NO: 263; SEQ ID NO: 264; SEQ ID NO: 265; and SEQ ID NO: 266.

81. The group of claim 57 wherein at least one of the immune cell activating epitopes is on a natural killer cell.

82. The group of claim 81 wherein a BS-BDC in the group comprises CDR sequences of 5C6, 1D11, mAb 33, P44-8, SK1, and/or 3G8.

83. The group of claim 81 wherein a BS-BDC in the group comprises a variable light chain region of SEQ ID NO: 232 and a variable heavy chain region of SEQ ID NO: 233.

84. The group of claim 57 wherein an immune cell activating epitope is on a macrophage.

85. The group of claim 84 wherein a BS-BDC in the group comprises CDR sequences of M1/70, KP1, and/or ab87099.

86. The group of claim 15 or 57 wherein at least one of the immune cell activating epitopes is on an immune cell suppressor.

87. The group of claim 85 wherein the immune cell suppressor comprises one or more of 4-1BB, PD-1, LAG3, TIM-3, BTLA, CTLA-4, CD200, and VISTA.

88. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 261; SEQ ID NO: 262; SEQ ID NO: 263; SEQ ID NO: 264; SEQ ID NO: 265; and SEQ ID NO: 266.

89. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 147; SEQ ID NO: 148; SEQ ID NO: 149; SEQ ID NO: 150; INH; and SEQ ID NO: 152.

90. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 154; SEQ ID NO: 155; SEQ ID NO: 156; SEQ ID NO: 157; SEQ ID NO: 158; and SEQ ID NO: 159.

91. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 160; SEQ ID NO: 161; SEQ ID NO: 162; SEQ ID NO: 163; SEQ ID

NO: 164; and SEQ ID NO: 165.

92. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 167; SEQ ID NO: 168; SEQ ID NO: 169; SEQ ID NO: 170; SEQ ID NO: 171; and SEQ ID NO: 172.

93. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 174; AAS; SEQ ID NO: 176; SEQ ID NO: 177; SEQ ID NO: 178; and SEQ ID NO: 179.

94. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 181; SEQ ID NO: 182; SEQ ID NO: 183; SEQ ID NO: 184; SEQ ID NO: 185; and SEQ ID NO: 186.

95. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 187; SEQ ID NO: 188; SEQ ID NO: 189; SEQ ID NO: 190; SEQ ID NO: 191; and SEQ ID NO: 192.

96. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from; SEQ ID NO: 194; SEQ ID NO: 195; SEQ ID NO: 196; SEQ ID NO: 197; SEQ ID NO: 198 and SEQ ID NO: 199.

97. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 200; SEQ ID NO: 201; SEQ ID NO: 202; SEQ ID NO: 203; SEQ ID NO: 204; and SEQ ID NO: 205.

98. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 206; SEQ ID NO: 207; SEQ ID NO: 208; SEQ ID NO: 209; SEQ ID NO: 210; and SEQ ID NO: 211.

99. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 213; SEQ ID NO: 214; SEQ ID NO: 215; SEQ ID NO: 216; SEQ ID NO: 217; and SEQ ID NO: 218.

100. The group of claim 15 or 57 wherein a BS-BDC in the group comprises CDR sequences selected from SEQ ID NO: 220; SEQ ID NO: 221; SEQ ID NO: 222; SEQ ID NO: 223; SAS; and SEQ ID NO: 225.

101. The group of claim 15 or 57 wherein the group includes two, three, or four BS-BDC.

102. A group of bi-specific binding domain constructs (BS-BDC) comprising at least two BS-BDC selected from SEQ ID NO: 238; SEQ ID NO: 239; SEQ ID NO: 240; SEQ ID NO: 241; SEQ ID NO: 242; SEQ ID NO: 243; SEQ ID NO: 244; SEQ ID NO: 245; SEQ ID NO: 246; SEQ ID NO: 247; SEQ ID NO: 248; SEQ ID NO: 249; SEQ ID NO: 250; SEQ ID NO: 251; and SEQ ID NO: 252.

103. A group of bi-specific binding domain constructs (BS-BDC) comprising three BS-BDC selected from SEQ ID NO: 238; SEQ ID NO: 239; SEQ ID NO: 240; SEQ ID NO: 241; SEQ ID NO: 242; SEQ ID NO: 243; SEQ ID NO: 244; SEQ ID NO: 245; SEQ ID NO: 246; SEQ ID NO: 247; SEQ ID NO: 248; SEQ ID NO: 249; SEQ ID NO: 250; SEQ ID NO: 251; and SEQ ID NO: 252.

104. A group of bi-specific binding domain constructs (BS-BDC) comprising four BS-BDC selected from SEQ ID NO: 238; SEQ ID NO: 239; SEQ ID NO: 240; SEQ ID NO: 241; SEQ ID NO: 242; SEQ ID NO: 243; SEQ ID NO: 244; SEQ ID NO: 245; SEQ ID NO: 246; SEQ ID NO: 247; SEQ ID NO: 248; SEQ ID NO: 249; SEQ ID NO: 250; SEQ ID NO: 251 and SEQ ID NO: 252.

105. The group of claim 15, 57, or 102 wherein the BS-BDC are scFv.

106. A composition comprising a group of claim 15, 57, or 102.

107. A method of treating cancer in a subject in need thereof comprising administering a therapeutically amount of a composition of claim 106 to a subject in need thereof, thereby treating the cancer in the subject in need thereof.

108. The method of claim 107 wherein the treating overcomes resistance of a cancer cell to a treatment.

109. The method of claim 107 comprising monitoring the subject for changes in the subject's cancer.

110. The method of claim 107 comprising administering a composition with a different group of BS-BDC.

111. The method of claim 110 comprising administering a composition with a different group of BS-BDC wherein the administering the composition with a different group of BS-BDC is based on results of the monitoring.

112. The method of claim 111 wherein the results of the monitoring indicate emergence of a clone.

113. The method of claim 111 wherein the results of the monitoring indicate emergence of a treatment resistant clone.

114. The method of claim 111 wherein the results of the monitoring indicate immune suppression in the tumor microenvironment.

115. The method of claim 111 wherein the results of the monitoring indicate T cell suppression in the tumor microenvironment.

116. A method of stimulating an immune response in a subject in need thereof comprising administering a therapeutically amount of a composition of claim 106 to a subject in need thereof,

thereby stimulating an immune response in the subject in need thereof.

FIG. 1A



T-CELL
CANCER CELL
CD3
COSTIMULATION
ROR1
CD28
BISPECIFIC SMITE Antibodies
anti-ROR1 epitope 1
anti-CD3
anti-ROR1 epitope 2
anti-CD28

FIG. 1B



V_H -Cancer Antigen Epitope
V_L -Cancer Antigen Epitope
V_H -Immune Activating Epitope
V_L-Immune Activating Epitope
leader
Linker A
Linker B
Linker A
Myc
His

FIG. 2



CD33+ AML Cell Lines
%Specific Cytotoxicity
ML-1
TF-1
CD19+ ALL Cell Lines
%Specific Cytotoxicity
RCH-ACV
REH
RS 4:11
Control
+CD28 Antibody

FIG. 3A



No CD3 Antibody
5ug/ml CD3 Antibody
ROR1 +
ROR1 +
CD69 Expression
% Increase Over Control
100
80
60
40
20
0
no Ab
CD28 MoAb
ROR1/CD28 (MDT346)
ROR1/CD28 (MDT 347)
TREATMENT

FIG. 3B



No CD3 Antibody
5ug/ml CD3 Antibody
ROR1 +
ROR1 +
CD25 Expression
% Increase Over Control
100
80
60
40
20
0
no Ab
CD28 MoAb
ROR1/CD28 (MDT346)
ROR1/CD28 (MDT 347)
TREATMENT

FIG. 4A



K562/ROR1
Δ DAPI+ Cells (%)
50
40
30
20
10
0
0
10
100
1000
ROR1/CD3 (MDT319; ng/mL)
No CD28 BiTE
ROR1/CD28 (10 ng/mL)
ROR1/CD28 (100 ng/mL)
ROR1/CD28 (1000 ng/mL)
n=3

FIG. 4B



K562/ROR1
Δ DAPI+ Cells (%)
60
45
30
15
0
0
10
100
1000
ROR1/CD3 (MDT319; ng/mL)
No Anti-CD28 Antibody
Anti-CD28 Ab (0.1ug/ml)
Anti-CD28 Ab (1.0 ug/ml)
Anti-CD28 Ab (2.5 ug/ml)
n=3

FIG. 4C



K562/ROR1
Δ DAPI+ Cells (%)
60
45
30
15
0
0
10
100
1000
n=3
ROR1/CD3 (MDT320; ng/mL)
No CD28 BiTE
ROR1/CD28 (10 ng/mL)
ROR1/CD28 (100 ng/mL)
ROR1/CD28 (1000 ng/mL)

FIG. 4D



K562/ROR1
Δ DAPI+ cells (%)
60
45
30
15
0
0
10
100
1000
ROR1/CD3 (MDT320; ng/mL)
No CD28 MoAb
CD28 MoAb (0.1 µg/mL)
CD28 MoAb (1.0 µg/mL)
CD28 MoAb (2.5 µg/mL)

FIG. 5



K562/ROR1 cells
Δ DAPI+ Cells (%)
20
15
10
5
0
0
100
500
2500
CD33/CD3 BiTE (pg/ml)
No ROR1/CD28
ROR1/CD28 (MDT347) .01 ng/ml
ROR1/CD28 (MDT347) 0.1 ng/ml
ROR1/CD28 (MDT347) 1 ng/ml
ROR1/CD28 (MDT347) 10 ng/ml
ROR1/CD28 (MDT347) 100 ng/ml

FIG. 6A




FIG. 6B




FIG. 6C




FIG. 7



NF-kB activation (avg of 2 wells)
0
2
4
No Treatment
2.0ug/mL OKT3
1.0ug/mL OKT3 + 2.0ug/mL CD28
OKT3 + 2A2-CD28
OKT3 + R11-CD28
OKT3 + R12-CD28
OKT3 + PDL1-CD28
R11-CD3
R11-CD3 + 2A2-CD28
R11-CD3 + 2A2-CD28 + ROR1
R11-CD3 + CD28
2A2-CD3
2A2-CD3 + R11-CD28
2A2-CD3 + R11-CD28 + ROR1
2A2-CD3 + CD28
R12-CD3
R12-CD3 + R11-CD28
R12-CD3 + R11-CD28 + ROR1
R12-CD3 + CD28
R11-CD3
R11-CD3 + 2A2-CD28
R11-CD3 + 2A2-CD28 + ROR1
R11-CD3 + R12-CD28
R11-CD3 + R12-CD28 + ROR1
R11-CD3 + CD28

FIG. 8

MDT000444
Ab_CD33_5D12_mmIgG2a_LC
Ab Specificity: FL
IgG2a
METDTLLLWVLLLWVPGSTGDIKMTQSPSSIYASLGERVTINCKASQDIKSYLSWYQQKPWKSPKTLIYYA
TTLADGVPSRFSGSGSGQDYSLTISSLESDDTATYYCLHHGESPWTFGEGTKLEIKRADAAPTVSIFPPSS
EQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNS
YTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 60)

MDT000445
Ab_CD33_5D12_mmIgG2a_HC
Ab Specificity: FL
IgG2a
METDTLLLWVLLLWVPGSTGQVQLQQSGAEVVKPGASVKISCRASGYAFSNYWMNWVKQRPGKGLEWI
GQIYPGNFNTDYNGQFKGKATLTVDKSSNTAYMQLSSLTSEDSAVYFCARFFDFGAYFTLDYWGQGTSV
TVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSS
SVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISL
SPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVN
NKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNT
EPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 61)

MDT000446
Ab_CD33_8F5_mmIgG2a_LC
Ab Specificity: FL
IgG2a
METDTLLLWVLLLWVPGSTGDIVMSQSPSSLPVSVGEKVTLSCKSSQSLLYSRNQYNFLAWYQQRPGQS
PKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPYTFGGGTKLEIKRADAAPT
VSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKD
EYERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 62)

MDT000447
Ab_CD33_8F5_mmIgG2a_HC
Ab Specificity: FL
IgG2a
METDTLLLWVLLLWVPGSTGEVKLVESGGGLVQPGGSLKLSCAASGFTFSDFYMYWVRQTPEKRLEWV
AFISNAGVTTYYPDTVEGRFTISRDNAKNTLYLQMSRLMSEDTAMYYCTKSDYDGAWFPYWGQGTLVTV
SAAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSV
TVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPI
VTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNK
DLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEP
VLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO: 63)

FIG. 8 (cont'd)

MDT000448
Ab_CD33_12B12_mmIgG2b_LC
Ab Specificity: ΔE2
IgG2b
METDTLLLWVLLLWVPGSTGDIVMTQAAFSNPVTLGTSASISCRSSQSLLHSNGITYLYWYLQKPGQSPQ
LLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGGGTKLEIKRADAAPTVS
IFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY
ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 64)

MDT000449
Ab_CD33_12B12_mmIgG2b_HC
Ab Specificity: ΔE2
IgG2b
METDTLLLWVLLLWVPGSTGEVQLQQSGTVLARPGASVKMSCKASGYTFTTYWMHWIKQSPGQGLEWI
GAIYPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCEIYDGYHFIYWGQGTTLTVSSA
KTTPPSVYPLAPGCGDTTGSSVTLGCLVKGYFPESVTVTWNSGSLSSSVHTFPALLQSGLYTMSSSVTV
PSSTWPSQTVTCSVAHPASSTTVDKKLEPSGPISTINPCPPCKECHKCPAPNLEGGPSVFIFPPNIKDVLM
ISLTPKVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTIRVVSTLPIQHQDWMSGKEFKCK
VNNKDLPSPIERTISKIKGLVRAPQVYILPPPAEQLSRKDVSLTCLVVGFNPGDISVEWTSNGHTEENYKD
TAPVLDSDGSYFIYSKLNMKTSKWEKTDSFSCNVRHEGLKNYYLKKTISRSPGK (SEQ ID NO: 65)

MDT000492
Ab_CD33_4H10_mmIgG1_Light Chain
Ab Specificity: ΔE2
IgG2a
METDTLLLWVLLLWVPGSTGDVVMTQTPLTLSVTIGQPASISCKSSQSLLYSNGKTYLHWFLQRPGQSPK
RLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCVQGTHFPRTFGGGTKLEIKADAAPTVSI
FPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEY
ERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 66)

MDT000491
Ab_CD33_4H10_mmIgG1_Heavy Chain
Ab Specificity: ΔE2
IgG2a
METDTLLLWVLLLWVPGSTGQVQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLEWI
GVIHPGNNSTSYNAKFRGKATLTADRSSSTAYMQLSSLTSEDSAVYFCARYGYDERNAMDYWGQGTSV
TVSSAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLS
SSVTVPSSPRPSETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVT
CVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAF
PAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMN
TNGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK (SEQ ID NO: 67)

FIG. 8 (cont'd)

MDT000494
Ab_CD33_11D5_mmIgG1_Light Chain
Ab Specificity: ΔE2
IgG1
METDTLLLWVLLLWVPGSTGDIVMTQAAFSNPVTLGTSASISCRSNKSLLHSNGITYLYWYLQKPGQSPQLLI
YQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGGGTKLEIKRADAAPTVSIFPP
SSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNS
YTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 68)

MDT000493
Ab_CD33_11D5_mmIgG1_Heavy Chain
Ab Specificity: ΔE2
IgG1
METDTLLLWVLLLWVPGSTGEVQFQQSETVLARPGTSVKLSCKASGYTFTSYWMHWLKQRPGQGLEWIGA
IYCGNSDTSYNQKFKGKAKLTAVTSATTAYMELSSLTNEDSAVYYCKIYDGYHFDYWGQGTTLTVSSAKTTP
PSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSPRP
SETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEV
QFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPK
APQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMNTNGSYFVYSKLNVQKS
NWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK (SEQ ID NO: 69)

MDT000499
Ab_CD33_13E11_mmIgG1_Light Chain
Ab Specificity: ΔE2
IgG1
METDTLLLWVLLLWVPGSTGDIVLTQSPVSLAVSLGQRATISCKASHGVEYAGAHYMNWYQQKPGQPPKLLI
YAASNLGSGTDFTLNIHPVEEEDSATYYCQQSNEDPRTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGAS
VVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTST
SPIVKSFNRNEC (SEQ ID NO: 70)

MDT000498
Ab_CD33_13E11_mmIgG1_Heavy Chain
Ab Specificity: ΔE2
IgG1
METDTLLLWVLLLWVPGSTGKVQLQQSGAELVKPGASVKLSCKASGYTFTDYTLHWLKQRSGQGLEWIGW
FYPTSGSINYNERFKDKATLTADKSSSTVYMELSRLTSVDSAVYFCARHKFGFDYWGQGTTLTVSSAKTTPP
SVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSPRPS
ETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQ
FSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAP
QVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMNTNGSYFVYSKLNVQKSNW
EAGNTFTCSVLHEGLHNHHTEKSLSHSPGK (SEQ ID NO: 71)

FIG. 8 (cont'd)

MDT000551
Ab_CD33_1H7_mmIgG1_Light Chain
Ab Specificity: FL and ΔE2
IgG1
METDTLLLWVLLLWVPGSTGDIQMTQTTSSLSASLGDRVTISCRASQDINYYLNWYQQKPDGTVKLL
IYYSSRLHSGVPSRFSGSGSGTDFSLTISNLEQEDIATYFCQQDDALPYTFGGGTKLEIKRADAAPTV
SIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTL
TKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 72)

MDT000552
Ab_CD33_1H7_mmIgG1_Heavy Chain
Ab Specificity: FL and ΔE2
IgG1
METDTLLLWVLLLWVPGSTGQVQLQQSGAELVKPGASVKISCKASGYAFSNYWMNWVKQRPGKG
LEWIGQINPGDGDTNYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCAREDRDYFDYWGQ
GTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQ
SDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIF
PPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQ
DWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDI
YVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFS
RTPGK (SEQ ID NO: 73)

MDT000553
Ab_CD33_11D11_mmIgG1_Light Chain
Ab Specificity: ΔE2
IgG2a
METDTLLLWVLLLWVPGSTGDIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLL
IYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGSTLPPTFGGGTKLEIKRADAAPTV
SIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTL
TKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 74)

MDT000554
Ab_CD33_11D11_mmIgG1_Heavy Chain
Ab Specificity: ΔE2
IgG2a
METDTLLLWVLLLWVPGSTGEVNLVESGGGLVQSGRSLRLSCATSGFTFSDFYMEWVRQAPGKGL
EWIAASRNKANDYTTEYKASVKGRFIVSRDTSQSILYLQMNALRAEDTAIYYCTRDTGPMDYWGQG
TSVTVSSAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQS
DLYTLSSSVTVPSSPRPSETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPKPKDV
LTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGK
EFKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWN
GQPAENYKNTQPIMNTNGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK
(SEQ ID NO: 75)

FIG. 8 (cont'd)

CD80
MGHTRRQGTSPSKCPYLNFFQLLVLAGLSHFCSGVIHVTKEVKEVATLSCGHNVSVEELAQT
RIYWQKEKKMVLTMMSGDMNIWPEYKNRTIFDITNNLSIVILALRPSDEGTYECVVLKYEKDAF
KREHLAEVTLSVKADFPTPSISDFEIPTSNIRRIICSTSGGFPEPHLSWLENGEELNAINTTVSQ
DPETELYAVSSKLDFNMTTNHSFMCLIKYGHLRVNQTFNWNTTKQEHFPDNLLPSWAITLISV
NGIFVICCLTYCFAPRCRERRRNERLRRESVRPV (SEQ ID NO: 137)

CD86
MDPQCTMGLSNILFVMAFLLSGAAPLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQEN
LVLNEVYLGKEKFDSVHSKYMGRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQ
MNSELSVLANFSQPEIVPISNITENVYINLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGVMQKSQ
DNVTELYDVSISLSVSFPDVTSNMTIFCILETDKTRLLSSPFSIELEDPQPPPDHIPWITAVLPTVI
ICVMVFCLILWKWKKKRPRNSYKCGTNTMEREESEQTKKREKIHIPERSDEAQRVFKSSKTS
SCDKSDTCF (SEQ ID NO: 138)

TLR2
MPHTLWMVWVLGVIISLSKEESSNQASLSCDRNGICKGSSGSLNSIPSGLTEAVKSLDLSNNR
ITYISNSDLQRCVNLQALVLTSNGINTIEEDSFSSLGSLEHLDLSYNYLSNLSSSWFKPLSSLTF
LNLLGNPYKTLGETSLFSHLTKLQILRVGNMDTFTKIQRKDFAGLTFLEELEIDASDLQSYEPKS
LKSIQNVSHLILHMKQHILLLEIFVDVTSSVECLELRDTDLDTFHFSELSTGETNSLIKKFTFRNV
KITDESLFQVMKLLNQISGLLELEFDDCTLNGVGNFRASDNDRVIDPGKVETLTIRRLHIPRFYL
FYDLSTLYSLTERVKRITVENSKVFLVPCLLSQHLKSLEYLDLSENLMVEEYLKNSACEDAWPS
LQTLILRQNHLASLEKTGETLLTLKNLTNIDISKNSFHSMPETCQWPEKMKYLNLSSTRIHSVTG
CIPKTLEILDVSNNNLNLFSLNLPQLKELYISRNKLMTLPDASLLPMLLVLKISRNAITTFSKEQLD
SFHTLKTLEAGGNNFICSCEFLSFTQEQQALAKVLIDWPANYLCDSPSHVRGQQVQDVRLSV
SECHRTALVSGMCCALFLLILLTGVLCHRFHGLWYMKMMWAWLQAKRKPRKAPSRNICYDA
FVSYSERDAYWVENLMVQELENFNPPFKLCLHKRDFIPGKWIIDNIIDSIEKSHKTVFVLSENFV
KSEWCKYELDFSHFRLFDENNDAAILILLEPIEKKAIPQRFCKLRKIMNTKTYLEWPMDEAQRE
GFWVNLRAAIKS (SEQ ID NO: 145)

4-1BB
MGNSCYNIVATLLLVLNFERTRSLQDPCSNCPAGTFCDNNRNQICSPCPPNSFSSAGGQR
TCDICRQCKGVFRTRKECSSTSNAECDCTPGFHCLGAGCSMCEQDCKQGQELTKKGCKDC
CFGTFNDQKRGICRPWTNCSLDGKSVLVNGTKERDVVCGPSPADLSPGASSVTPPAPARE
PGHSPQIISFFLALTSTALLFLLFFLTLRFSVVKRGRKKLLYIFKQPFMRPVQTTQEEDG
CSCRFPEEEEGGCEL (SEQ ID NO: 146)

PD-1
MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTS
ESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGT
YLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQTLVVGVVGGLLGSLVL
LVWVLAVICSRAARGTIGARRTGQPLKEDPSAVPVFSVDYGELDFQWREKTPEPPVPCVPEQ
TEYATIVFPSGMGTSSPARRGSADGPRSAQPLRPEDGHCSWPL (SEQ ID NO: 153)

FIG. 8 (cont'd)

LAG3
MWEAQFLGLLFLQPLWVAPVKPLQPGAEVPVVWAQEGAPAQLPCSPTIPLQDLSLLRRA
GVTWQHQPDSGPPAAAPGHPLAPGPHPAAPSSWGPRPRRYTVLSVGPGGLRSGRLPLQ
PRVQLDERGRQRGDFSLWLRPARRADAGEYRAAVHLRDRALSCRLRLRLGQASMTASP
PGSLRASDWVILNCSFSRPDRPASVHWFRNRGQGRVPVRESPHHHLAESFLFLPQVSPM
DSGPWGCILTYRDGFNVSIMYNLTVLGLEPPTPLTVYAGAGSRVGLPCRLPAGVGTRSFL
TAKWTPPGGGPDLLVTGDNGDFTLRLEDVSQAQAGTYTCHIHLQEQQLNATVTLAIITVTP
KSFGSPGSLGKLLCEVTPVSGQERFVWSSLDTPSQRSFSGPWLEAQEAQLLSQPWQCQ
LYQGERLLGAAVYFTELSSPGAQRSGRAPGALPAGHLLLFLILGVLSLLLLVTGAFGFHLW
RRQWRPRRFSALEQGIHPPQAQSKIEELEQEPEPEPEPEPEPEPEPEPEQL (SEQ ID NO:
166)

TIM-3
MFSHLPFDCVLLLLLLLLTRSSEVEYRAEVGQNAYLPCFYTPAAPGNLVPVCWGKGACPV
FECGNVVLRTDERDVNYWTSRYWLNGDFRKGDVSLTIENVTLADSGIYCCRIQIPGIMNDE
KFNLKLVIKPAKVTPAPTRQRDFTAAFPRMLTTRGHGPAETQTLGSLPDINLTQISTLANEL
RDSRLANDLRDSGATIRIGIYIGAGICAGLALALIFGALIFKWYSHSKEKIQNLSLISLANLPPS
GLANAVAEGIRSEENIYTIEENVYEVEEPNEYYCYVSSRQQPSQPLGCRFAMP (SEQ ID
NO: 173)

BTLA
MKTLPAMLGTGKLFWVFFLIPYLDIWNIHGKESCDVQLYIKRQSEHSILAGDPFELECPVKY
CANRPHVTWCKLNGTTCVKLEDRQTSWKEEKNISFFILHFEPVLPNDNGSYRCSANFQSN
LIESHSTTLYVTDVKSASERPSKDEMASRPWLLYRLLPLGGLPLLITTCFCLFCCLRRHQG
KQNELSDTAGREINLVDAHLKSEQTEASTRQNSQVLLSETGIYDNDPDLCFRMQEGSEVY
SNPCLEENKPGIVYASLNHSVIGPNSRLARNVKEAPTEYASICVRS (SEQ ID NO: 180)

CTLA-4
MACLGFQRHKAQLNLATRTWPCTLLFFLLFIPVFCKAMHVAQPAVVLASSRGIASFVCEYA
SPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRA
MDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDFLLWILAAVSSGLFFYSFLLTAV
SLSKMLKKRSPLTTGVYVKMPPTEPECEKQFQPYFIPIN (SEQ ID NO: 193)

CD200
MERLVIRMPFSHLSTYSLVWVMAAVVLCTAQVQVVTQDEREQLYTPASLKCSLQNAQEAL
IVTWQKKKAVSPENMVTFSENHGVVIQPAYKDKINITQLGLQNSTITFWNITLEDEGCYMCL
FNTFGFGKISGTACLTVYVQPIVSLHYKFSEDHLNITCSATARPAPMVFWKVPRSGIENSTV
TLSHPNGTTSVTSILHIKDPKNQVGKEVICQVLHLGTVTDFKQTVNKGYWFSVPLLLSIVSL
VILLVLISILLYWKRHRNQDRGELSQGVQKMT (SEQ ID NO: 212)

FIG. 8 (cont'd)

VISTA
MGVPTALEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLL
GPVDKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDL
AQRHGLESASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQT
GKDAPSNCVVYPSSSQDSENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQE
LVRMDSNIQGIENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLS
PPGPGDVFFPSLDPVPDSPNFEVI (SEQ ID NO: 219)

CD40
MVRLPLQCVLWGCLLTAVHPEPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTET
ECLPCGESEFLDTWNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTS
EACESCVLHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETK
DLVVQQAGTNKTDVVCGPQDRLRALVVIPIIFGILFAILLVLVFIKKVAKKPTNKAPHPKQ
EPQEINFPDDLPGSNTAAPVQETLHGCQPVTQEDGKESRISVQERQ (SEQ ID NO:
234)

PD-L1
MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEM
EDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMIS
YGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVL
SGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPP
NERTHLVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNSKKQSDTHLEET (SEQ
ID NO: 235)

PD-L2
MLLLLPILNLSLQLHPVAALFTVTAPKEVYTVDVGSSVSLECDFDRRECTELEGIRASLQ
KVENDTSLQSERATLLEEQLPLGKALFHIPSVQVRDSGQYRCLVICGAAWDYKYLTVK
VKASYMRIDTRILEVPGTGEVQLTCQARGYPLAEVSWQNVSVPANTSHIRTPEGLYQV
TSVLRLKPQPSRNFSCMFWNAHMKELTSAIIDPLSRMEPKVPRTWPLHVFIPACTIALIF
LAIVIIQRKRI (SEQ ID NO: 236)

Gal-9
MAFSGSQAPYLSPAVPFSGTIQGGLQDGLQITVNGTVLSSSGTRFAVNFQTGFSGNDI
AFHFNPRFEDGGYVVCNTRQNGSWGPEERKTHMPFQKGMPFDLCFLVQSSDFKVM
VNGILFVQYFHRVPFHRVDTISVNGSVQLSYISFQNPRTVPVQPAFSTVPFSQPVCFPP
RPRGRRQKPPGVWPANPAPITQTVIHTVQSAPGQMFSTPAIPPMMYPHPAYPMPFITT
ILGGLYPSKSILLSGTVLPSAQRFHINLCSGNHIAFHLNPRFDENAVVRNTQIDNSWGS
EERSLPRKMPFVRGQSFSVWILCEAHCLKVAVDGQHLFEYYHRLRNLPTINRLEVGG
DIQLTHVQT(SEQ ID NO: 237)

FIG. 8 (cont'd)

MLLLVTSLLLCELPHPAFLLIPDIVMTQSQKIMSTTVGDRVSITCKASQNVDAAVAWYQQKPGQ
SPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQYDIYPYTFGGGTKLEI
KGGGGSGGGGSGGGGSQVQLQQSGAELVRPGASVTLSCKASGYTFSDYEMHWVIQTPVHG
LEWIGAIDPETGGTAYNQKFKGKAILTADKSSSTAYMELRSLTSEDSAVYYCTGYYDYDSFTY
WGQGTLVTVSAGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYIHWVRQAPGQG
LEWIGCIYPGNVNTNYNEKFKDRATLTVDTSISTAYMELSRLRSDDTAVYFCTRSHYGLDWNF
DVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCHASQNIYVWL
NWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGQTYPY
TFGGGTKVEIKEQKLISEEDLHHHHHH (SEQ ID NO: 238)

MLLLVTSLLLCELPHPAFLLIPDIVMTQSQKIMSTTVGDRVSITCKASQNVDAAVAWYQQKPGQ
SPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQYDIYPYTFGGGTKLEI
KGGGGSGGGGSGGGGSQVQLQQSGAELVRPGASVTLSCKASGYTFSDYEMHWVIQTPVHG
LEWIGAIDPETGGTAYNQKFKGKAILTADKSSSTAYMELRSLTSEDSAVYYCTGYYDYDSFTY
WGQGTLVTVSAGGGGSQVQLLESGPELLKPGASVKMSCKASGYTFTDYNMHWVKQSHGKS
LEWIGYIYPYTGGTGYNQKFKNKATLTVDSSSSTAYMELRSLTSEDSAVYYCARNFRYTYWYF
DVWGQGTTVTVSSGGGGSGGGGSGGGGSDIVMTQSPASLAVSLGQRATISCRASESVDSYD
NSLMHWYQQKPGQPPKVLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQN
NEDPYTFGGGTKLEIKRHHHHHH (SEQ ID NO: 239)

MLLLVTSLLLCELPHPAFLLIPELVMTQTPSSTSGAVGGTVTINCQASQSIDSNLAWFQQKPGQ
PPTLLIYRASNLASGVPSRFSGSRSGTEYTLTISGVQREDAATYYCLGGVGNVSYRTSFGGGT
EVVVKGGGGSGGGGSGGGGSQSVKESEGDLVTPAGNLTLTCTASGSDINDYPISWVRQAPG
KGLEWIGFINSGGSTWYASWVKGRFTISRTSTTVDLKMTSLTTDDTATYFCARGYSTYYGDFN
IWGPGTLVTISSGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGL
EWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDY
WGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYM
NWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSN
PLTFGAGTKLELKEQKLISEEDLHHHHHH (SEQ ID NO: 240)

METDTLLLWVLLLWVPGSTGELVMTQTPSSTSGAVGGTVTINCQASQSIDSNLAWFQQKPGQ
PPTLLIYRASNLASGVPSRFSGSRSGTEYTLTISGVQREDAATYYCLGGVGNVSYRTSFGGGT
EVVVKGGGGSGGGGSGGGGSQSVKESEGDLVTPAGNLTLTCTASGSDINDYPISWVRQAPG
KGLEWIGFINSGGSTWYASWVKGRFTISRTSTTVDLKMTSLTTDDTATYFCARGYSTYYGDFN
IWGPGTLVTISSGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGL
EWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDY
WGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYM
NWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSN
PLTFGAGTKLELKHHHHHH (SEQ ID NO: 241)

FIG. 8 (cont'd)

METDTLLLWVLLLWVPGSTGELVMTQTPSSTSGAVGGTVTINCQASQSIDSNLAWFQQKPGQPP
TLLIYRASNLASGVPSRFSGSRSGTEYTLTISGVQREDAATYYCLGGVGNVSYRTSFGGGTEVVV
KGGGGSGGGGSGGGGSQSVKESEGDLVTPAGNLTLTCTASGSDINDYPISWVRQAPGKGLEWI
GFINSGGSTWYASWVKGRFTISRTSTTVDLKMTSLTTDDTATYFCARGYSTYYGDFNIWGPGTL
VTISSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYIHWVRQAPGQGLEWIGCIYPG
NVNTNYNEKFKDRATLTVDTSISTAYMELSRLRSDDTAVYFCTRSHYGLDWNFDVWGQGTTVTV
SSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCHASQNIYVWLNWYQQKPGKAPK
LLIYKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGQTYPYTFGGGTKVEIKHHH
HHH (SEQ ID NO: 242)

METDTLLLWVLLLWVPGSTGELVLTQSPSVSAALGSPAKITCTLSSAHKTDTIDWYQQLQGEAPR
YLMQVQSDGSYTKRPGVPDRFSGSSSGADRYLIIPSVQADDEADYYCGADYIGGYVFGGGTQLT
VTGGGGGSGGGGSGGGGSQEQLVESGGRLVTPGGSLTLSCKASGFDFSAYYMSWVRQAPGK
GLEWIATIYPSSGKTYYATWVNGRFTISSDNAQNTVDLQMNSLTAADRATYFCARDSYADDGAL
FNIWGPGTLVTISSGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQG
LEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDY
WGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMN
WYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLT
FGAGTKLELKHHHHHH (SEQ ID NO: 243)

METDTLLLWVLLLWVPGSTGELVLTQSPSVSAALGSPAKITCTLSSAHKTDTIDWYQQLQGEAPR
YLMQVQSDGSYTKRPGVPDRFSGSSSGADRYLIIPSVQADDEADYYCGADYIGGYVFGGGTQLT
VTGGGGGSGGGGSGGGGSQEQLVESGGRLVTPGGSLTLSCKASGFDFSAYYMSWVRQAPGK
GLEWIATIYPSSGKTYYATWVNGRFTISSDNAQNTVDLQMNSLTAADRATYFCARDSYADDGAL
FNIWGPGTLVTISSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYIHWVRQAPGQG
LEWIGCIYPGNVNTNYNEKFKDRATLTVDTSISTAYMELSRLRSDDTAVYFCTRSHYGLDWNFDV
WGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCHASQNIYVWLNWY
QQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGQTYPYTFGG
GTKVEIKHHHHHH (SEQ ID NO: 244)

METDTLLLWVLLLWVPGSTGDIVMTQSQKIMSTTVGDRVSITCKASQNVDAAVAWYQQKPGQSP
KLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQYDIYPYTFGGGTKLEIKGG
GGSGGGGSGGGGSQVQLQQSGAELVRPGASVTLSCKASGYTFSDYEMHWVIQTPVHGLEWIG
AIDPETGGTAYNQKFKGKAILTADKSSSTAYMELRSLTSEDSAVYYCTGYYDYDSFTYWGQGTL
VTVSAGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINP
SRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLT
VSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGT
SPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLEL
KHHHHHH (SEQ ID NO: 245)

FIG. 8 (cont'd)

METDTLLLWVLLLWVPGSTGDIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLI
YSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKGGGGSGGGG
SGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYY
ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSSGGGGSQVQ
LVQSGAEVKKPGASVKVSCKASGYTFTSYYIHWVRQAPGQGLEWIGCIYPGNVNTNYNEKFKDRATLT
VDTSISTAYMELSRLRSDDTAVYFCTRSHYGLDWNFDVWGQGTTVTVSSGGGGSGGGGSGGGGSDI
QMTQSPSSLSASVGDRVTITCHASQNIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTD
FTLTISSLQPEDFATYYCQQGQTYPYTFGGGTKVEIKHHHHHH (SEQ ID NO: 246)

METDTLLLWVLLLWVPGSTGDIQMTQSPSSLSASVGDRVTITCHASQNIYVWLNWYQQKPGKAPKLLI
YKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGQTYPYTFGGGTKVEIKGGGGSGGG
GSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYIHWVRQAPGQGLEWIGCIYPGNVNTNY
NEKFKDRATLTVDTSISTAYMELSRLRSDDTAVYFCTRSHYGLDWNFDVWGQGTTVTVSSHHHHHH
(SEQ ID NO: 247)

METDTLLLWVLLLWVPGSTGDIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLI
YSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKGGGGSGGGG
SGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYY
ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSSHHHHHH
(SEQ ID NO: 248)

METDTLLLWVLLLWVPGSTGDIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPP
KLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIKGGGGSG
GGGSGGGGSQVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDG
DTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVS
SGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNY
NQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGS
GGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASG
VPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHH (SEQ ID NO:
249)

METDTLLLWVLLLWVPGSTGQVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQGLE
WMGWINTYTGEPTYADKFQGRVTMTTDTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYFDYW
GQGTSVTVSSGGGGSGGGGSGGGGSDIVMTQSPDSLTVSLGERTTINCKSSQSVLDSSTNKNSLAW
YQQKPGQPPKLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSPQPEDSATYYCQQSAHFPITFGQGTR
LEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYN
NYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTV
SSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRG
LIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLHHHHHH
(SEQ ID NO: 250)

FIG. 8 (cont'd)

METDTLLLWVLLLWVPGSTGDIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQP
PKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIKGGGG
SGGGGSGGGGSQVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWP
GDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGT
TVTVSSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYIHWVRQAPGQGLEWIGCIYPGN
VNTNYNEKFKDRATLTVDTSISTAYMELSRLRSDDTAVYFCTRSHYGLDWNFDVWGQGTTVTVSSG
GGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCHASQNIYVWLNWYQQKPGKAPKLLIYKAS
NLHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGQTYPYTFGGGTKVEIKHHHHHH (SEQ ID
NO: 251)

METDTLLLWVLLLWVPGSTGELVLTQSPSVSAALGSPAKITCTLSSAHKTDTIDWYQQLQGEAPRYLM
QVQSDGSYTKRPGVPDRFSGSSSGADRYLIIPSVQADDEADYYCGADYIGGYVFGGGTQLTVTGGG
GGSGGGGSGGGGSQEQLVESGGRLVTPGGSLTLSCKASGFDFSAYYMSWVRQAPGKGLEWIATIY
PSSGKTYYATWVNGRFTISSDNAQNTVDLQMNSLTAADRATYFCARDSYADDGALFNIWGPGTLVTI
SSGGGGSEVQLVQSGAEVKKPGESLRISCKGSGYSFSTYWISWVRQMPGKGLEWMGKIYPGDSYT
NYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGYGIFDYWGQGTLVTVSSGGGGSGGG
GSGGGGSSYELTQPPSVSVSPGQTASITCSGDNIGDQYAHWYQQKPGQSPVLVIYQDKNRPSGIPE
RFSGSNSGNTATLTISGTQAMDEADYYCATYTGFGSLAVFGGGTKLTVLHHHHHH (SEQ ID NO:
252)

SEQUENCE LISTING

<110> Fred Hutchinson Cancer Research Center

<120> MULTIPLE BI-SPECIFIC BINDING DOMAIN CONSTRUCTS WITH DIFFERENT EPITOPE BINDING TO TREAT CANCER

<130> F053-0052PCT

<150> US 62/362,397
<151> 2016-07-14

<150> US 62/480,230
<151> 2017-03-31

<160> 277

<170> PatentIn version 3.5

<210> 1
<211> 707
<212> PRT
<213> Homo sapiens

<400> 1

Lys Ser Ser Asn Glu Ala Thr Asn Ile Thr Pro Lys His Asn Met Lys
1 5 10 15

Ala Phe Leu Asp Glu Leu Lys Ala Glu Asn Ile Lys Lys Phe Leu Tyr
20 25 30

Asn Phe Thr Gln Ile Pro His Leu Ala Gly Thr Glu Gln Asn Phe Gln
35 40 45

Leu Ala Lys Gln Ile Gln Ser Gln Trp Lys Glu Phe Gly Leu Asp Ser
50 55 60

Val Glu Leu Ala His Tyr Asp Val Leu Leu Ser Tyr Pro Asn Lys Thr
65 70 75 80

His Pro Asn Tyr Ile Ser Ile Ile Asn Glu Asp Gly Asn Glu Ile Phe
85 90 95

Asn Thr Ser Leu Phe Glu Pro Pro Pro Pro Gly Tyr Glu Asn Val Ser
100 105 110

Asp Ile Val Pro Pro Phe Ser Ala Phe Ser Pro Gln Gly Met Pro Glu
115 120 125

Gly Asp Leu Val Tyr Val Asn Tyr Ala Arg Thr Glu Asp Phe Phe Lys
130 135 140

Leu Glu Arg Asp Met Lys Ile Asn Cys Ser Gly Lys Ile Val Ile Ala

```
145                 150                 155                 160

Arg Tyr Gly Lys Val Phe Arg Gly Asn Lys Val Lys Asn Ala Gln Leu
                165                 170                 175

Ala Gly Ala Lys Gly Val Ile Leu Tyr Ser Asp Pro Ala Asp Tyr Phe
            180                 185                 190

Ala Pro Gly Val Lys Ser Tyr Pro Asp Gly Trp Asn Leu Pro Gly Gly
        195                 200                 205

Gly Val Gln Arg Gly Asn Ile Leu Asn Leu Asn Gly Ala Gly Asp Pro
    210                 215                 220

Leu Thr Pro Gly Tyr Pro Ala Asn Glu Tyr Ala Tyr Arg Arg Gly Ile
225                 230                 235                 240

Ala Glu Ala Val Gly Leu Pro Ser Ile Pro Val His Pro Ile Gly Tyr
                245                 250                 255

Tyr Asp Ala Gln Lys Leu Leu Glu Lys Met Gly Gly Ser Ala Pro Pro
            260                 265                 270

Asp Ser Ser Trp Arg Gly Ser Leu Lys Val Pro Tyr Asn Val Gly Pro
        275                 280                 285

Gly Phe Thr Gly Asn Phe Ser Thr Gln Lys Val Lys Met His Ile His
    290                 295                 300

Ser Thr Asn Glu Val Thr Arg Ile Tyr Asn Val Ile Gly Thr Leu Arg
305                 310                 315                 320

Gly Ala Val Glu Pro Asp Arg Tyr Val Ile Leu Gly Gly His Arg Asp
                325                 330                 335

Ser Trp Val Phe Gly Gly Ile Asp Pro Gln Ser Gly Ala Ala Val Val
            340                 345                 350

His Glu Ile Val Arg Ser Phe Gly Thr Leu Lys Lys Glu Gly Trp Arg
        355                 360                 365

Pro Arg Arg Thr Ile Leu Phe Ala Ser Trp Asp Ala Glu Glu Phe Gly
    370                 375                 380

Leu Leu Gly Ser Thr Glu Trp Ala Glu Glu Asn Ser Arg Leu Leu Gln
385                 390                 395                 400
```

```
Glu Arg Gly Val Ala Tyr Ile Asn Ala Asp Ser Ser Ile Glu Gly Asn
                405                 410                 415

Tyr Thr Leu Arg Val Asp Cys Thr Pro Leu Met Tyr Ser Leu Val His
            420                 425                 430

Asn Leu Thr Lys Glu Leu Lys Ser Pro Asp Glu Gly Phe Glu Gly Lys
        435                 440                 445

Ser Leu Tyr Glu Ser Trp Thr Lys Lys Ser Pro Ser Pro Glu Phe Ser
    450                 455                 460

Gly Met Pro Arg Ile Ser Lys Leu Gly Ser Gly Asn Asp Phe Glu Val
465                 470                 475                 480

Phe Phe Gln Arg Leu Gly Ile Ala Ser Gly Arg Ala Arg Tyr Thr Lys
                485                 490                 495

Asn Trp Glu Thr Asn Lys Phe Ser Gly Tyr Pro Leu Tyr His Ser Val
            500                 505                 510

Tyr Glu Thr Tyr Glu Leu Val Glu Lys Phe Tyr Asp Pro Met Phe Lys
        515                 520                 525

Tyr His Leu Thr Val Ala Gln Val Arg Gly Gly Met Val Phe Glu Leu
    530                 535                 540

Ala Asn Ser Ile Val Leu Pro Phe Asp Cys Arg Asp Tyr Ala Val Val
545                 550                 555                 560

Leu Arg Lys Tyr Ala Asp Lys Ile Tyr Ser Ile Ser Met Lys His Pro
                565                 570                 575

Gln Glu Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala
            580                 585                 590

Val Lys Asn Phe Thr Glu Ile Ala Ser Lys Phe Ser Glu Arg Leu Gln
        595                 600                 605

Asp Phe Asp Lys Ser Asn Pro Ile Val Leu Arg Met Met Asn Asp Gln
    610                 615                 620

Leu Met Phe Leu Glu Arg Ala Phe Ile Asp Pro Leu Gly Leu Pro Asp
625                 630                 635                 640

Arg Pro Phe Tyr Arg His Val Ile Tyr Ala Pro Ser Ser His Asn Lys
                645                 650                 655
```

```
Tyr Ala Gly Glu Ser Phe Pro Gly Ile Tyr Asp Ala Leu Phe Asp Ile
            660                 665                 670

Glu Ser Lys Val Asp Pro Ser Lys Ala Trp Gly Glu Val Lys Arg Gln
        675                 680                 685

Ile Tyr Val Ala Ala Phe Thr Val Gln Ala Ala Ala Glu Thr Leu Ser
    690                 695                 700

Glu Val Ala
705
```

<210> 2
<211> 123
<212> PRT
<213> Homo sapiens

<400> 2

```
Met Lys Ala Val Leu Leu Ala Leu Leu Met Ala Gly Leu Ala Leu Gln
1               5                   10                  15

Pro Gly Thr Ala Leu Leu Cys Tyr Ser Cys Lys Ala Gln Val Ser Asn
            20                  25                  30

Glu Asp Cys Leu Gln Val Glu Asn Cys Thr Gln Leu Gly Glu Gln Cys
        35                  40                  45

Trp Thr Ala Arg Ile Arg Ala Val Gly Leu Leu Thr Val Ile Ser Lys
    50                  55                  60

Gly Cys Ser Leu Asn Cys Val Asp Asp Ser Gln Asp Tyr Tyr Val Gly
65                  70                  75                  80

Lys Lys Asn Ile Thr Cys Cys Asp Thr Asp Leu Cys Asn Ala Ser Gly
                85                  90                  95

Ala His Ala Leu Gln Pro Ala Ala Ala Ile Leu Ala Leu Leu Pro Ala
            100                 105                 110

Leu Gly Leu Leu Leu Trp Gly Pro Gly Gln Leu
        115                 120
```

<210> 3
<211> 622
<212> PRT
<213> Homo sapiens

<400> 3

```
Met Ala Leu Pro Thr Ala Arg Pro Leu Leu Gly Ser Cys Gly Thr Pro
1               5                   10                  15

Ala Leu Gly Ser Leu Leu Phe Leu Leu Phe Ser Leu Gly Trp Val Gln
            20                  25                  30

Pro Ser Arg Thr Leu Ala Gly Glu Thr Gly Gln Glu Ala Ala Pro Leu
        35                  40                  45

Asp Gly Val Leu Ala Asn Pro Pro Asn Ile Ser Ser Leu Ser Pro Arg
    50                  55                  60

Gln Leu Leu Gly Phe Pro Cys Ala Glu Val Ser Gly Leu Ser Thr Glu
65                  70                  75                  80

Arg Val Arg Glu Leu Ala Val Ala Leu Ala Gln Lys Asn Val Lys Leu
                85                  90                  95

Ser Thr Glu Gln Leu Arg Cys Leu Ala His Arg Leu Ser Glu Pro Pro
            100                 105                 110

Glu Asp Leu Asp Ala Leu Pro Leu Asp Leu Leu Leu Phe Leu Asn Pro
        115                 120                 125

Asp Ala Phe Ser Gly Pro Gln Ala Cys Thr His Phe Phe Ser Arg Ile
    130                 135                 140

Thr Lys Ala Asn Val Asp Leu Leu Pro Arg Gly Ala Pro Glu Arg Gln
145                 150                 155                 160

Arg Leu Leu Pro Ala Ala Leu Ala Cys Trp Gly Val Arg Gly Ser Leu
                165                 170                 175

Leu Ser Glu Ala Asp Val Arg Ala Leu Gly Gly Leu Ala Cys Asp Leu
            180                 185                 190

Pro Gly Arg Phe Val Ala Glu Ser Ala Glu Val Leu Leu Pro Arg Leu
        195                 200                 205

Val Ser Cys Pro Gly Pro Leu Asp Gln Asp Gln Gln Glu Ala Ala Arg
    210                 215                 220

Ala Ala Leu Gln Gly Gly Gly Pro Pro Tyr Gly Pro Pro Ser Thr Trp
225                 230                 235                 240

Ser Val Ser Thr Met Asp Ala Leu Arg Gly Leu Leu Pro Val Leu Gly
                245                 250                 255
```

```
Gln Pro Ile Ile Arg Ser Ile Pro Gln Gly Ile Val Ala Ala Trp Arg
            260                 265                 270

Gln Arg Ser Ser Arg Asp Pro Ser Trp Arg Gln Pro Glu Arg Thr Ile
        275                 280                 285

Leu Arg Pro Arg Phe Arg Arg Glu Val Glu Lys Thr Ala Cys Pro Ser
    290                 295                 300

Gly Lys Lys Ala Arg Glu Ile Asp Glu Ser Leu Ile Phe Tyr Lys Lys
305                 310                 315                 320

Trp Glu Leu Glu Ala Cys Val Asp Ala Ala Leu Leu Ala Thr Gln Met
                325                 330                 335

Asp Arg Val Asn Ala Ile Pro Phe Thr Tyr Glu Gln Leu Asp Val Leu
            340                 345                 350

Lys His Lys Leu Asp Glu Leu Tyr Pro Gln Gly Tyr Pro Glu Ser Val
        355                 360                 365

Ile Gln His Leu Gly Tyr Leu Phe Leu Lys Met Ser Pro Glu Asp Ile
    370                 375                 380

Arg Lys Trp Asn Val Thr Ser Leu Glu Thr Leu Lys Ala Leu Leu Glu
385                 390                 395                 400

Val Asn Lys Gly His Glu Met Ser Pro Gln Val Ala Thr Leu Ile Asp
                405                 410                 415

Arg Phe Val Lys Gly Arg Gly Gln Leu Asp Lys Asp Thr Leu Asp Thr
            420                 425                 430

Leu Thr Ala Phe Tyr Pro Gly Tyr Leu Cys Ser Leu Ser Pro Glu Glu
        435                 440                 445

Leu Ser Ser Val Pro Pro Ser Ser Ile Trp Ala Val Arg Pro Gln Asp
    450                 455                 460

Leu Asp Thr Cys Asp Pro Arg Gln Leu Asp Val Leu Tyr Pro Lys Ala
465                 470                 475                 480

Arg Leu Ala Phe Gln Asn Met Asn Gly Ser Glu Tyr Phe Val Lys Ile
                485                 490                 495

Gln Ser Phe Leu Gly Gly Ala Pro Thr Glu Asp Leu Lys Ala Leu Ser
            500                 505                 510
```

```
Gln Gln Asn Val Ser Met Asp Leu Ala Thr Phe Met Lys Leu Arg Thr
        515                 520                 525

Asp Ala Val Leu Pro Leu Thr Val Ala Glu Val Gln Lys Leu Leu Gly
    530                 535                 540

Pro His Val Glu Gly Leu Lys Ala Glu Glu Arg His Arg Pro Val Arg
545                 550                 555                 560

Asp Trp Ile Leu Arg Gln Arg Gln Asp Asp Leu Asp Thr Leu Gly Leu
                565                 570                 575

Gly Leu Gln Gly Gly Ile Pro Asn Gly Tyr Leu Val Leu Asp Leu Ser
            580                 585                 590

Val Gln Glu Ala Leu Ser Gly Thr Pro Cys Leu Leu Gly Pro Gly Pro
        595                 600                 605

Val Leu Thr Val Leu Ala Leu Leu Leu Ala Ser Thr Leu Ala
    610                 615                 620
```

<210> 4
<211> 556
<212> PRT
<213> Homo sapiens

<400> 4

```
Met Pro Pro Pro Arg Leu Leu Phe Phe Leu Leu Phe Leu Thr Pro Met
1               5                   10                  15

Glu Val Arg Pro Glu Glu Pro Leu Val Val Lys Val Glu Glu Gly Asp
            20                  25                  30

Asn Ala Val Leu Gln Cys Leu Lys Gly Thr Ser Asp Gly Pro Thr Gln
        35                  40                  45

Gln Leu Thr Trp Ser Arg Glu Ser Pro Leu Lys Pro Phe Leu Lys Leu
    50                  55                  60

Ser Leu Gly Leu Pro Gly Leu Gly Ile His Met Arg Pro Leu Ala Ser
65                  70                  75                  80

Trp Leu Phe Ile Phe Asn Val Ser Gln Gln Met Gly Gly Phe Tyr Leu
                85                  90                  95

Cys Gln Pro Gly Pro Pro Ser Glu Lys Ala Trp Gln Pro Gly Trp Thr
            100                 105                 110
```

```
Val Asn Val Glu Gly Ser Gly Glu Leu Phe Arg Trp Asn Val Ser Asp
        115                 120                 125

Leu Gly Gly Leu Gly Cys Gly Leu Lys Asn Arg Ser Ser Glu Gly Pro
    130                 135                 140

Ser Ser Pro Ser Gly Lys Leu Met Ser Pro Lys Leu Tyr Val Trp Ala
145                 150                 155                 160

Lys Asp Arg Pro Glu Ile Trp Glu Gly Glu Pro Pro Cys Val Pro Pro
                165                 170                 175

Arg Asp Ser Leu Asn Gln Ser Leu Ser Gln Asp Leu Thr Met Ala Pro
            180                 185                 190

Gly Ser Thr Leu Trp Leu Ser Cys Gly Val Pro Pro Asp Ser Val Ser
        195                 200                 205

Arg Gly Pro Leu Ser Trp Thr His Val His Pro Lys Gly Pro Lys Ser
    210                 215                 220

Leu Leu Ser Leu Glu Leu Lys Asp Asp Arg Pro Ala Arg Asp Met Trp
225                 230                 235                 240

Val Met Glu Thr Gly Leu Leu Leu Pro Arg Ala Thr Ala Gln Asp Ala
                245                 250                 255

Gly Lys Tyr Tyr Cys His Arg Gly Asn Leu Thr Met Ser Phe His Leu
            260                 265                 270

Glu Ile Thr Ala Arg Pro Val Leu Trp His Trp Leu Leu Arg Thr Gly
        275                 280                 285

Gly Trp Lys Val Ser Ala Val Thr Leu Ala Tyr Leu Ile Phe Cys Leu
    290                 295                 300

Cys Ser Leu Val Gly Ile Leu His Leu Gln Arg Ala Leu Val Leu Arg
305                 310                 315                 320

Arg Lys Arg Lys Arg Met Thr Asp Pro Thr Arg Arg Phe Phe Lys Val
                325                 330                 335

Thr Pro Pro Pro Gly Ser Gly Pro Gln Asn Gln Tyr Gly Asn Val Leu
            340                 345                 350

Ser Leu Pro Thr Pro Thr Ser Gly Leu Gly Arg Ala Gln Arg Trp Ala
```

355 360 365

Ala Gly Leu Gly Gly Thr Ala Pro Ser Tyr Gly Asn Pro Ser Ser Asp
370 375 380

Val Gln Ala Asp Gly Ala Leu Gly Ser Arg Ser Pro Pro Gly Val Gly
385 390 395 400

Pro Glu Glu Glu Glu Gly Glu Gly Tyr Glu Glu Pro Asp Ser Glu Glu
405 410 415

Asp Ser Glu Phe Tyr Glu Asn Asp Ser Asn Leu Gly Gln Asp Gln Leu
420 425 430

Ser Gln Asp Gly Ser Gly Tyr Glu Asn Pro Glu Asp Glu Pro Leu Gly
435 440 445

Pro Glu Asp Glu Asp Ser Phe Ser Asn Ala Glu Ser Tyr Glu Asn Glu
450 455 460

Asp Glu Glu Leu Thr Gln Pro Val Ala Arg Thr Met Asp Phe Leu Ser
465 470 475 480

Pro His Gly Ser Ala Trp Asp Pro Ser Arg Glu Ala Thr Ser Leu Gly
485 490 495

Ser Gln Ser Tyr Glu Asp Met Arg Gly Ile Leu Tyr Ala Ala Pro Gln
500 505 510

Leu Arg Ser Ile Arg Gly Gln Pro Gly Pro Asn His Glu Glu Asp Ala
515 520 525

Asp Ser Tyr Glu Asn Met Asp Asn Pro Asp Gly Pro Asp Pro Ala Trp
530 535 540

Gly Gly Gly Gly Arg Met Gly Thr Trp Ser Thr Arg
545 550 555

<210> 5
<211> 297
<212> PRT
<213> Homo sapiens

<400> 5

Met Thr Thr Pro Arg Asn Ser Val Asn Gly Thr Phe Pro Ala Glu Pro
1 5 10 15

Met Lys Gly Pro Ile Ala Met Gln Ser Gly Pro Lys Pro Leu Phe Arg

```
            20                  25                  30

Arg Met Ser Ser Leu Val Gly Pro Thr Gln Ser Phe Phe Met Arg Glu
        35                  40                  45

Ser Lys Thr Leu Gly Ala Val Gln Ile Met Asn Gly Leu Phe His Ile
    50                  55                  60

Ala Leu Gly Gly Leu Leu Met Ile Pro Ala Gly Ile Tyr Ala Pro Ile
65                  70                  75                  80

Cys Val Thr Val Trp Tyr Pro Leu Trp Gly Gly Ile Met Tyr Ile Ile
                85                  90                  95

Ser Gly Ser Leu Leu Ala Ala Thr Glu Lys Asn Ser Arg Lys Cys Leu
            100                 105                 110

Val Lys Gly Lys Met Ile Met Asn Ser Leu Ser Leu Phe Ala Ala Ile
        115                 120                 125

Ser Gly Met Ile Leu Ser Ile Met Asp Ile Leu Asn Ile Lys Ile Ser
    130                 135                 140

His Phe Leu Lys Met Glu Ser Leu Asn Phe Ile Arg Ala His Thr Pro
145                 150                 155                 160

Tyr Ile Asn Ile Tyr Asn Cys Glu Pro Ala Asn Pro Ser Glu Lys Asn
                165                 170                 175

Ser Pro Ser Thr Gln Tyr Cys Tyr Ser Ile Gln Ser Leu Phe Leu Gly
            180                 185                 190

Ile Leu Ser Val Met Leu Ile Phe Ala Phe Phe Gln Glu Leu Val Ile
        195                 200                 205

Ala Gly Ile Val Glu Asn Glu Trp Lys Arg Thr Cys Ser Arg Pro Lys
    210                 215                 220

Ser Asn Ile Val Leu Leu Ser Ala Glu Glu Lys Lys Glu Gln Thr Ile
225                 230                 235                 240

Glu Ile Lys Glu Glu Val Val Gly Leu Thr Glu Thr Ser Ser Gln Pro
                245                 250                 255

Lys Asn Glu Glu Asp Ile Glu Ile Ile Pro Ile Gln Glu Glu Glu Glu
            260                 265                 270
```

Glu Glu Thr Glu Thr Asn Phe Pro Glu Pro Pro Gln Asp Gln Glu Ser
275 280 285

Ser Pro Ile Glu Asn Asp Ser Ser Pro
290 295

<210> 6
<211> 364
<212> PRT
<213> Homo sapiens

<400> 6

Met Pro Leu Leu Leu Leu Leu Pro Leu Leu Trp Ala Gly Ala Leu Ala
1 5 10 15

Met Asp Pro Asn Phe Trp Leu Gln Val Gln Glu Ser Val Thr Val Gln
20 25 30

Glu Gly Leu Cys Val Leu Val Pro Cys Thr Phe Phe His Pro Ile Pro
35 40 45

Tyr Tyr Asp Lys Asn Ser Pro Val His Gly Tyr Trp Phe Arg Glu Gly
50 55 60

Ala Ile Ile Ser Arg Asp Ser Pro Val Ala Thr Asn Lys Leu Asp Gln
65 70 75 80

Glu Val Gln Glu Glu Thr Gln Gly Arg Phe Arg Leu Leu Gly Asp Pro
85 90 95

Ser Arg Asn Asn Cys Ser Leu Ser Ile Val Asp Ala Arg Arg Arg Asp
100 105 110

Asn Gly Ser Tyr Phe Phe Arg Met Glu Arg Gly Ser Thr Lys Tyr Ser
115 120 125

Tyr Lys Ser Pro Gln Leu Ser Val His Val Thr Asp Leu Thr His Arg
130 135 140

Pro Lys Ile Leu Ile Pro Gly Thr Leu Glu Pro Gly His Ser Lys Asn
145 150 155 160

Leu Thr Cys Ser Val Ser Trp Ala Cys Glu Gln Gly Thr Pro Pro Ile
165 170 175

Phe Ser Trp Leu Ser Ala Ala Pro Thr Ser Leu Gly Pro Arg Thr Thr
180 185 190

```
His Ser Ser Val Leu Ile Ile Thr Pro Arg Pro Gln Asp His Gly Thr
        195                 200                 205

Asn Leu Thr Cys Gln Val Lys Phe Ala Gly Ala Gly Val Thr Thr Glu
    210                 215                 220

Arg Thr Ile Gln Leu Asn Val Thr Tyr Val Pro Gln Asn Pro Thr Thr
225                 230                 235                 240

Gly Ile Phe Pro Gly Asp Gly Ser Gly Lys Gln Glu Thr Arg Ala Gly
                245                 250                 255

Val Val His Gly Ala Ile Gly Gly Ala Gly Val Thr Ala Leu Leu Ala
            260                 265                 270

Leu Cys Leu Cys Leu Ile Phe Phe Ile Val Lys Thr His Arg Arg Lys
        275                 280                 285

Ala Ala Arg Thr Ala Val Gly Arg Asn Asp Thr His Pro Thr Thr Gly
    290                 295                 300

Ser Ala Ser Pro Lys His Gln Lys Lys Ser Lys Leu His Gly Pro Thr
305                 310                 315                 320

Glu Thr Ser Ser Cys Ser Gly Ala Ala Pro Thr Val Glu Met Asp Glu
                325                 330                 335

Glu Leu His Tyr Ala Ser Leu Asn Phe His Gly Met Asn Pro Ser Lys
            340                 345                 350

Asp Thr Ser Thr Glu Tyr Ser Glu Val Arg Thr Gln
        355                 360
```

<210> 7
<211> 237
<212> PRT
<213> Homo sapiens

<400> 7

```
Met Pro Leu Leu Leu Leu Leu Pro Leu Leu Trp Ala Asp Leu Thr His
1               5                   10                  15

Arg Pro Lys Ile Leu Ile Pro Gly Thr Leu Glu Pro Gly His Ser Lys
            20                  25                  30

Asn Leu Thr Cys Ser Val Ser Trp Ala Cys Glu Gln Gly Thr Pro Pro
        35                  40                  45
```

```
Ile Phe Ser Trp Leu Ser Ala Ala Pro Thr Ser Leu Gly Pro Arg Thr
    50                  55                  60

Thr His Ser Ser Val Leu Ile Ile Thr Pro Arg Pro Gln Asp His Gly
65                  70                  75                  80

Thr Asn Leu Thr Cys Gln Val Lys Phe Ala Gly Ala Gly Val Thr Thr
                85                  90                  95

Glu Arg Thr Ile Gln Leu Asn Val Thr Tyr Val Pro Gln Asn Pro Thr
            100                 105                 110

Thr Gly Ile Phe Pro Gly Asp Gly Ser Gly Lys Gln Glu Thr Arg Ala
        115                 120                 125

Gly Val Val His Gly Ala Ile Gly Gly Ala Gly Val Thr Ala Leu Leu
    130                 135                 140

Ala Leu Cys Leu Cys Leu Ile Phe Phe Ile Val Lys Thr His Arg Arg
145                 150                 155                 160

Lys Ala Ala Arg Thr Ala Val Gly Arg Asn Asp Thr His Pro Thr Thr
                165                 170                 175

Gly Ser Ala Ser Pro Lys His Gln Lys Lys Ser Lys Leu His Gly Pro
            180                 185                 190

Thr Glu Thr Ser Ser Cys Ser Gly Ala Ala Pro Thr Val Glu Met Asp
        195                 200                 205

Glu Glu Leu His Tyr Ala Ser Leu Asn Phe His Gly Met Asn Pro Ser
    210                 215                 220

Lys Asp Thr Ser Thr Glu Tyr Ser Glu Val Arg Thr Gln
225                 230                 235


<210>  8
<211>  310
<212>  PRT
<213>  Homo sapiens

<400>  8

Met Pro Leu Leu Leu Leu Leu Pro Leu Leu Trp Ala Gly Ala Leu Ala
1               5                   10                  15

Met Asp Pro Asn Phe Trp Leu Gln Val Gln Glu Ser Val Thr Val Gln
            20                  25                  30
```

```
Glu Gly Leu Cys Val Leu Val Pro Cys Thr Phe Phe His Pro Ile Pro
        35                  40                  45

Tyr Tyr Asp Lys Asn Ser Pro Val His Gly Tyr Trp Phe Arg Glu Gly
    50                  55                  60

Ala Ile Ile Ser Arg Asp Ser Pro Val Ala Thr Asn Lys Leu Asp Gln
65                  70                  75                  80

Glu Val Gln Glu Glu Thr Gln Gly Arg Phe Arg Leu Leu Gly Asp Pro
                85                  90                  95

Ser Arg Asn Asn Cys Ser Leu Ser Ile Val Asp Ala Arg Arg Arg Asp
            100                 105                 110

Asn Gly Ser Tyr Phe Phe Arg Met Glu Arg Gly Ser Thr Lys Tyr Ser
        115                 120                 125

Tyr Lys Ser Pro Gln Leu Ser Val His Val Thr Asp Leu Thr His Arg
    130                 135                 140

Pro Lys Ile Leu Ile Pro Gly Thr Leu Glu Pro Gly His Ser Lys Asn
145                 150                 155                 160

Leu Thr Cys Ser Val Ser Trp Ala Cys Glu Gln Gly Thr Pro Pro Ile
                165                 170                 175

Phe Ser Trp Leu Ser Ala Ala Pro Thr Ser Leu Gly Pro Arg Thr Thr
            180                 185                 190

His Ser Ser Val Leu Ile Ile Thr Pro Arg Pro Gln Asp His Gly Thr
        195                 200                 205

Asn Leu Thr Cys Gln Val Lys Phe Ala Gly Ala Gly Val Thr Thr Glu
    210                 215                 220

Arg Thr Ile Gln Leu Asn Val Thr Tyr Val Pro Gln Asn Pro Thr Thr
225                 230                 235                 240

Gly Ile Phe Pro Gly Asp Gly Ser Gly Lys Gln Glu Thr Arg Ala Gly
                245                 250                 255

Val Val His Gly Ala Ile Gly Gly Ala Gly Val Thr Ala Leu Leu Ala
            260                 265                 270

Leu Cys Leu Cys Leu Ile Phe Phe Ile Val Lys Thr His Arg Arg Lys
        275                 280                 285
```

```
Ala Ala Arg Thr Ala Val Gly Arg Asn Asp Thr His Pro Thr Thr Gly
    290                 295                 300

Ser Ala Ser Pro Val Arg
305                 310

<210>  9
<211>  937
<212>  PRT
<213>  Homo sapiens

<400>  9

Met His Arg Pro Arg Arg Arg Gly Thr Arg Pro Pro Leu Leu Ala Leu
1               5                   10                  15

Leu Ala Ala Leu Leu Leu Ala Ala Arg Gly Ala Ala Ala Gln Glu Thr
            20                  25                  30

Glu Leu Ser Val Ser Ala Glu Leu Val Pro Thr Ser Ser Trp Asn Ile
        35                  40                  45

Ser Ser Glu Leu Asn Lys Asp Ser Tyr Leu Thr Leu Asp Glu Pro Met
    50                  55                  60

Asn Asn Ile Thr Thr Ser Leu Gly Gln Thr Ala Glu Leu His Cys Lys
65                  70                  75                  80

Val Ser Gly Asn Pro Pro Pro Thr Ile Arg Trp Phe Lys Asn Asp Ala
                85                  90                  95

Pro Val Val Gln Glu Pro Arg Arg Leu Ser Phe Arg Ser Thr Ile Tyr
            100                 105                 110

Gly Ser Arg Leu Arg Ile Arg Asn Leu Asp Thr Thr Asp Thr Gly Tyr
        115                 120                 125

Phe Gln Cys Val Ala Thr Asn Gly Lys Glu Val Val Ser Ser Thr Gly
    130                 135                 140

Val Leu Phe Val Lys Phe Gly Pro Pro Pro Thr Ala Ser Pro Gly Tyr
145                 150                 155                 160

Ser Asp Glu Tyr Glu Glu Asp Gly Phe Cys Gln Pro Tyr Arg Gly Ile
                165                 170                 175

Ala Cys Ala Arg Phe Ile Gly Asn Arg Thr Val Tyr Met Glu Ser Leu
            180                 185                 190
```

```
His Met Gln Gly Glu Ile Glu Asn Gln Ile Thr Ala Ala Phe Thr Met
        195                 200                 205

Ile Gly Thr Ser Ser His Leu Ser Asp Lys Cys Ser Gln Phe Ala Ile
    210                 215                 220

Pro Ser Leu Cys His Tyr Ala Phe Pro Tyr Cys Asp Glu Thr Ser Ser
225                 230                 235                 240

Val Pro Lys Pro Arg Asp Leu Cys Arg Asp Glu Cys Glu Ile Leu Glu
                245                 250                 255

Asn Val Leu Cys Gln Thr Glu Tyr Ile Phe Ala Arg Ser Asn Pro Met
            260                 265                 270

Ile Leu Met Arg Leu Lys Leu Pro Asn Cys Glu Asp Leu Pro Gln Pro
        275                 280                 285

Glu Ser Pro Glu Ala Ala Asn Cys Ile Arg Ile Gly Ile Pro Met Ala
    290                 295                 300

Asp Pro Ile Asn Lys Asn His Lys Cys Tyr Asn Ser Thr Gly Val Asp
305                 310                 315                 320

Tyr Arg Gly Thr Val Ser Val Thr Lys Ser Gly Arg Gln Cys Gln Pro
                325                 330                 335

Trp Asn Ser Gln Tyr Pro His Thr His Thr Phe Thr Ala Leu Arg Phe
            340                 345                 350

Pro Glu Leu Asn Gly Gly His Ser Tyr Cys Arg Asn Pro Gly Asn Gln
        355                 360                 365

Lys Glu Ala Pro Trp Cys Phe Thr Leu Asp Glu Asn Phe Lys Ser Asp
    370                 375                 380

Leu Cys Asp Ile Pro Ala Cys Asp Ser Lys Asp Ser Lys Glu Lys Asn
385                 390                 395                 400

Lys Met Glu Ile Leu Tyr Ile Leu Val Pro Ser Val Ala Ile Pro Leu
                405                 410                 415

Ala Ile Ala Leu Leu Phe Phe Phe Ile Cys Val Cys Arg Asn Asn Gln
            420                 425                 430

Lys Ser Ser Ser Ala Pro Val Gln Arg Gln Pro Lys His Val Arg Gly
        435                 440                 445
```

```
Gln Asn Val Glu Met Ser Met Leu Asn Ala Tyr Lys Pro Lys Ser Lys
    450                 455                 460

Ala Lys Glu Leu Pro Leu Ser Ala Val Arg Phe Met Glu Glu Leu Gly
465                 470                 475                 480

Glu Cys Ala Phe Gly Lys Ile Tyr Lys Gly His Leu Tyr Leu Pro Gly
                485                 490                 495

Met Asp His Ala Gln Leu Val Ala Ile Lys Thr Leu Lys Asp Tyr Asn
            500                 505                 510

Asn Pro Gln Gln Trp Thr Glu Phe Gln Gln Glu Ala Ser Leu Met Ala
        515                 520                 525

Glu Leu His His Pro Asn Ile Val Cys Leu Leu Gly Ala Val Thr Gln
    530                 535                 540

Glu Gln Pro Val Cys Met Leu Phe Glu Tyr Ile Asn Gln Gly Asp Leu
545                 550                 555                 560

His Glu Phe Leu Ile Met Arg Ser Pro His Ser Asp Val Gly Cys Ser
                565                 570                 575

Ser Asp Glu Asp Gly Thr Val Lys Ser Ser Leu Asp His Gly Asp Phe
            580                 585                 590

Leu His Ile Ala Ile Gln Ile Ala Ala Gly Met Glu Tyr Leu Ser Ser
        595                 600                 605

His Phe Phe Val His Lys Asp Leu Ala Ala Arg Asn Ile Leu Ile Gly
    610                 615                 620

Glu Gln Leu His Val Lys Ile Ser Asp Leu Gly Leu Ser Arg Glu Ile
625                 630                 635                 640

Tyr Ser Ala Asp Tyr Tyr Arg Val Gln Ser Lys Ser Leu Leu Pro Ile
                645                 650                 655

Arg Trp Met Pro Pro Glu Ala Ile Met Tyr Gly Lys Phe Ser Ser Asp
            660                 665                 670

Ser Asp Ile Trp Ser Phe Gly Val Val Leu Trp Glu Ile Phe Ser Phe
        675                 680                 685

Gly Leu Gln Pro Tyr Tyr Gly Phe Ser Asn Gln Glu Val Ile Glu Met
```

690 695 700

Val Arg Lys Arg Gln Leu Leu Pro Cys Ser Glu Asp Cys Pro Pro Arg
705 710 715 720

Met Tyr Ser Leu Met Thr Glu Cys Trp Asn Glu Ile Pro Ser Arg Arg
725 730 735

Pro Arg Phe Lys Asp Ile His Val Arg Leu Arg Ser Trp Glu Gly Leu
740 745 750

Ser Ser His Thr Ser Ser Thr Thr Pro Ser Gly Gly Asn Ala Thr Thr
755 760 765

Gln Thr Thr Ser Leu Ser Ala Ser Pro Val Ser Asn Leu Ser Asn Pro
770 775 780

Arg Tyr Pro Asn Tyr Met Phe Pro Ser Gln Gly Ile Thr Pro Gln Gly
785 790 795 800

Gln Ile Ala Gly Phe Ile Gly Pro Pro Ile Pro Gln Asn Gln Arg Phe
805 810 815

Ile Pro Ile Asn Gly Tyr Pro Ile Pro Pro Gly Tyr Ala Ala Phe Pro
820 825 830

Ala Ala His Tyr Gln Pro Thr Gly Pro Pro Arg Val Ile Gln His Cys
835 840 845

Pro Pro Pro Lys Ser Arg Ser Pro Ser Ser Ala Ser Gly Ser Thr Ser
850 855 860

Thr Gly His Val Thr Ser Leu Pro Ser Ser Gly Ser Asn Gln Glu Ala
865 870 875 880

Asn Ile Pro Leu Leu Pro His Met Ser Ile Pro Asn His Pro Gly Gly
885 890 895

Met Gly Ile Thr Val Phe Gly Asn Lys Ser Gln Lys Pro Tyr Lys Ile
900 905 910

Asp Ser Lys Gln Ala Ser Leu Leu Gly Asp Ala Asn Ile His Gly His
915 920 925

Thr Glu Ser Met Ile Ser Ala Glu Leu
930 935

<210> 10
<211> 152
<212> PRT
<213> Homo sapiens

<400> 10

```
Ile Glu Gly Arg His Met Arg Arg Val Pro Gly Val Ala Pro Thr Leu
1               5                   10                  15


Val Arg Ser Ala Ser Glu Thr Ser Glu Lys Arg Pro Phe Met Cys Ala
            20                  25                  30


Tyr Pro Gly Cys Asn Lys Arg Tyr Phe Lys Leu Ser His Leu Gln Met
        35                  40                  45


His Ser Arg Lys His Thr Gly Glu Lys Pro Tyr Gln Cys Asp Phe Lys
    50                  55                  60


Asp Cys Glu Arg Arg Phe Phe Arg Ser Asp Gln Leu Lys Arg His Gln
65                  70                  75                  80


Arg Arg His Thr Gly Val Lys Pro Phe Gln Cys Lys Thr Cys Gln Arg
                85                  90                  95


Lys Phe Ser Arg Ser Asp His Leu Lys Thr His Thr Arg Thr His Thr
            100                 105                 110


Gly Glu Lys Pro Phe Ser Cys Arg Trp Pro Ser Cys Gln Lys Lys Phe
        115                 120                 125


Ala Arg Ser Asp Glu Leu Val Arg His His Asn Met His Gln Arg Asn
    130                 135                 140


Met Thr Lys Leu Gln Leu Ala Leu
145                 150
```

<210> 11
<211> 378
<212> PRT
<213> Homo sapiens

<400> 11

```
Met Val Leu Leu Trp Leu Thr Leu Leu Leu Ile Ala Leu Pro Cys Leu
1               5                   10                  15


Leu Gln Thr Lys Glu Asp Pro Asn Pro Pro Ile Thr Asn Leu Arg Met
            20                  25                  30


Lys Ala Lys Ala Gln Gln Leu Thr Trp Asp Leu Asn Arg Asn Val Thr
```

35 40 45

Asp Ile Glu Cys Val Lys Asp Ala Asp Tyr Ser Met Pro Ala Val Asn
50 55 60

Asn Ser Tyr Cys Gln Phe Gly Ala Ile Ser Leu Cys Glu Val Thr Asn
65 70 75 80

Tyr Thr Val Arg Val Ala Asn Pro Pro Phe Ser Thr Trp Ile Leu Phe
85 90 95

Pro Glu Asn Ser Gly Lys Pro Trp Ala Gly Ala Glu Asn Leu Thr Cys
100 105 110

Trp Ile His Asp Val Asp Phe Leu Ser Cys Ser Trp Ala Val Gly Pro
115 120 125

Gly Ala Pro Ala Asp Val Gln Tyr Asp Leu Tyr Leu Asn Val Ala Asn
130 135 140

Arg Arg Gln Gln Tyr Glu Cys Leu His Tyr Lys Thr Asp Ala Gln Gly
145 150 155 160

Thr Arg Ile Gly Cys Arg Phe Asp Asp Ile Ser Arg Leu Ser Ser Gly
165 170 175

Ser Gln Ser Ser His Ile Leu Val Arg Gly Arg Ser Ala Ala Phe Gly
180 185 190

Ile Pro Cys Thr Asp Lys Phe Val Val Phe Ser Gln Ile Glu Ile Leu
195 200 205

Thr Pro Pro Asn Met Thr Ala Lys Cys Asn Lys Thr His Ser Phe Met
210 215 220

His Trp Lys Met Arg Ser His Phe Asn Arg Lys Phe Arg Tyr Glu Leu
225 230 235 240

Gln Ile Gln Lys Arg Met Gln Pro Val Ile Thr Glu Gln Val Arg Asp
245 250 255

Arg Thr Ser Phe Gln Leu Leu Asn Pro Gly Thr Tyr Thr Val Gln Ile
260 265 270

Arg Ala Arg Glu Arg Val Tyr Glu Phe Leu Ser Ala Trp Ser Thr Pro
275 280 285

Gln Arg Phe Glu Cys Asp Gln Glu Glu Gly Ala Asn Thr Arg Ala Trp
290 295 300

Arg Thr Ser Leu Leu Ile Ala Leu Gly Thr Leu Leu Ala Leu Val Cys
305 310 315 320

Val Phe Val Ile Cys Arg Arg Tyr Leu Val Met Gln Arg Leu Phe Pro
325 330 335

Arg Ile Pro His Met Lys Asp Pro Ile Gly Asp Ser Phe Gln Asn Asp
340 345 350

Lys Leu Val Val Trp Glu Ala Gly Lys Ala Gly Leu Glu Glu Cys Leu
355 360 365

Val Thr Glu Val Gln Val Val Gln Lys Thr
370 375

<210> 12
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-ROR1 CDR

<400> 12

Ala Ser Gly Phe Asp Phe Ser Ala Tyr Tyr Met
1 5 10

<210> 13
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-ROR1 CDR

<400> 13

Thr Ile Tyr Pro Ser Ser Gly
1 5

<210> 14
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-ROR1 CDR

<400> 14

Ala Asp Arg Ala Thr Tyr Phe Cys Ala

1 5

<210> 15
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-ROR1 CDR

<400> 15

Asp Thr Ile Asp Trp Tyr
1 5

<210> 16
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-ROR1 CDR

<400> 16

Val Gln Ser Asp Gly Ser Tyr Thr Lys Arg Pro Gly Val Pro Asp Arg
1 5 10 15

<210> 17
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> R11 CDR

<400> 17

Tyr Ile Gly Gly Tyr Val Phe Gly
1 5

<210> 18
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> R11 CDR

<400> 18

Gln Ala Ser Gln Ser Ile Asp Ser Asn Leu Ala
1 5 10

<210> 19
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> R11 CDR

<400> 19

Arg Ala Ser Asn Leu Ala Ser
1   5

<210> 20
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> R11 CDR

<400> 20

Leu Gly Gly Val Gly Asn Val Ser Tyr Arg Thr Ser
1   5   10

<210> 21
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> R11 CDR

<400> 21

Asp Tyr Pro Ile Ser
1   5

<210> 22
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> R11 CDR

<400> 22

Phe Ile Asn Ser Gly Gly Ser Thr Trp Tyr Ala Ser Trp Val Lys Gly
1   5   10   15

<210> 23
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> R11 CDR

<400> 23

Gly Tyr Ser Thr Tyr Tyr Cys Asp Phe Asn Ile

1 5 10

<210> 24
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> R12 CDR

<400> 24

Thr Leu Ser Ser Ala His Lys Thr Asp Thr Ile Asp
1 5 10

<210> 25
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> R12 CDR

<400> 25

Gly Ser Tyr Thr Lys Arg Pro
1 5

<210> 26
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> R12 CDR

<400> 26

Gly Ala Asp Tyr Ile Gly Gly Tyr Val
1 5

<210> 27
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> R12 CDR

<400> 27

Ala Tyr Tyr Met Ser
1 5

<210> 28
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> R12 CDR

<400> 28

Thr Ile Tyr Pro Ser Ser Gly Lys Thr Tyr Tyr Ala Thr Trp Val Asn
1   5   10   15

Gly

<210> 29
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> R12 CDR

<400> 29

Asp Ser Tyr Ala Asp Asp Gly Ala Leu Phe Asn Ile
1   5   10

<210> 30
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> 2A2 CDR

<400> 30

Lys Ala Ser Gln Asn Val Asp Ala Ala Val Ala
1   5   10

<210> 31
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> 2A2 CDR

<400> 31

Ser Ala Ser Asn Arg Tyr Thr
1   5

<210> 32
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> 2A2 CDR

<400> 32

Gln Gln Tyr Asp Ile Tyr Pro Tyr Thr
1 5

<210> 33
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> 2A2 CDR

<400> 33

Asp Tyr Glu Met His
1 5

<210> 34
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> 2A2 CDR

<400> 34

Ala Ile Asp Pro Glu Thr Gly Gly Thr Ala Tyr Asn Gln Lys Phe Lys
1 5 10 15

Gly

<210> 35
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> 2A2 CDR

<400> 35

Tyr Tyr Asp Tyr Asp Ser Phe Thr Tyr
1 5

<210> 36
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Y31 CDR

<400> 36

Gln Ala Ser Gln Ser Ile Gly Ser Tyr Leu Ala
1 5 10

<210> 37
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Y31 CDR

<400> 37

Tyr Ala Ser Asn Leu Ala Ser
1 5

<210> 38
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Y31 CDR

<400> 38

Leu Gly Ser Leu Ser Asn Ser Asp Asn Val
1 5 10

<210> 39
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Y31 CDR

<400> 39

Ser His Trp Met Ser
1 5

<210> 40
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Y31 CDR

<400> 40

Ile Ile Ala Ala Ser Gly Ser Thr Tyr Tyr Ala Asn Trp Ala Lys Gly
1 5 10 15

<210> 41
<211> 12
<212> PRT

<213> Artificial Sequence

<220>
<223> Y31 CDR

<400> 41

Asp Tyr Gly Asp Tyr Arg Leu Val Thr Phe Asn Ile
1 5 10

<210> 42
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CD19 CDR

<400> 42

Arg Ala Ser Gln Asp Ile Ser Lys Tyr Leu Asn
1 5 10

<210> 43
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CD19 CDR

<400> 43

Ser Arg Leu His Ser Gly Val
1 5

<210> 44
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CD19 CDR

<400> 44

Gly Asn Thr Leu Pro Tyr Thr Phe Gly
1 5

<210> 45
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CD19 CDR

<400> 45

Asp Tyr Gly Val Ser
1 5

<210> 46
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CD19 CDR

<400> 46

Val Thr Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser
1 5 10 15

<210> 47
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CD19 CDR

<400> 47

Tyr Ala Met Asp Tyr Trp Gly
1 5

<210> 48
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> 2B8 CDR

<400> 48

Arg Ala Ser Ser Ser Val Ser Tyr Ile His
1 5 10

<210> 49
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> 2B8 CDR

<400> 49

Ala Thr Ser Asn Leu Ala Ser
1 5

<210> 50
<211> 9
<212> PRT

<213> Artificial Sequence

<220>
<223> 2B8 CDR

<400> 50

Gln Gln Trp Thr Ser Asn Pro Pro Thr
1 5

<210> 51
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> 2B8 CDR

<400> 51

Ser Tyr Asn Met His
1 5

<210> 52
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> 2B8 CDR

<400> 52

Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys
1 5 10 15

Gly

<210> 53
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> 2B8 CDR

<400> 53

Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val
1 5 10

<210> 54
<211> 12
<212> PRT
<213> Artificial Sequence

<220>

<223> 4D5 CDR

<400> 54

Arg Ala Ser Gln Asp Val Asn Thr Ala Val Ala Trp
1   5   10

<210> 55
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> 4D5 CDR

<400> 55

Tyr Ser Ala Ser Phe Leu Glu Ser
1   5

<210> 56
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> 4D5 CDR

<400> 56

Gln Gln His Tyr Thr Thr Pro Thr
1   5

<210> 57
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> 4D5 CDR

<400> 57

Ser Gly Phe Asn Thr Lys Asp Thr Tyr Ile His Trp
1   5   10

<210> 58
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> 4D5 CDR

<400> 58

Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys
1   5   10   15

Gly Arg

<210> 59
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> 4D5 CDR

<400> 59

Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Val
1 5 10

<210> 60
<211> 234
<212> PRT
<213> Mus musculus

<400> 60

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15

Gly Ser Thr Gly Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Ile Tyr
20 25 30

Ala Ser Leu Gly Glu Arg Val Thr Ile Asn Cys Lys Ala Ser Gln Asp
35 40 45

Ile Lys Ser Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Trp Lys Ser Pro
50 55 60

Lys Thr Leu Ile Tyr Tyr Ala Thr Thr Leu Ala Asp Gly Val Pro Ser
65 70 75 80

Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser
85 90 95

Ser Leu Glu Ser Asp Asp Thr Ala Thr Tyr Tyr Cys Leu His His Gly
100 105 110

Glu Ser Pro Trp Thr Phe Gly Glu Gly Thr Lys Leu Glu Ile Lys Arg
115 120 125

Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln
130 135 140

Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr

145 150 155 160

Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln
165 170 175

Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr
180 185 190

Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg
195 200 205

His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro
210 215 220

Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
225 230

<210> 61
<211> 471
<212> PRT
<213> Mus musculus

<400> 61

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15

Gly Ser Thr Gly Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Val
20 25 30

Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Arg Ala Ser Gly Tyr Ala
35 40 45

Phe Ser Asn Tyr Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly
50 55 60

Leu Glu Trp Ile Gly Gln Ile Tyr Pro Gly Asn Phe Asn Thr Asp Tyr
65 70 75 80

Asn Gly Gln Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser
85 90 95

Asn Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala
100 105 110

Val Tyr Phe Cys Ala Arg Phe Phe Asp Phe Gly Ala Tyr Phe Thr Leu
115 120 125

Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr

130 135 140

Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr
145 150 155 160

Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu
165 170 175

Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His
180 185 190

Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser
195 200 205

Val Thr Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn
210 215 220

Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro
225 230 235 240

Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro
245 250 255

Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys
260 265 270

Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val
275 280 285

Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn
290 295 300

Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr
305 310 315 320

Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp
325 330 335

Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu
340 345 350

Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg
355 360 365

Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys
370 375 380

Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp
385 390 395 400

Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys
405 410 415

Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser
420 425 430

Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser
435 440 445

Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser
450 455 460

Phe Ser Arg Thr Pro Gly Lys
465 470

<210> 62
<211> 240
<212> PRT
<213> Mus musculus

<400> 62

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15

Gly Ser Thr Gly Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Pro
20 25 30

Val Ser Val Gly Glu Lys Val Thr Leu Ser Cys Lys Ser Ser Gln Ser
35 40 45

Leu Leu Tyr Ser Arg Asn Gln Tyr Asn Phe Leu Ala Trp Tyr Gln Gln
50 55 60

Arg Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg
65 70 75 80

Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp
85 90 95

Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr
100 105 110

Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr
115 120 125

Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe
130 135 140

Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys
145 150 155 160

Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile
165 170 175

Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln
180 185 190

Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr
195 200 205

Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His
210 215 220

Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
225 230 235 240

<210> 63
<211> 469
<212> PRT
<213> Mus musculus

<400> 63

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15

Gly Ser Thr Gly Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val
20 25 30

Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr
35 40 45

Phe Ser Asp Phe Tyr Met Tyr Trp Val Arg Gln Thr Pro Glu Lys Arg
50 55 60

Leu Glu Trp Val Ala Phe Ile Ser Asn Ala Gly Val Thr Thr Tyr Tyr
65 70 75 80

Pro Asp Thr Val Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys
85 90 95

Asn Thr Leu Tyr Leu Gln Met Ser Arg Leu Met Ser Glu Asp Thr Ala
100 105 110

```
Met Tyr Tyr Cys Thr Lys Ser Asp Tyr Asp Gly Ala Trp Phe Pro Tyr
        115                 120                 125

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Ala
    130                 135                 140

Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser
145                 150                 155                 160

Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val
                165                 170                 175

Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe
            180                 185                 190

Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr
        195                 200                 205

Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala
    210                 215                 220

His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly
225                 230                 235                 240

Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu
                245                 250                 255

Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val
            260                 265                 270

Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val
        275                 280                 285

Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val
    290                 295                 300

Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser
305                 310                 315                 320

Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met
                325                 330                 335

Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala
            340                 345                 350

Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro
        355                 360                 365
```

```
Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln
    370                 375                 380

Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr
385                 390                 395                 400

Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr
                405                 410                 415

Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu
            420                 425                 430

Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser
        435                 440                 445

Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser
    450                 455                 460

Arg Thr Pro Gly Lys
465
```

<210> 64
<211> 239
<212> PRT
<213> Mus musculus

<400> 64

```
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1               5                   10                  15

Gly Ser Thr Gly Asp Ile Val Met Thr Gln Ala Ala Phe Ser Asn Pro
            20                  25                  30

Val Thr Leu Gly Thr Ser Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser
        35                  40                  45

Leu Leu His Ser Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys
    50                  55                  60

Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Ala
65                  70                  75                  80

Ser Gly Val Pro Asp Arg Phe Ser Ser Ser Gly Ser Gly Thr Asp Phe
                85                  90                  95

Thr Leu Arg Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
            100                 105                 110
```

```
Cys Ala Gln Asn Leu Glu Leu Pro Pro Thr Phe Gly Gly Gly Thr Lys
        115                 120                 125

Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro
    130                 135                 140

Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe
145                 150                 155                 160

Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp
                165                 170                 175

Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp
            180                 185                 190

Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys
        195                 200                 205

Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys
    210                 215                 220

Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
225                 230                 235
```

<210> 65
<211> 473
<212> PRT
<213> Mus musculus

<400> 65

```
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1               5                   10                  15

Gly Ser Thr Gly Glu Val Gln Leu Gln Gln Ser Gly Thr Val Leu Ala
            20                  25                  30

Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr
        35                  40                  45

Phe Thr Thr Tyr Trp Met His Trp Ile Lys Gln Ser Pro Gly Gln Gly
    50                  55                  60

Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr
65                  70                  75                  80

Asn Gln Lys Phe Lys Gly Lys Ala Lys Leu Thr Ala Val Thr Ser Ala
                85                  90                  95
```

```
Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Asn Glu Asp Ser Ala
            100                 105                 110

Val Tyr Tyr Cys Glu Ile Tyr Asp Gly Tyr His Phe Ile Tyr Trp Gly
        115                 120                 125

Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser
    130                 135                 140

Val Tyr Pro Leu Ala Pro Gly Cys Gly Asp Thr Thr Gly Ser Ser Val
145                 150                 155                 160

Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Ser Val Thr Val
                165                 170                 175

Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Val His Thr Phe Pro Ala
            180                 185                 190

Leu Leu Gln Ser Gly Leu Tyr Thr Met Ser Ser Ser Val Thr Val Pro
        195                 200                 205

Ser Ser Thr Trp Pro Ser Gln Thr Val Thr Cys Ser Val Ala His Pro
    210                 215                 220

Ala Ser Ser Thr Thr Val Asp Lys Lys Leu Glu Pro Ser Gly Pro Ile
225                 230                 235                 240

Ser Thr Ile Asn Pro Cys Pro Pro Cys Lys Glu Cys His Lys Cys Pro
                245                 250                 255

Ala Pro Asn Leu Glu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Asn
            260                 265                 270

Ile Lys Asp Val Leu Met Ile Ser Leu Thr Pro Lys Val Thr Cys Val
        275                 280                 285

Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe
    290                 295                 300

Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu
305                 310                 315                 320

Asp Tyr Asn Ser Thr Ile Arg Val Val Ser Thr Leu Pro Ile Gln His
                325                 330                 335

Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys
            340                 345                 350
```

```
Asp Leu Pro Ser Pro Ile Glu Arg Thr Ile Ser Lys Ile Lys Gly Leu
        355                 360                 365

Val Arg Ala Pro Gln Val Tyr Ile Leu Pro Pro Ala Glu Gln Leu
    370                 375                 380

Ser Arg Lys Asp Val Ser Leu Thr Cys Leu Val Val Gly Phe Asn Pro
385                 390                 395                 400

Gly Asp Ile Ser Val Glu Trp Thr Ser Asn Gly His Thr Glu Glu Asn
                405                 410                 415

Tyr Lys Asp Thr Ala Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Ile
            420                 425                 430

Tyr Ser Lys Leu Asn Met Lys Thr Ser Lys Trp Glu Lys Thr Asp Ser
        435                 440                 445

Phe Ser Cys Asn Val Arg His Glu Gly Leu Lys Asn Tyr Tyr Leu Lys
    450                 455                 460

Lys Thr Ile Ser Arg Ser Pro Gly Lys
465                 470
```

<210> 66
<211> 238
<212> PRT
<213> Mus musculus

<400> 66

```
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1               5                   10                  15

Gly Ser Thr Gly Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser
            20                  25                  30

Val Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
        35                  40                  45

Leu Leu Tyr Ser Asn Gly Lys Thr Tyr Leu His Trp Phe Leu Gln Arg
    50                  55                  60

Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp
65                  70                  75                  80

Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe
                85                  90                  95
```

```
Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr
            100                 105                 110

Cys Val Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys
        115                 120                 125

Leu Glu Ile Lys Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro
    130                 135                 140

Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu
145                 150                 155                 160

Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly
                165                 170                 175

Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser
            180                 185                 190

Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp
        195                 200                 205

Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr
    210                 215                 220

Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
225                 230                 235
```

<210> 67
<211> 464
<212> PRT
<213> Mus musculus

<400> 67

```
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1               5                   10                  15

Gly Ser Thr Gly Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val
            20                  25                  30

Arg Pro Gly Thr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala
        35                  40                  45

Phe Thr Asn Tyr Leu Ile Glu Trp Val Lys Gln Arg Pro Gly Gln Gly
    50                  55                  60

Leu Glu Trp Ile Gly Val Ile His Pro Gly Asn Asn Ser Thr Ser Tyr
65                  70                  75                  80
```

```
Asn Ala Lys Phe Arg Gly Lys Ala Thr Leu Thr Ala Asp Arg Ser Ser
                85                  90                  95

Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala
            100                 105                 110

Val Tyr Phe Cys Ala Arg Tyr Gly Tyr Asp Glu Arg Asn Ala Met Asp
        115                 120                 125

Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr
    130                 135                 140

Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn
145                 150                 155                 160

Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro
                165                 170                 175

Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr
            180                 185                 190

Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val
        195                 200                 205

Thr Val Pro Ser Ser Pro Arg Pro Ser Glu Thr Val Thr Cys Asn Val
    210                 215                 220

Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg
225                 230                 235                 240

Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser
                245                 250                 255

Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu
            260                 265                 270

Thr Pro Lys Val Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro
        275                 280                 285

Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala
    290                 295                 300

Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val
305                 310                 315                 320

Ser Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe
```

325 330 335

Lys Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr
340 345 350

Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile
355 360 365

Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys
370 375 380

Met Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp
385 390 395 400

Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asn
405 410 415

Thr Asn Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn Val Gln Lys Ser
420 425 430

Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly
435 440 445

Leu His Asn His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys
450 455 460

<210> 68
<211> 239
<212> PRT
<213> Mus musculus

<400> 68

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15

Gly Ser Thr Gly Asp Ile Val Met Thr Gln Ala Ala Phe Ser Asn Pro
20 25 30

Val Thr Leu Gly Thr Ser Ala Ser Ile Ser Cys Arg Ser Asn Lys Ser
35 40 45

Leu Leu His Ser Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys
50 55 60

Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Ala
65 70 75 80

Ser Gly Val Pro Asp Arg Phe Ser Ser Ser Gly Ser Gly Thr Asp Phe

85 90 95

Thr Leu Arg Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
100 105 110

Cys Ala Gln Asn Leu Glu Leu Pro Pro Thr Phe Gly Gly Gly Thr Lys
115 120 125

Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro
130 135 140

Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe
145 150 155 160

Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp
165 170 175

Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp
180 185 190

Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys
195 200 205

Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys
210 215 220

Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
225 230 235

<210> 69
<211> 461
<212> PRT
<213> Mus musculus

<400> 69

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15

Gly Ser Thr Gly Glu Val Gln Phe Gln Gln Ser Glu Thr Val Leu Ala
20 25 30

Arg Pro Gly Thr Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr
35 40 45

Phe Thr Ser Tyr Trp Met His Trp Leu Lys Gln Arg Pro Gly Gln Gly
50 55 60

Leu Glu Trp Ile Gly Ala Ile Tyr Cys Gly Asn Ser Asp Thr Ser Tyr

```
65                  70                  75                  80

Asn Gln Lys Phe Lys Gly Lys Ala Lys Leu Thr Ala Val Thr Ser Ala
                85                  90                  95

Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Asn Glu Asp Ser Ala
            100                 105                 110

Val Tyr Tyr Cys Lys Ile Tyr Asp Gly Tyr His Phe Asp Tyr Trp Gly
        115                 120                 125

Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser
    130                 135                 140

Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val
145                 150                 155                 160

Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val
                165                 170                 175

Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala
            180                 185                 190

Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro
        195                 200                 205

Ser Ser Pro Arg Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro
    210                 215                 220

Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly
225                 230                 235                 240

Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val Phe Ile
                245                 250                 255

Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys
            260                 265                 270

Val Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu Val Gln
        275                 280                 285

Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gln Thr Gln
    290                 295                 300

Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu
305                 310                 315                 320
```

Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg
325 330 335

Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
340 345 350

Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro
355 360 365

Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr
370 375 380

Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn Gly Gln
385 390 395 400

Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asn Thr Asn Gly
405 410 415

Ser Tyr Phe Val Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn Trp Glu
420 425 430

Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu His Asn
435 440 445

His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys
450 455 460

<210> 70
<211> 227
<212> PRT
<213> Mus musculus

<400> 70

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15

Gly Ser Thr Gly Asp Ile Val Leu Thr Gln Ser Pro Val Ser Leu Ala
20 25 30

Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser His Gly
35 40 45

Val Glu Tyr Ala Gly Ala His Tyr Met Asn Trp Tyr Gln Gln Lys Pro
50 55 60

Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gly Ser
65 70 75 80

```
Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ser
                85                  90                  95

Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Arg Thr Phe Gly
            100                 105                 110

Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val
        115                 120                 125

Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser
    130                 135                 140

Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys
145                 150                 155                 160

Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp
                165                 170                 175

Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu
            180                 185                 190

Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu
        195                 200                 205

Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg
    210                 215                 220

Asn Glu Cys
225
```

<210> 71
<211> 460
<212> PRT
<213> Mus musculus

<400> 71

```
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1               5                   10                  15

Gly Ser Thr Gly Lys Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val
            20                  25                  30

Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr
        35                  40                  45

Phe Thr Asp Tyr Thr Leu His Trp Leu Lys Gln Arg Ser Gly Gln Gly
    50                  55                  60
```

```
Leu Glu Trp Ile Gly Trp Phe Tyr Pro Thr Ser Gly Ser Ile Asn Tyr
65                  70                  75                  80

Asn Glu Arg Phe Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser
                85                  90                  95

Ser Thr Val Tyr Met Glu Leu Ser Arg Leu Thr Ser Val Asp Ser Ala
            100                 105                 110

Val Tyr Phe Cys Ala Arg His Lys Phe Gly Phe Asp Tyr Trp Gly Gln
        115                 120                 125

Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val
    130                 135                 140

Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr
145                 150                 155                 160

Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr
                165                 170                 175

Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val
            180                 185                 190

Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser
        195                 200                 205

Ser Pro Arg Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala
    210                 215                 220

Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Cys
225                 230                 235                 240

Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val Phe Ile Phe
                245                 250                 255

Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys Val
            260                 265                 270

Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu Val Gln Phe
        275                 280                 285

Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gln Thr Gln Pro
    290                 295                 300

Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu Pro
305                 310                 315                 320
```

```
Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg Val
                325                 330                 335

Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr
            340                 345                 350

Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys
        355                 360                 365

Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr Asp
    370                 375                 380

Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn Gly Gln Pro
385                 390                 395                 400

Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asn Thr Asn Gly Ser
                405                 410                 415

Tyr Phe Val Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn Trp Glu Ala
            420                 425                 430

Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu His Asn His
        435                 440                 445

His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys
    450                 455                 460
```

<210> 72
<211> 234
<212> PRT
<213> Mus musculus

<400> 72

```
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1               5                   10                  15

Gly Ser Thr Gly Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser
            20                  25                  30

Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp
        35                  40                  45

Ile Asn Tyr Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val
    50                  55                  60

Lys Leu Leu Ile Tyr Tyr Ser Ser Arg Leu His Ser Gly Val Pro Ser
65                  70                  75                  80
```

```
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser
                85                  90                  95

Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Asp Asp
            100                 105                 110

Ala Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg
        115                 120                 125

Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln
    130                 135                 140

Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr
145                 150                 155                 160

Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln
                165                 170                 175

Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr
            180                 185                 190

Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg
        195                 200                 205

His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro
    210                 215                 220

Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
225                 230


<210>  73
<211>  467
<212>  PRT
<213>  Mus musculus

<400>  73

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1               5                   10                  15

Gly Ser Thr Gly Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val
            20                  25                  30

Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala
        35                  40                  45

Phe Ser Asn Tyr Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly
    50                  55                  60
```

```
Leu Glu Trp Ile Gly Gln Ile Asn Pro Gly Asp Gly Asp Thr Asn Tyr
65                  70                  75                  80

Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser
                85                  90                  95

Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala
            100                 105                 110

Val Tyr Phe Cys Ala Arg Glu Asp Arg Asp Tyr Phe Asp Tyr Trp Gly
        115                 120                 125

Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser
    130                 135                 140

Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val
145                 150                 155                 160

Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu
                165                 170                 175

Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala
            180                 185                 190

Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr
        195                 200                 205

Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro
    210                 215                 220

Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr
225                 230                 235                 240

Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly
                245                 250                 255

Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
            260                 265                 270

Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu
        275                 280                 285

Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
    290                 295                 300

His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu
305                 310                 315                 320
```

```
Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly
                325                 330                 335

Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile
            340                 345                 350

Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
        355                 360                 365

Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr
    370                 375                 380

Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
385                 390                 395                 400

Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
                405                 410                 415

Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
            420                 425                 430

Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
        435                 440                 445

His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr
    450                 455                 460

Pro Gly Lys
465
```

<210> 74
<211> 234
<212> PRT
<213> Mus musculus

<400> 74

```
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1               5                   10                  15

Gly Ser Thr Gly Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser
            20                  25                  30

Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp
        35                  40                  45

Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val
    50                  55                  60
```

```
Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser
65                  70                  75                  80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser
                85                  90                  95

Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Ser
            100                 105                 110

Thr Leu Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg
        115                 120                 125

Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln
    130                 135                 140

Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr
145                 150                 155                 160

Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln
                165                 170                 175

Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr
            180                 185                 190

Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg
        195                 200                 205

His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro
    210                 215                 220

Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
225                 230


<210>  75
<211>  462
<212>  PRT
<213>  Mus musculus

<400>  75

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1               5                   10                  15

Gly Ser Thr Gly Glu Val Asn Leu Val Glu Ser Gly Gly Gly Leu Val
            20                  25                  30

Gln Ser Gly Arg Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr
        35                  40                  45
```

```
Phe Ser Asp Phe Tyr Met Glu Trp Val Arg Gln Ala Pro Gly Lys Gly
    50                  55                  60

Leu Glu Trp Ile Ala Ala Ser Arg Asn Lys Ala Asn Asp Tyr Thr Thr
65                  70                  75                  80

Glu Tyr Lys Ala Ser Val Lys Gly Arg Phe Ile Val Ser Arg Asp Thr
                85                  90                  95

Ser Gln Ser Ile Leu Tyr Leu Gln Met Asn Ala Leu Arg Ala Glu Asp
            100                 105                 110

Thr Ala Ile Tyr Tyr Cys Thr Arg Asp Thr Gly Pro Met Asp Tyr Trp
        115                 120                 125

Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro
    130                 135                 140

Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met
145                 150                 155                 160

Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr
                165                 170                 175

Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro
            180                 185                 190

Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val
        195                 200                 205

Pro Ser Ser Pro Arg Pro Ser Glu Thr Val Thr Cys Asn Val Ala His
    210                 215                 220

Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys
225                 230                 235                 240

Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val Phe
                245                 250                 255

Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr Pro
            260                 265                 270

Lys Val Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu Val
        275                 280                 285

Gln Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gln Thr
```

290 295 300

Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser Glu
305 310 315 320

Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys
325 330 335

Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser
340 345 350

Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro
355 360 365

Pro Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met Ile
370 375 380

Thr Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn Gly
385 390 395 400

Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asn Thr Asn
405 410 415

Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn Trp
420 425 430

Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu His
435 440 445

Asn His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys
450 455 460

<210> 76
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> M195 CDR

<400> 76

Arg Ala Ser Glu Val Asp Asn Tyr Gly Ile Ser Phe Met Asn
1 5 10

<210> 77
<211> 7
<212> PRT
<213> Artificial Sequence

<220>

<223> M195 CDR

<400> 77

Ala Ala Ser Asn Gln Gly Ser
1 5

<210> 78
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> M195 CDR

<400> 78

Gln Gln Ser Lys Glu Val Pro Trp
1 5

<210> 79
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> M195 CDR

<400> 79

Asp Tyr Asn Met His
1 5

<210> 80
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> M195 CDR

<400> 80

Tyr Ile Tyr Pro Tyr Asn Gly Gly Thr Gly Tyr Asn Gln Lys Phe Lys
1 5 10 15

Ser

<210> 81
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> M195 CDR

<400> 81

Gly Arg Pro Ala Met Asp Tyr
1 5

<210> 82
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> 3G10 CDR

<400> 82

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu
1 5 10

<210> 83
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> 3G10 CDR

<400> 83

Asp Ala Ser Asn Arg Ala Thr
1 5

<210> 84
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> 3G10 CDR

<400> 84

Gln Gln Arg Ser Asn Trp Pro Arg Thr
1 5

<210> 85
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> 3G10 CDR

<400> 85

Asp Tyr Gly Phe Ser
1 5

<210> 86
<211> 17

<212> PRT
<213> Artificial Sequence

<220>
<223> 3G10 CDR

<400> 86

Trp Ile Thr Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln
1 5 10 15

Gly

<210> 87
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> 3G10 CDR

<400> 87

Asp Tyr Phe Tyr Gly Met Asp Tyr
1 5

<210> 88
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> 32716 CDR

<400> 88

Arg Ala Ser Glu Ser Val Asp Asn Tyr Gly Asn Thr Phe Met His
1 5 10 15

<210> 89
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> 32716 CDR

<400> 89

Arg Ala Ser Asn Leu Glu Ser
1 5

<210> 90
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> 32716 CDR

<400> 90

Gln Gln Ser Asn Glu Asp Pro Pro Thr
1   5

<210> 91
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> 32716 CDR

<400> 91

Asn Tyr Gly Met Asn
1   5

<210> 92
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> 32716 CDR

<400> 92

Trp Ile Asn Thr Tyr Thr Gly Glu Ser Thr Tyr Ser Ala Asp Phe Lys
1   5   10   15

Gly

<210> 93
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> 32716 CDR

<400> 93

Ser Gly Gly Tyr Asp Pro Met Asp Tyr
1   5

<210> 94
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> 32703 CDR

<400> 94

Arg Ser Asn Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr
1 5 10 15

<210> 95
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> 32703 CDR

<400> 95

Arg Met Ser Asn Leu Ala Ser
1 5

<210> 96
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> 32703 CDR

<400> 96

Met Gln His Leu Glu Tyr Pro Tyr Thr
1 5

<210> 97
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> 32703 CDR

<400> 97

Asn Tyr Trp Met Asn
1 5

<210> 98
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> 32703 CDR

<400> 98

Arg Ile Asp Pro Ser Asp Ser Glu Ser His Tyr Asn Gln Lys Phe Lys
1 5 10 15

Asp

<210> 99
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> 32703 CDR

<400> 99

Tyr Asp Tyr Asp Asp Thr Met Asp Tyr
1   5

<210> 100
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> OKT3 CDR

<400> 100

Ser Ala Ser Ser Ser Val Ser Tyr Met Asn
1   5   10

<210> 101
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> OKT3 CDR

<400> 101

Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser
1   5   10

<210> 102
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> OKT3 CDR

<400> 102

Gln Gln Trp Ser Ser Asn Pro Phe Thr
1   5

<210> 103
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> OKT3 CDR

<400> 103

Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr Thr Met His
1   5   10

<210> 104
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> OKT3 CDR

<400> 104

Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe Lys Asp
1   5   10   15

<210> 105
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> OKT3 CDR

<400> 105

Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr
1   5   10

<210> 106
<211> 242
<212> PRT
<213> Artificial Sequence

<220>
<223> scFv from OKT3

<400> 106

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
1   5   10   15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr
            20   25   30

Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
        35   40   45

Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe
    50   55   60

```
Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                85                  90                  95

Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly
            100                 105                 110

Thr Thr Leu Thr Val Ser Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly
        115                 120                 125

Gly Ser Gly Gly Gly Gly Ser Gln Ile Val Leu Thr Gln Ser Pro Ala
    130                 135                 140

Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala
145                 150                 155                 160

Ser Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys Ser Gly Thr
                165                 170                 175

Ser Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val
            180                 185                 190

Pro Ala His Phe Arg Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr
        195                 200                 205

Ile Ser Gly Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln
    210                 215                 220

Trp Ser Ser Asn Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile
225                 230                 235                 240

Asn Arg
```

<210> 107
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> 20G6-F3 CDR

<400> 107

```
Gln Ser Leu Val His Asn Asn Gly Asn Thr Tyr
1               5                   10
```

<210> 108
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> linker

<400> 108

Gly Gly Gly Ser Gly Gly Gly Ser
1 5

<210> 109
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> 20G6-F3 CDR

<400> 109

Gly Gln Gly Thr Gln Tyr Pro Phe Thr
1 5

<210> 110
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> 20G6-F3 CDR

<400> 110

Gly Phe Thr Phe Thr Lys Ala Trp
1 5

<210> 111
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> 20G6-F3 CDR

<400> 111

Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr
1 5 10

<210> 112
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> 20G6-F3 CDR

<400> 112

Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr
1 5 10

<210> 113
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> 4B4-D7 CDR

<400> 113

Gln Ser Leu Val His Asp Asn Gly Asn Thr Tyr
1 5 10

<210> 114
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> linker

<400> 114

Gly Gly Ser Gly Gly Ser
1 5

<210> 115
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> 4B4-D7 CDR

<400> 115

Gly Gln Gly Thr Gln Tyr Pro Phe Thr
1 5

<210> 116
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> 4B4-D7 CDR

<400> 116

Gly Phe Thr Phe Ser Asn Ala Trp
1 5

<210> 117
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> 4B4-D7 CDR

<400> 117

Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr
1 5 10

<210> 118
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> 4B4-D7 CDR

<400> 118

Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr
1 5 10

<210> 119
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> 4E7-C9 CDR

<400> 119

Gln Ser Leu Glu His Asn Asn Gly Asn Thr Tyr
1 5 10

<210> 120
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> linker

<400> 120

Gly Gly Ser Gly Gly Gly Ser Gly Gly Ser Gly
1 5 10

<210> 121
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> 4E7-C9 CDR

<400> 121

Gly Gln Gly Thr Gln Tyr Pro Phe Thr
1 5

<210> 122
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> 4E7-C9 CDR

<400> 122

Gly Phe Thr Phe Ser Asn Ala Trp
1 5

<210> 123
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> 4E7-C9 CDR

<400> 123

Ile Lys Asp Lys Ser Asn Asn Tyr Ala Thr
1 5 10

<210> 124
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> 4E7-C9 CDR

<400> 124

Arg Tyr Val His Tyr Gly Ile Gly Tyr Ala Met Asp Ala
1 5 10

<210> 125
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> 18F-H10 CDR

<400> 125

Gln Ser Leu Val His Thr Asn Gly Asn Thr Tyr
1 5 10

<210> 126
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Avi tag

<400> 126

Gly Leu Asn Asp Ile Phe Glu Ala Gln Lys Ile Glu Trp His Glu
1 5 10 15

<210> 127
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> 18F-H10 CDR

<400> 127

Gly Gln Gly Thr His Tyr Pro Phe Thr
1 5

<210> 128
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> 18F-H10 CDR

<400> 128

Gly Phe Thr Phe Thr Asn Ala Trp
1 5

<210> 129
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> 18F-H10 CDR

<400> 129

Lys Asp Lys Ser Asn Asn Tyr Ala Thr
1 5

<210> 130
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> 18F-H10 CDR

<400> 130

Arg Tyr Val His Tyr Arg Phe Ala Tyr Ala Leu Asp Ala
1 5 10

<210> 131
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> TGN1412 CDR

<400> 131

His Ala Ser Gln Asn Ile Tyr Val Trp Leu Asn
1 5 10

<210> 132
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> TGN1412 CDR

<400> 132

Lys Ala Ser Asn Leu His Thr
1 5

<210> 133
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> TGN1412 CDR

<400> 133

Gln Gln Gly Gln Thr Tyr Pro Tyr Thr
1 5

<210> 134
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> TGN1412 CDR

<400> 134

Ser Tyr Tyr Ile His
1 5

<210> 135
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> TGN1412 CDR

<400> 135

Cys Ile Tyr Pro Gly Asn Val Asn Thr Asn Tyr Asn Glu Lys Phe Lys
1 5 10 15

Asp

<210> 136
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> TGN1412 CDR

<400> 136

Ser His Tyr Gly Leu Asp Trp Asn Phe Asp Val
1 5 10

<210> 137
<211> 288
<212> PRT
<213> Homo sapiens

<400> 137

Met Gly His Thr Arg Arg Gln Gly Thr Ser Pro Ser Lys Cys Pro Tyr
1 5 10 15

Leu Asn Phe Phe Gln Leu Leu Val Leu Ala Gly Leu Ser His Phe Cys
20 25 30

Ser Gly Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu
35 40 45

Ser Cys Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile
50 55 60

Tyr Trp Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp
65 70 75 80

Met Asn Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr
85 90 95

```
Asn Asn Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly
            100                 105                 110

Thr Tyr Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg
        115                 120                 125

Glu His Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr
    130                 135                 140

Pro Ser Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile
145                 150                 155                 160

Ile Cys Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu
                165                 170                 175

Glu Asn Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp
            180                 185                 190

Pro Glu Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met
        195                 200                 205

Thr Thr Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg
    210                 215                 220

Val Asn Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro
225                 230                 235                 240

Asp Asn Leu Leu Pro Ser Trp Ala Ile Thr Leu Ile Ser Val Asn Gly
                245                 250                 255

Ile Phe Val Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg Cys Arg
            260                 265                 270

Glu Arg Arg Arg Asn Glu Arg Leu Arg Arg Glu Ser Val Arg Pro Val
        275                 280                 285


<210>  138
<211>  329
<212>  PRT
<213>  Homo sapiens

<400>  138

Met Asp Pro Gln Cys Thr Met Gly Leu Ser Asn Ile Leu Phe Val Met
1               5                   10                  15

Ala Phe Leu Leu Ser Gly Ala Ala Pro Leu Lys Ile Gln Ala Tyr Phe
            20                  25                  30
```

```
Asn Glu Thr Ala Asp Leu Pro Cys Gln Phe Ala Asn Ser Gln Asn Gln
        35                  40                  45

Ser Leu Ser Glu Leu Val Val Phe Trp Gln Asp Gln Glu Asn Leu Val
    50                  55                  60

Leu Asn Glu Val Tyr Leu Gly Lys Glu Lys Phe Asp Ser Val His Ser
65                  70                  75                  80

Lys Tyr Met Gly Arg Thr Ser Phe Asp Ser Asp Ser Trp Thr Leu Arg
                85                  90                  95

Leu His Asn Leu Gln Ile Lys Asp Lys Gly Leu Tyr Gln Cys Ile Ile
            100                 105                 110

His His Lys Lys Pro Thr Gly Met Ile Arg Ile His Gln Met Asn Ser
        115                 120                 125

Glu Leu Ser Val Leu Ala Asn Phe Ser Gln Pro Glu Ile Val Pro Ile
    130                 135                 140

Ser Asn Ile Thr Glu Asn Val Tyr Ile Asn Leu Thr Cys Ser Ser Ile
145                 150                 155                 160

His Gly Tyr Pro Glu Pro Lys Lys Met Ser Val Leu Leu Arg Thr Lys
                165                 170                 175

Asn Ser Thr Ile Glu Tyr Asp Gly Val Met Gln Lys Ser Gln Asp Asn
            180                 185                 190

Val Thr Glu Leu Tyr Asp Val Ser Ile Ser Leu Ser Val Ser Phe Pro
        195                 200                 205

Asp Val Thr Ser Asn Met Thr Ile Phe Cys Ile Leu Glu Thr Asp Lys
    210                 215                 220

Thr Arg Leu Leu Ser Ser Pro Phe Ser Ile Glu Leu Glu Asp Pro Gln
225                 230                 235                 240

Pro Pro Pro Asp His Ile Pro Trp Ile Thr Ala Val Leu Pro Thr Val
                245                 250                 255

Ile Ile Cys Val Met Val Phe Cys Leu Ile Leu Trp Lys Trp Lys Lys
            260                 265                 270

Lys Lys Arg Pro Arg Asn Ser Tyr Lys Cys Gly Thr Asn Thr Met Glu
        275                 280                 285
```

Arg Glu Glu Ser Glu Gln Thr Lys Lys Arg Glu Lys Ile His Ile Pro
290 295 300

Glu Arg Ser Asp Glu Ala Gln Arg Val Phe Lys Ser Ser Lys Thr Ser
305 310 315 320

Ser Cys Asp Lys Ser Asp Thr Cys Phe
325

<210> 139
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CD80/CD86 CDR

<400> 139

Ser Val Ser Ser Ser Ile Ser Ser Ser Asn Leu His
1 5 10

<210> 140
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CD80/CD86 CDR

<400> 140

Gly Thr Ser Asn Leu Ala Ser
1 5

<210> 141
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CD80/CD86 CDR

<400> 141

Gln Gln Trp Ser Ser Tyr Pro Leu Thr
1 5

<210> 142
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CD80/CD86 CDR

<400> 142

Asp Tyr Tyr Met His
1 5

<210> 143
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CD80/CD86 CDR

<400> 143

Trp Ile Asp Pro Glu Asn Gly Asn Thr Leu Tyr Asp Pro Lys Phe Gln
1 5 10 15

Gly

<210> 144
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CD80/CD86 CDR

<400> 144

Glu Gly Leu Phe Phe Ala Tyr
1 5

<210> 145
<211> 784
<212> PRT
<213> Homo sapiens

<400> 145

Met Pro His Thr Leu Trp Met Val Trp Val Leu Gly Val Ile Ile Ser
1 5 10 15

Leu Ser Lys Glu Glu Ser Ser Asn Gln Ala Ser Leu Ser Cys Asp Arg
20 25 30

Asn Gly Ile Cys Lys Gly Ser Ser Gly Ser Leu Asn Ser Ile Pro Ser
35 40 45

Gly Leu Thr Glu Ala Val Lys Ser Leu Asp Leu Ser Asn Asn Arg Ile
50 55 60

Thr Tyr Ile Ser Asn Ser Asp Leu Gln Arg Cys Val Asn Leu Gln Ala
65 70 75 80

```
Leu Val Leu Thr Ser Asn Gly Ile Asn Thr Ile Glu Glu Asp Ser Phe
                85                  90                  95

Ser Ser Leu Gly Ser Leu Glu His Leu Asp Leu Ser Tyr Asn Tyr Leu
            100                 105                 110

Ser Asn Leu Ser Ser Ser Trp Phe Lys Pro Leu Ser Ser Leu Thr Phe
        115                 120                 125

Leu Asn Leu Leu Gly Asn Pro Tyr Lys Thr Leu Gly Glu Thr Ser Leu
    130                 135                 140

Phe Ser His Leu Thr Lys Leu Gln Ile Leu Arg Val Gly Asn Met Asp
145                 150                 155                 160

Thr Phe Thr Lys Ile Gln Arg Lys Asp Phe Ala Gly Leu Thr Phe Leu
                165                 170                 175

Glu Glu Leu Glu Ile Asp Ala Ser Asp Leu Gln Ser Tyr Glu Pro Lys
            180                 185                 190

Ser Leu Lys Ser Ile Gln Asn Val Ser His Leu Ile Leu His Met Lys
        195                 200                 205

Gln His Ile Leu Leu Leu Glu Ile Phe Val Asp Val Thr Ser Ser Val
    210                 215                 220

Glu Cys Leu Glu Leu Arg Asp Thr Asp Leu Asp Thr Phe His Phe Ser
225                 230                 235                 240

Glu Leu Ser Thr Gly Glu Thr Asn Ser Leu Ile Lys Lys Phe Thr Phe
                245                 250                 255

Arg Asn Val Lys Ile Thr Asp Glu Ser Leu Phe Gln Val Met Lys Leu
            260                 265                 270

Leu Asn Gln Ile Ser Gly Leu Leu Glu Leu Glu Phe Asp Asp Cys Thr
        275                 280                 285

Leu Asn Gly Val Gly Asn Phe Arg Ala Ser Asp Asn Asp Arg Val Ile
    290                 295                 300

Asp Pro Gly Lys Val Glu Thr Leu Thr Ile Arg Arg Leu His Ile Pro
305                 310                 315                 320

Arg Phe Tyr Leu Phe Tyr Asp Leu Ser Thr Leu Tyr Ser Leu Thr Glu
```

325 330 335

Arg Val Lys Arg Ile Thr Val Glu Asn Ser Lys Val Phe Leu Val Pro
340 345 350

Cys Leu Leu Ser Gln His Leu Lys Ser Leu Glu Tyr Leu Asp Leu Ser
355 360 365

Glu Asn Leu Met Val Glu Glu Tyr Leu Lys Asn Ser Ala Cys Glu Asp
370 375 380

Ala Trp Pro Ser Leu Gln Thr Leu Ile Leu Arg Gln Asn His Leu Ala
385 390 395 400

Ser Leu Glu Lys Thr Gly Glu Thr Leu Leu Thr Leu Lys Asn Leu Thr
405 410 415

Asn Ile Asp Ile Ser Lys Asn Ser Phe His Ser Met Pro Glu Thr Cys
420 425 430

Gln Trp Pro Glu Lys Met Lys Tyr Leu Asn Leu Ser Ser Thr Arg Ile
435 440 445

His Ser Val Thr Gly Cys Ile Pro Lys Thr Leu Glu Ile Leu Asp Val
450 455 460

Ser Asn Asn Asn Leu Asn Leu Phe Ser Leu Asn Leu Pro Gln Leu Lys
465 470 475 480

Glu Leu Tyr Ile Ser Arg Asn Lys Leu Met Thr Leu Pro Asp Ala Ser
485 490 495

Leu Leu Pro Met Leu Leu Val Leu Lys Ile Ser Arg Asn Ala Ile Thr
500 505 510

Thr Phe Ser Lys Glu Gln Leu Asp Ser Phe His Thr Leu Lys Thr Leu
515 520 525

Glu Ala Gly Gly Asn Asn Phe Ile Cys Ser Cys Glu Phe Leu Ser Phe
530 535 540

Thr Gln Glu Gln Gln Ala Leu Ala Lys Val Leu Ile Asp Trp Pro Ala
545 550 555 560

Asn Tyr Leu Cys Asp Ser Pro Ser His Val Arg Gly Gln Gln Val Gln
565 570 575

```
Asp Val Arg Leu Ser Val Ser Glu Cys His Arg Thr Ala Leu Val Ser
            580                 585                 590

Gly Met Cys Cys Ala Leu Phe Leu Leu Ile Leu Leu Thr Gly Val Leu
        595                 600                 605

Cys His Arg Phe His Gly Leu Trp Tyr Met Lys Met Met Trp Ala Trp
    610                 615                 620

Leu Gln Ala Lys Arg Lys Pro Arg Lys Ala Pro Ser Arg Asn Ile Cys
625                 630                 635                 640

Tyr Asp Ala Phe Val Ser Tyr Ser Glu Arg Asp Ala Tyr Trp Val Glu
                645                 650                 655

Asn Leu Met Val Gln Glu Leu Glu Asn Phe Asn Pro Pro Phe Lys Leu
            660                 665                 670

Cys Leu His Lys Arg Asp Phe Ile Pro Gly Lys Trp Ile Ile Asp Asn
        675                 680                 685

Ile Ile Asp Ser Ile Glu Lys Ser His Lys Thr Val Phe Val Leu Ser
    690                 695                 700

Glu Asn Phe Val Lys Ser Glu Trp Cys Lys Tyr Glu Leu Asp Phe Ser
705                 710                 715                 720

His Phe Arg Leu Phe Asp Glu Asn Asn Asp Ala Ala Ile Leu Ile Leu
                725                 730                 735

Leu Glu Pro Ile Glu Lys Lys Ala Ile Pro Gln Arg Phe Cys Lys Leu
            740                 745                 750

Arg Lys Ile Met Asn Thr Lys Thr Tyr Leu Glu Trp Pro Met Asp Glu
        755                 760                 765

Ala Gln Arg Glu Gly Phe Trp Val Asn Leu Arg Ala Ala Ile Lys Ser
    770                 775                 780


<210>  146
<211>  255
<212>  PRT
<213>  Homo sapiens

<400>  146

Met Gly Asn Ser Cys Tyr Asn Ile Val Ala Thr Leu Leu Leu Val Leu
1               5                   10                  15
```

```
Asn Phe Glu Arg Thr Arg Ser Leu Gln Asp Pro Cys Ser Asn Cys Pro
            20                  25                  30

Ala Gly Thr Phe Cys Asp Asn Asn Arg Asn Gln Ile Cys Ser Pro Cys
        35                  40                  45

Pro Pro Asn Ser Phe Ser Ser Ala Gly Gly Gln Arg Thr Cys Asp Ile
    50                  55                  60

Cys Arg Gln Cys Lys Gly Val Phe Arg Thr Arg Lys Glu Cys Ser Ser
65                  70                  75                  80

Thr Ser Asn Ala Glu Cys Asp Cys Thr Pro Gly Phe His Cys Leu Gly
                85                  90                  95

Ala Gly Cys Ser Met Cys Glu Gln Asp Cys Lys Gln Gly Gln Glu Leu
            100                 105                 110

Thr Lys Lys Gly Cys Lys Asp Cys Cys Phe Gly Thr Phe Asn Asp Gln
        115                 120                 125

Lys Arg Gly Ile Cys Arg Pro Trp Thr Asn Cys Ser Leu Asp Gly Lys
    130                 135                 140

Ser Val Leu Val Asn Gly Thr Lys Glu Arg Asp Val Val Cys Gly Pro
145                 150                 155                 160

Ser Pro Ala Asp Leu Ser Pro Gly Ala Ser Ser Val Thr Pro Pro Ala
                165                 170                 175

Pro Ala Arg Glu Pro Gly His Ser Pro Gln Ile Ile Ser Phe Phe Leu
            180                 185                 190

Ala Leu Thr Ser Thr Ala Leu Leu Phe Leu Leu Phe Phe Leu Thr Leu
        195                 200                 205

Arg Phe Ser Val Val Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe
    210                 215                 220

Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly
225                 230                 235                 240

Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu
                245                 250                 255
```

<210> 147
<211> 7
<212> PRT

<213> Artificial Sequence

<220>
<223> anti-4-1BB 1 CDR

<400> 147

Arg Ala Ser Gln Ser Val Ser
1 5

<210> 148
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-4-1BB 1 CDR

<400> 148

Ala Ser Asn Arg Ala Thr
1 5

<210> 149
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-4-1BB 1 CDR

<400> 149

Gln Arg Ser Asn Trp Pro Pro Ala Leu Thr
1 5 10

<210> 150
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-4-1BB 1 CDR

<400> 150

Tyr Tyr Trp Ser
1

<210> 151
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> linker

<400> 151

Gly Gly Ser Gly Gly Gly Ser Gly Ser Gly
1 5 10

<210> 152
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-4-1BB 1 CDR

<400> 152

Tyr Gly Pro Gly Asn Tyr Asp Trp Tyr Phe Asp Leu
1 5 10

<210> 153
<211> 288
<212> PRT
<213> Homo sapiens

<400> 153

Met Gln Ile Pro Gln Ala Pro Trp Pro Val Val Trp Ala Val Leu Gln
1 5 10 15

Leu Gly Trp Arg Pro Gly Trp Phe Leu Asp Ser Pro Asp Arg Pro Trp
20 25 30

Asn Pro Pro Thr Phe Ser Pro Ala Leu Leu Val Val Thr Glu Gly Asp
35 40 45

Asn Ala Thr Phe Thr Cys Ser Phe Ser Asn Thr Ser Glu Ser Phe Val
50 55 60

Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr Asp Lys Leu Ala
65 70 75 80

Ala Phe Pro Glu Asp Arg Ser Gln Pro Gly Gln Asp Cys Arg Phe Arg
85 90 95

Val Thr Gln Leu Pro Asn Gly Arg Asp Phe His Met Ser Val Val Arg
100 105 110

Ala Arg Arg Asn Asp Ser Gly Thr Tyr Leu Cys Gly Ala Ile Ser Leu
115 120 125

Ala Pro Lys Ala Gln Ile Lys Glu Ser Leu Arg Ala Glu Leu Arg Val
130 135 140

Thr Glu Arg Arg Ala Glu Val Pro Thr Ala His Pro Ser Pro Ser Pro
145 150 155 160

Arg Pro Ala Gly Gln Phe Gln Thr Leu Val Val Gly Val Val Gly Gly
165 170 175

Leu Leu Gly Ser Leu Val Leu Leu Val Trp Val Leu Ala Val Ile Cys
180 185 190

Ser Arg Ala Ala Arg Gly Thr Ile Gly Ala Arg Arg Thr Gly Gln Pro
195 200 205

Leu Lys Glu Asp Pro Ser Ala Val Pro Val Phe Ser Val Asp Tyr Gly
210 215 220

Glu Leu Asp Phe Gln Trp Arg Glu Lys Thr Pro Glu Pro Pro Val Pro
225 230 235 240

Cys Val Pro Glu Gln Thr Glu Tyr Ala Thr Ile Val Phe Pro Ser Gly
245 250 255

Met Gly Thr Ser Ser Pro Ala Arg Arg Gly Ser Ala Asp Gly Pro Arg
260 265 270

Ser Ala Gln Pro Leu Arg Pro Glu Asp Gly His Cys Ser Trp Pro Leu
275 280 285

<210> 154
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-1 1 CDR

<400> 154

Arg Ala Ser Gln Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His
1 5 10 15

<210> 155
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-1 1 CDR

<400> 155

Phe Gly Ser Asn Leu Glu Ser
1 5

<210> 156

<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-1 1 CDR

<400> 156

Gln His Ser Trp Glu Ile Pro Tyr Thr
1 5

<210> 157
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-1 1 CDR

<400> 157

Ser Ser Trp Ile His
1 5

<210> 158
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-1 1 CDR

<400> 158

Tyr Ile Tyr Pro Ser Thr Gly Phe Thr Glu Tyr Asn Gln Lys Phe Lys
1 5 10 15

Asp

<210> 159
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-1 1 CDR

<400> 159

Trp Arg Asp Ser Ser Gly Tyr His Ala Met Asp Tyr
1 5 10

<210> 160
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-1 2 CDR

<400> 160

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1   5   10

<210> 161
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-1 2 CDR

<400> 161

Asp Ala Ser Asn Arg Ala Thr
1   5

<210> 162
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-1 2 CDR

<400> 162

Gln Gln Ser Ser Asn Trp Pro Arg Thr
1   5

<210> 163
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-1 2 CDR

<400> 163

Asn Ser Gly Met His
1   5

<210> 164
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-1 2 CDR

<400> 164

Val Leu Trp Tyr Asp Gly Ser Lys Arg Tyr Tyr Ala Asp Ser Val Lys

1 5 10 15

Gly

<210> 165
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-1 2 CDR

<400> 165

Asn Asp Asp Tyr
1

<210> 166
<211> 525
<212> PRT
<213> Homo sapiens

<400> 166

Met Trp Glu Ala Gln Phe Leu Gly Leu Leu Phe Leu Gln Pro Leu Trp
1 5 10 15

Val Ala Pro Val Lys Pro Leu Gln Pro Gly Ala Glu Val Pro Val Val
20 25 30

Trp Ala Gln Glu Gly Ala Pro Ala Gln Leu Pro Cys Ser Pro Thr Ile
35 40 45

Pro Leu Gln Asp Leu Ser Leu Leu Arg Arg Ala Gly Val Thr Trp Gln
50 55 60

His Gln Pro Asp Ser Gly Pro Pro Ala Ala Ala Pro Gly His Pro Leu
65 70 75 80

Ala Pro Gly Pro His Pro Ala Ala Pro Ser Ser Trp Gly Pro Arg Pro
85 90 95

Arg Arg Tyr Thr Val Leu Ser Val Gly Pro Gly Gly Leu Arg Ser Gly
100 105 110

Arg Leu Pro Leu Gln Pro Arg Val Gln Leu Asp Glu Arg Gly Arg Gln
115 120 125

Arg Gly Asp Phe Ser Leu Trp Leu Arg Pro Ala Arg Arg Ala Asp Ala
130 135 140

```
Gly Glu Tyr Arg Ala Ala Val His Leu Arg Asp Arg Ala Leu Ser Cys
145                 150                 155                 160

Arg Leu Arg Leu Arg Leu Gly Gln Ala Ser Met Thr Ala Ser Pro Pro
                165                 170                 175

Gly Ser Leu Arg Ala Ser Asp Trp Val Ile Leu Asn Cys Ser Phe Ser
            180                 185                 190

Arg Pro Asp Arg Pro Ala Ser Val His Trp Phe Arg Asn Arg Gly Gln
        195                 200                 205

Gly Arg Val Pro Val Arg Glu Ser Pro His His His Leu Ala Glu Ser
    210                 215                 220

Phe Leu Phe Leu Pro Gln Val Ser Pro Met Asp Ser Gly Pro Trp Gly
225                 230                 235                 240

Cys Ile Leu Thr Tyr Arg Asp Gly Phe Asn Val Ser Ile Met Tyr Asn
                245                 250                 255

Leu Thr Val Leu Gly Leu Glu Pro Pro Thr Pro Leu Thr Val Tyr Ala
            260                 265                 270

Gly Ala Gly Ser Arg Val Gly Leu Pro Cys Arg Leu Pro Ala Gly Val
        275                 280                 285

Gly Thr Arg Ser Phe Leu Thr Ala Lys Trp Thr Pro Pro Gly Gly Gly
    290                 295                 300

Pro Asp Leu Leu Val Thr Gly Asp Asn Gly Asp Phe Thr Leu Arg Leu
305                 310                 315                 320

Glu Asp Val Ser Gln Ala Gln Ala Gly Thr Tyr Thr Cys His Ile His
                325                 330                 335

Leu Gln Glu Gln Gln Leu Asn Ala Thr Val Thr Leu Ala Ile Ile Thr
            340                 345                 350

Val Thr Pro Lys Ser Phe Gly Ser Pro Gly Ser Leu Gly Lys Leu Leu
        355                 360                 365

Cys Glu Val Thr Pro Val Ser Gly Gln Glu Arg Phe Val Trp Ser Ser
    370                 375                 380

Leu Asp Thr Pro Ser Gln Arg Ser Phe Ser Gly Pro Trp Leu Glu Ala
385                 390                 395                 400
```

Gln Glu Ala Gln Leu Leu Ser Gln Pro Trp Gln Cys Gln Leu Tyr Gln
405 410 415

Gly Glu Arg Leu Leu Gly Ala Ala Val Tyr Phe Thr Glu Leu Ser Ser
420 425 430

Pro Gly Ala Gln Arg Ser Gly Arg Ala Pro Gly Ala Leu Pro Ala Gly
435 440 445

His Leu Leu Leu Phe Leu Ile Leu Gly Val Leu Ser Leu Leu Leu Leu
450 455 460

Val Thr Gly Ala Phe Gly Phe His Leu Trp Arg Arg Gln Trp Arg Pro
465 470 475 480

Arg Arg Phe Ser Ala Leu Glu Gln Gly Ile His Pro Pro Gln Ala Gln
485 490 495

Ser Lys Ile Glu Glu Leu Glu Gln Glu Pro Glu Pro Glu Pro Glu Pro
500 505 510

Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu Gln Leu
515 520 525

<210> 167
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-LAG3 CDR

<400> 167

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ala
1 5 10

<210> 168
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-LAG3 CDR

<400> 168

Asp Ala Ser Asn Arg Ala Thr
1 5

<210> 169

<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-LAG3 CDR

<400> 169

Gln Gln Arg Ser Asn Trp Pro Leu Thr
1 5

<210> 170
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-LAG3 CDR

<400> 170

Asp Tyr Tyr Trp Asn
1 5

<210> 171
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-LAG3 CDR

<400> 171

Glu Ile Asn His Arg Gly Ser Thr Asn Ser Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> 172
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-LAG3 CDR

<400> 172

Gly Tyr Ser Asp Tyr Glu Tyr Asn Trp Phe Asp Pro
1 5 10

<210> 173
<211> 301
<212> PRT
<213> Homo sapiens

<400> 173

Met Phe Ser His Leu Pro Phe Asp Cys Val Leu Leu Leu Leu Leu Leu

```
1               5                   10                  15

Leu Leu Thr Arg Ser Ser Glu Val Glu Tyr Arg Ala Glu Val Gly Gln
            20                  25                  30

Asn Ala Tyr Leu Pro Cys Phe Tyr Thr Pro Ala Ala Pro Gly Asn Leu
        35                  40                  45

Val Pro Val Cys Trp Gly Lys Gly Ala Cys Pro Val Phe Glu Cys Gly
    50                  55                  60

Asn Val Val Leu Arg Thr Asp Glu Arg Asp Val Asn Tyr Trp Thr Ser
65                  70                  75                  80

Arg Tyr Trp Leu Asn Gly Asp Phe Arg Lys Gly Asp Val Ser Leu Thr
                85                  90                  95

Ile Glu Asn Val Thr Leu Ala Asp Ser Gly Ile Tyr Cys Cys Arg Ile
            100                 105                 110

Gln Ile Pro Gly Ile Met Asn Asp Glu Lys Phe Asn Leu Lys Leu Val
        115                 120                 125

Ile Lys Pro Ala Lys Val Thr Pro Ala Pro Thr Arg Gln Arg Asp Phe
    130                 135                 140

Thr Ala Ala Phe Pro Arg Met Leu Thr Thr Arg Gly His Gly Pro Ala
145                 150                 155                 160

Glu Thr Gln Thr Leu Gly Ser Leu Pro Asp Ile Asn Leu Thr Gln Ile
                165                 170                 175

Ser Thr Leu Ala Asn Glu Leu Arg Asp Ser Arg Leu Ala Asn Asp Leu
            180                 185                 190

Arg Asp Ser Gly Ala Thr Ile Arg Ile Gly Ile Tyr Ile Gly Ala Gly
        195                 200                 205

Ile Cys Ala Gly Leu Ala Leu Ala Leu Ile Phe Gly Ala Leu Ile Phe
    210                 215                 220

Lys Trp Tyr Ser His Ser Lys Glu Lys Ile Gln Asn Leu Ser Leu Ile
225                 230                 235                 240

Ser Leu Ala Asn Leu Pro Pro Ser Gly Leu Ala Asn Ala Val Ala Glu
                245                 250                 255
```

Gly Ile Arg Ser Glu Glu Asn Ile Tyr Thr Ile Glu Glu Asn Val Tyr
260 265 270

Glu Val Glu Glu Pro Asn Glu Tyr Tyr Cys Tyr Val Ser Ser Arg Gln
275 280 285

Gln Pro Ser Gln Pro Leu Gly Cys Arg Phe Ala Met Pro
290 295 300

<210> 174
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-TIM-3 CDR

<400> 174

Ser Glu Ser Val Glu Tyr Tyr Gly Thr Ser Leu
1 5 10

<210> 175
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> linker

<400> 175

Gly Gly Ser Gly Gly Gly Ser Gly
1 5

<210> 176
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-TIM-3 CDR

<400> 176

Ser Arg Lys Asp Pro Ser
1 5

<210> 177
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-TIM-3 CDR

<400> 177

Gly Tyr Thr Phe Thr Ser Tyr
1 5

<210> 178
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-TIM-3 CDR

<400> 178

Tyr Pro Gly Asn Gly Asp
1 5

<210> 179
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-TIM-3 CDR

<400> 179

Val Gly Gly Ala Phe Pro Met Asp Tyr
1 5

<210> 180
<211> 289
<212> PRT
<213> Homo sapiens

<400> 180

Met Lys Thr Leu Pro Ala Met Leu Gly Thr Gly Lys Leu Phe Trp Val
1 5 10 15

Phe Phe Leu Ile Pro Tyr Leu Asp Ile Trp Asn Ile His Gly Lys Glu
20 25 30

Ser Cys Asp Val Gln Leu Tyr Ile Lys Arg Gln Ser Glu His Ser Ile
35 40 45

Leu Ala Gly Asp Pro Phe Glu Leu Glu Cys Pro Val Lys Tyr Cys Ala
50 55 60

Asn Arg Pro His Val Thr Trp Cys Lys Leu Asn Gly Thr Thr Cys Val
65 70 75 80

Lys Leu Glu Asp Arg Gln Thr Ser Trp Lys Glu Glu Lys Asn Ile Ser
85 90 95

```
Phe Phe Ile Leu His Phe Glu Pro Val Leu Pro Asn Asp Asn Gly Ser
            100                 105                 110

Tyr Arg Cys Ser Ala Asn Phe Gln Ser Asn Leu Ile Glu Ser His Ser
        115                 120                 125

Thr Thr Leu Tyr Val Thr Asp Val Lys Ser Ala Ser Glu Arg Pro Ser
    130                 135                 140

Lys Asp Glu Met Ala Ser Arg Pro Trp Leu Leu Tyr Arg Leu Leu Pro
145                 150                 155                 160

Leu Gly Gly Leu Pro Leu Leu Ile Thr Thr Cys Phe Cys Leu Phe Cys
                165                 170                 175

Cys Leu Arg Arg His Gln Gly Lys Gln Asn Glu Leu Ser Asp Thr Ala
            180                 185                 190

Gly Arg Glu Ile Asn Leu Val Asp Ala His Leu Lys Ser Glu Gln Thr
        195                 200                 205

Glu Ala Ser Thr Arg Gln Asn Ser Gln Val Leu Leu Ser Glu Thr Gly
    210                 215                 220

Ile Tyr Asp Asn Asp Pro Asp Leu Cys Phe Arg Met Gln Glu Gly Ser
225                 230                 235                 240

Glu Val Tyr Ser Asn Pro Cys Leu Glu Glu Asn Lys Pro Gly Ile Val
                245                 250                 255

Tyr Ala Ser Leu Asn His Ser Val Ile Gly Pro Asn Ser Arg Leu Ala
            260                 265                 270

Arg Asn Val Lys Glu Ala Pro Thr Glu Tyr Ala Ser Ile Cys Val Arg
        275                 280                 285

Ser
```

<210> 181
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-BTLA 1 CDR

<400> 181

Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala
1 5 10

<210> 182
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-BTLA 1 CDR

<400> 182

Gly Ala Ser Ser Arg Ala Thr
1 5

<210> 183
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-BTLA 1 CDR

<400> 183

Gln Gln Tyr Gly Ser Ser Ile Thr
1 5

<210> 184
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-BTLA 1 CDR

<400> 184

Thr Ile Gly Val Gly Val Asn
1 5

<210> 185
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-BTLA 1 CDR

<400> 185

Leu Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Ser Pro Ser Leu Lys Arg
1 5 10 15

<210> 186
<211> 18
<212> PRT

<213> Artificial Sequence

<220>
<223> anti-BTLA 1 CDR

<400> 186

Ser Gly Ile Thr Glu Val Arg Gly Val Ile Ile His Tyr Tyr Gly Met
1 5 10 15

Asp Val

<210> 187
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-BTLA 2 CDR

<400> 187

Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala
1 5 10

<210> 188
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-BTLA 2 CDR

<400> 188

Gly Ala Ser Ser Arg Ala Thr
1 5

<210> 189
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-BTLA 2 CDR

<400> 189

Gln Gln Tyr Gly Ser Ser Pro Pro Ile Thr
1 5 10

<210> 190
<211> 7
<212> PRT
<213> Artificial Sequence

<220>

<223> anti-BTLA 2 CDR

<400> 190

Thr Ser Gly Met Cys Val Ser
1 5

<210> 191
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-BTLA 2 CDR

<400> 191

Leu Ile Asp Trp Asp Asp Val Lys Tyr Tyr Ser Ser Ser Leu Lys Thr
1 5 10 15

<210> 192
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-BTLA 2 CDR

<400> 192

Ile Arg Phe Thr Met Phe Arg Gly Val Tyr Tyr Tyr Tyr Tyr Gly Leu
1 5 10 15

Asp Val

<210> 193
<211> 223
<212> PRT
<213> Homo sapiens

<400> 193

Met Ala Cys Leu Gly Phe Gln Arg His Lys Ala Gln Leu Asn Leu Ala
1 5 10 15

Thr Arg Thr Trp Pro Cys Thr Leu Leu Phe Phe Leu Leu Phe Ile Pro
20 25 30

Val Phe Cys Lys Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala
35 40 45

Ser Ser Arg Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly
50 55 60

Lys Ala Thr Glu Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln
65 70 75 80

Val Thr Glu Val Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr
85 90 95

Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val
100 105 110

Asn Leu Thr Ile Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile
115 120 125

Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly
130 135 140

Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser
145 150 155 160

Asp Phe Leu Leu Trp Ile Leu Ala Ala Val Ser Ser Gly Leu Phe Phe
165 170 175

Tyr Ser Phe Leu Leu Thr Ala Val Ser Leu Ser Lys Met Leu Lys Lys
180 185 190

Arg Ser Pro Leu Thr Thr Gly Val Tyr Val Lys Met Pro Pro Thr Glu
195 200 205

Pro Glu Cys Glu Lys Gln Phe Gln Pro Tyr Phe Ile Pro Ile Asn
210 215 220

<210> 194
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CTLA-4 1 CDR

<400> 194

Arg Ala Ser Gln Ser Val Gly Ser Ser Tyr Leu Ala
1 5 10

<210> 195
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CTLA-4 1 CDR

<400> 195

Gly Ala Phe Ser Arg Ala Thr
1 5

<210> 196
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CTLA-4 1 CDR

<400> 196

Gln Gln Tyr Gly Ser Ser Pro Trp Thr
1 5

<210> 197
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CTLA-4 1 CDR

<400> 197

Ser Tyr Thr Met His
1 5

<210> 198
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CTLA-4 1 CDR

<400> 198

Phe Ile Ser Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

<210> 199
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CTLA-4 1 CDR

<400> 199

Thr Gly Trp Leu Gly Pro Phe Asp Tyr
1 5

<210> 200
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CTLA-4 2 CDR

<400> 200

Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala
1 5 10

<210> 201
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CTLA-4 2 CDR

<400> 201

Ala Ala Ser Ser Leu Gln Ser
1 5

<210> 202
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CTLA-4 2 CDR

<400> 202

Gln Gln Tyr Asn Ser Tyr Pro Pro Thr
1 5

<210> 203
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CTLA-4 2 CDR

<400> 203

Ser Tyr Gly Met His
1 5

<210> 204
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CTLA-4 2 CDR

<400> 204

Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

<210> 205
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CTLA-4 2 CDR

<400> 205

Ala Pro Asn Tyr Ile Gly Ala Phe Asp Val
1 5 10

<210> 206
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CTLA-4 3 CDR

<400> 206

Ser Ala Thr Ser Ser Ile Thr Tyr Met Ser
1 5 10

<210> 207
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CTLA-4 3 CDR

<400> 207

Asp Thr Ser Asn Leu Ala Ser
1 5

<210> 208
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CTLA-4 3 CDR

<400> 208

Gln Gln Trp Ser Ser Tyr Pro Leu Thr
1 5

<210> 209
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CTLA-4 3 CDR

<400> 209

Ser Tyr Gly Val Tyr
1 5

<210> 210
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CTLA-4 3 CDR

<400> 210

Val Ile Trp Ala Gly Gly Thr Thr Asn Tyr Asn Ser Ala Leu Met Ser
1 5 10 15

<210> 211
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CTLA-4 3 CDR

<400> 211

Gly Pro Pro His Ala Met Met Lys Arg Gly Tyr Ala Met Asp Tyr
1 5 10 15

<210> 212
<211> 278
<212> PRT
<213> Homo sapiens

<400> 212

Met Glu Arg Leu Val Ile Arg Met Pro Phe Ser His Leu Ser Thr Tyr
1 5 10 15

Ser Leu Val Trp Val Met Ala Ala Val Val Leu Cys Thr Ala Gln Val
20 25 30

```
Gln Val Val Thr Gln Asp Glu Arg Glu Gln Leu Tyr Thr Pro Ala Ser
        35                  40                  45

Leu Lys Cys Ser Leu Gln Asn Ala Gln Glu Ala Leu Ile Val Thr Trp
    50                  55                  60

Gln Lys Lys Lys Ala Val Ser Pro Glu Asn Met Val Thr Phe Ser Glu
65                  70                  75                  80

Asn His Gly Val Val Ile Gln Pro Ala Tyr Lys Asp Lys Ile Asn Ile
                85                  90                  95

Thr Gln Leu Gly Leu Gln Asn Ser Thr Ile Thr Phe Trp Asn Ile Thr
            100                 105                 110

Leu Glu Asp Glu Gly Cys Tyr Met Cys Leu Phe Asn Thr Phe Gly Phe
        115                 120                 125

Gly Lys Ile Ser Gly Thr Ala Cys Leu Thr Val Tyr Val Gln Pro Ile
    130                 135                 140

Val Ser Leu His Tyr Lys Phe Ser Glu Asp His Leu Asn Ile Thr Cys
145                 150                 155                 160

Ser Ala Thr Ala Arg Pro Ala Pro Met Val Phe Trp Lys Val Pro Arg
                165                 170                 175

Ser Gly Ile Glu Asn Ser Thr Val Thr Leu Ser His Pro Asn Gly Thr
            180                 185                 190

Thr Ser Val Thr Ser Ile Leu His Ile Lys Asp Pro Lys Asn Gln Val
        195                 200                 205

Gly Lys Glu Val Ile Cys Gln Val Leu His Leu Gly Thr Val Thr Asp
    210                 215                 220

Phe Lys Gln Thr Val Asn Lys Gly Tyr Trp Phe Ser Val Pro Leu Leu
225                 230                 235                 240

Leu Ser Ile Val Ser Leu Val Ile Leu Leu Val Leu Ile Ser Ile Leu
                245                 250                 255

Leu Tyr Trp Lys Arg His Arg Asn Gln Asp Arg Gly Glu Leu Ser Gln
            260                 265                 270

Gly Val Gln Lys Met Thr
        275
```

<210> 213
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CD200 CDR

<400> 213

Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His
1 5 10 15

<210> 214
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CD200 CDR

<400> 214

Arg Ala Ser Asn Leu Glu Ser
1 5

<210> 215
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CD200 CDR

<400> 215

Gln Gln Ser Asn Glu Asp Pro Arg Thr
1 5

<210> 216
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CD200 CDR

<400> 216

Gly Phe Thr Phe Ser Gly Phe Ala Met Ser
1 5 10

<210> 217
<211> 16
<212> PRT
<213> Artificial Sequence

<220>

<223> anti-CD200 CDR

<400> 217

Ser Ile Ser Ser Gly Gly Thr Thr Tyr Tyr Leu Asp Ser Val Lys Gly
1 5 10 15

<210> 218
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-CD200 CDR

<400> 218

Gly Asn Tyr Tyr Ser Gly Thr Ser Tyr Asp Tyr
1 5 10

<210> 219
<211> 311
<212> PRT
<213> Homo sapiens

<400> 219

Met Gly Val Pro Thr Ala Leu Glu Ala Gly Ser Trp Arg Trp Gly Ser
1 5 10 15

Leu Leu Phe Ala Leu Phe Leu Ala Ala Ser Leu Gly Pro Val Ala Ala
20 25 30

Phe Lys Val Ala Thr Pro Tyr Ser Leu Tyr Val Cys Pro Glu Gly Gln
35 40 45

Asn Val Thr Leu Thr Cys Arg Leu Leu Gly Pro Val Asp Lys Gly His
50 55 60

Asp Val Thr Phe Tyr Lys Thr Trp Tyr Arg Ser Ser Arg Gly Glu Val
65 70 75 80

Gln Thr Cys Ser Glu Arg Arg Pro Ile Arg Asn Leu Thr Phe Gln Asp
85 90 95

Leu His Leu His His Gly Gly His Gln Ala Ala Asn Thr Ser His Asp
100 105 110

Leu Ala Gln Arg His Gly Leu Glu Ser Ala Ser Asp His His Gly Asn
115 120 125

Phe Ser Ile Thr Met Arg Asn Leu Thr Leu Leu Asp Ser Gly Leu Tyr
130 135 140

```
Cys Cys Leu Val Val Glu Ile Arg His His His Ser Glu His Arg Val
145                 150                 155                 160

His Gly Ala Met Glu Leu Gln Val Gln Thr Gly Lys Asp Ala Pro Ser
                165                 170                 175

Asn Cys Val Val Tyr Pro Ser Ser Ser Gln Asp Ser Glu Asn Ile Thr
            180                 185                 190

Ala Ala Ala Leu Ala Thr Gly Ala Cys Ile Val Gly Ile Leu Cys Leu
        195                 200                 205

Pro Leu Ile Leu Leu Leu Val Tyr Lys Gln Arg Gln Ala Ala Ser Asn
    210                 215                 220

Arg Arg Ala Gln Glu Leu Val Arg Met Asp Ser Asn Ile Gln Gly Ile
225                 230                 235                 240

Glu Asn Pro Gly Phe Glu Ala Ser Pro Pro Ala Gln Gly Ile Pro Glu
                245                 250                 255

Ala Lys Val Arg His Pro Leu Ser Tyr Val Ala Gln Arg Gln Pro Ser
            260                 265                 270

Glu Ser Gly Arg His Leu Leu Ser Glu Pro Ser Thr Pro Leu Ser Pro
        275                 280                 285

Pro Gly Pro Gly Asp Val Phe Phe Pro Ser Leu Asp Pro Val Pro Asp
    290                 295                 300

Ser Pro Asn Phe Glu Val Ile
305                 310


<210>  220
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-VISTA CDR

<400>  220

Gly Gly Thr Phe Ser Ser Tyr
1               5


<210>  221
<211>  7
<212>  PRT
```

<213> Artificial Sequence

<220>
<223> anti-VISTA CDR

<400> 221

Ile Ile Pro Ile Phe Gly Thr
1   5

<210> 222
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-VISTA CDR

<400> 222

Ala Arg Ser Ser Tyr Gly Trp
1   5

<210> 223
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-VISTA CDR

<400> 223

Gln Ser Ile Asp Thr Arg
1   5

<210> 224
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> linker

<400> 224

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1   5   10

<210> 225
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-VISTA CDR

<400> 225

Gln Gln Ser Ala Tyr Asn Pro
1 5

<210> 226
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-OKT8 CDR

<400> 226

Arg Thr Ser Arg Ser Ile Ser Gln Tyr Leu Ala
1 5 10

<210> 227
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-OKT8 CDR

<400> 227

Ser Gly Ser Thr Leu Gln Ser
1 5

<210> 228
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-OKT8 CDR

<400> 228

Gln Gln His Asn Glu Asn Pro Leu Thr
1 5

<210> 229
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-OKT8 CDR

<400> 229

Gly Phe Asn Ile Lys Asp
1 5

<210> 230
<211> 9
<212> PRT

<213> Artificial Sequence

<220>
<223> anti-OKT8 CDR

<400> 230

Arg Ile Asp Pro Ala Asn Asp Asn Thr
1 5

<210> 231
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-OKT8 CDR

<400> 231

Gly Tyr Gly Tyr Tyr Val Phe Asp His
1 5

<210> 232
<211> 109
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-KIR2DL1 light chain

<400> 232

Glu Ile Val Leu Thr Gln Ser Pro Val Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45

Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Met Tyr
85 90 95

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr
100 105

<210> 233
<211> 123
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-KIR2DL1 heavy chain

<400> 233

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Phe Tyr
20 25 30

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Gly Phe Ile Pro Ile Phe Gly Ala Ala Asn Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Ile Pro Ser Gly Ser Tyr Tyr Tyr Asp Tyr Asp Met Asp Val
100 105 110

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 234
<211> 277
<212> PRT
<213> Homo sapiens

<400> 234

Met Val Arg Leu Pro Leu Gln Cys Val Leu Trp Gly Cys Leu Leu Thr
1 5 10 15

Ala Val His Pro Glu Pro Pro Thr Ala Cys Arg Glu Lys Gln Tyr Leu
20 25 30

Ile Asn Ser Gln Cys Cys Ser Leu Cys Gln Pro Gly Gln Lys Leu Val
35 40 45

Ser Asp Cys Thr Glu Phe Thr Glu Thr Glu Cys Leu Pro Cys Gly Glu
50 55 60

```
Ser Glu Phe Leu Asp Thr Trp Asn Arg Glu Thr His Cys His Gln His
65                  70                  75                  80

Lys Tyr Cys Asp Pro Asn Leu Gly Leu Arg Val Gln Gln Lys Gly Thr
                85                  90                  95

Ser Glu Thr Asp Thr Ile Cys Thr Cys Glu Glu Gly Trp His Cys Thr
            100                 105                 110

Ser Glu Ala Cys Glu Ser Cys Val Leu His Arg Ser Cys Ser Pro Gly
        115                 120                 125

Phe Gly Val Lys Gln Ile Ala Thr Gly Val Ser Asp Thr Ile Cys Glu
    130                 135                 140

Pro Cys Pro Val Gly Phe Phe Ser Asn Val Ser Ser Ala Phe Glu Lys
145                 150                 155                 160

Cys His Pro Trp Thr Ser Cys Glu Thr Lys Asp Leu Val Val Gln Gln
                165                 170                 175

Ala Gly Thr Asn Lys Thr Asp Val Val Cys Gly Pro Gln Asp Arg Leu
            180                 185                 190

Arg Ala Leu Val Val Ile Pro Ile Ile Phe Gly Ile Leu Phe Ala Ile
        195                 200                 205

Leu Leu Val Leu Val Phe Ile Lys Lys Val Ala Lys Lys Pro Thr Asn
    210                 215                 220

Lys Ala Pro His Pro Lys Gln Glu Pro Gln Glu Ile Asn Phe Pro Asp
225                 230                 235                 240

Asp Leu Pro Gly Ser Asn Thr Ala Ala Pro Val Gln Glu Thr Leu His
                245                 250                 255

Gly Cys Gln Pro Val Thr Gln Glu Asp Gly Lys Glu Ser Arg Ile Ser
            260                 265                 270

Val Gln Glu Arg Gln
        275

<210>  235
<211>  290
<212>  PRT
<213>  Homo sapiens
```

<400> 235

Met Arg Ile Phe Ala Val Phe Ile Phe Met Thr Tyr Trp His Leu Leu
1 5 10 15

Asn Ala Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Val Glu Tyr
20 25 30

Gly Ser Asn Met Thr Ile Glu Cys Lys Phe Pro Val Glu Lys Gln Leu
35 40 45

Asp Leu Ala Ala Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile
50 55 60

Ile Gln Phe Val His Gly Glu Glu Asp Leu Lys Val Gln His Ser Ser
65 70 75 80

Tyr Arg Gln Arg Ala Arg Leu Leu Lys Asp Gln Leu Ser Leu Gly Asn
85 90 95

Ala Ala Leu Gln Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val Tyr
100 105 110

Arg Cys Met Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Val
115 120 125

Lys Val Asn Ala Pro Tyr Asn Lys Ile Asn Gln Arg Ile Leu Val Val
130 135 140

Asp Pro Val Thr Ser Glu His Glu Leu Thr Cys Gln Ala Glu Gly Tyr
145 150 155 160

Pro Lys Ala Glu Val Ile Trp Thr Ser Ser Asp His Gln Val Leu Ser
165 170 175

Gly Lys Thr Thr Thr Thr Asn Ser Lys Arg Glu Glu Lys Leu Phe Asn
180 185 190

Val Thr Ser Thr Leu Arg Ile Asn Thr Thr Thr Asn Glu Ile Phe Tyr
195 200 205

Cys Thr Phe Arg Arg Leu Asp Pro Glu Glu Asn His Thr Ala Glu Leu
210 215 220

Val Ile Pro Glu Leu Pro Leu Ala His Pro Pro Asn Glu Arg Thr His
225 230 235 240

Leu Val Ile Leu Gly Ala Ile Leu Leu Cys Leu Gly Val Ala Leu Thr

245 250 255

Phe Ile Phe Arg Leu Arg Lys Gly Arg Met Met Asp Val Lys Lys Cys
260 265 270

Gly Ile Gln Asp Thr Asn Ser Lys Lys Gln Ser Asp Thr His Leu Glu
275 280 285

Glu Thr
290

<210> 236
<211> 247
<212> PRT
<213> Homo sapiens

<400> 236

Met Leu Leu Leu Leu Pro Ile Leu Asn Leu Ser Leu Gln Leu His Pro
1 5 10 15

Val Ala Ala Leu Phe Thr Val Thr Ala Pro Lys Glu Val Tyr Thr Val
20 25 30

Asp Val Gly Ser Ser Val Ser Leu Glu Cys Asp Phe Asp Arg Arg Glu
35 40 45

Cys Thr Glu Leu Glu Gly Ile Arg Ala Ser Leu Gln Lys Val Glu Asn
50 55 60

Asp Thr Ser Leu Gln Ser Glu Arg Ala Thr Leu Leu Glu Glu Gln Leu
65 70 75 80

Pro Leu Gly Lys Ala Leu Phe His Ile Pro Ser Val Gln Val Arg Asp
85 90 95

Ser Gly Gln Tyr Arg Cys Leu Val Ile Cys Gly Ala Ala Trp Asp Tyr
100 105 110

Lys Tyr Leu Thr Val Lys Val Lys Ala Ser Tyr Met Arg Ile Asp Thr
115 120 125

Arg Ile Leu Glu Val Pro Gly Thr Gly Glu Val Gln Leu Thr Cys Gln
130 135 140

Ala Arg Gly Tyr Pro Leu Ala Glu Val Ser Trp Gln Asn Val Ser Val
145 150 155 160

Pro Ala Asn Thr Ser His Ile Arg Thr Pro Glu Gly Leu Tyr Gln Val

165 170 175

Thr Ser Val Leu Arg Leu Lys Pro Gln Pro Ser Arg Asn Phe Ser Cys
180 185 190

Met Phe Trp Asn Ala His Met Lys Glu Leu Thr Ser Ala Ile Ile Asp
195 200 205

Pro Leu Ser Arg Met Glu Pro Lys Val Pro Arg Thr Trp Pro Leu His
210 215 220

Val Phe Ile Pro Ala Cys Thr Ile Ala Leu Ile Phe Leu Ala Ile Val
225 230 235 240

Ile Ile Gln Arg Lys Arg Ile
245

<210> 237
<211> 355
<212> PRT
<213> Homo sapiens

<400> 237

Met Ala Phe Ser Gly Ser Gln Ala Pro Tyr Leu Ser Pro Ala Val Pro
1 5 10 15

Phe Ser Gly Thr Ile Gln Gly Gly Leu Gln Asp Gly Leu Gln Ile Thr
20 25 30

Val Asn Gly Thr Val Leu Ser Ser Ser Gly Thr Arg Phe Ala Val Asn
35 40 45

Phe Gln Thr Gly Phe Ser Gly Asn Asp Ile Ala Phe His Phe Asn Pro
50 55 60

Arg Phe Glu Asp Gly Gly Tyr Val Val Cys Asn Thr Arg Gln Asn Gly
65 70 75 80

Ser Trp Gly Pro Glu Glu Arg Lys Thr His Met Pro Phe Gln Lys Gly
85 90 95

Met Pro Phe Asp Leu Cys Phe Leu Val Gln Ser Ser Asp Phe Lys Val
100 105 110

Met Val Asn Gly Ile Leu Phe Val Gln Tyr Phe His Arg Val Pro Phe
115 120 125

His Arg Val Asp Thr Ile Ser Val Asn Gly Ser Val Gln Leu Ser Tyr

130 135 140

Ile Ser Phe Gln Asn Pro Arg Thr Val Pro Val Gln Pro Ala Phe Ser
145 150 155 160

Thr Val Pro Phe Ser Gln Pro Val Cys Phe Pro Pro Arg Pro Arg Gly
165 170 175

Arg Arg Gln Lys Pro Pro Gly Val Trp Pro Ala Asn Pro Ala Pro Ile
180 185 190

Thr Gln Thr Val Ile His Thr Val Gln Ser Ala Pro Gly Gln Met Phe
195 200 205

Ser Thr Pro Ala Ile Pro Pro Met Met Tyr Pro His Pro Ala Tyr Pro
210 215 220

Met Pro Phe Ile Thr Thr Ile Leu Gly Gly Leu Tyr Pro Ser Lys Ser
225 230 235 240

Ile Leu Leu Ser Gly Thr Val Leu Pro Ser Ala Gln Arg Phe His Ile
245 250 255

Asn Leu Cys Ser Gly Asn His Ile Ala Phe His Leu Asn Pro Arg Phe
260 265 270

Asp Glu Asn Ala Val Val Arg Asn Thr Gln Ile Asp Asn Ser Trp Gly
275 280 285

Ser Glu Glu Arg Ser Leu Pro Arg Lys Met Pro Phe Val Arg Gly Gln
290 295 300

Ser Phe Ser Val Trp Ile Leu Cys Glu Ala His Cys Leu Lys Val Ala
305 310 315 320

Val Asp Gly Gln His Leu Phe Glu Tyr Tyr His Arg Leu Arg Asn Leu
325 330 335

Pro Thr Ile Asn Arg Leu Glu Val Gly Gly Asp Ile Gln Leu Thr His
340 345 350

Val Gln Thr
355

<210> 238
<211> 525
<212> PRT
<213> Artificial Sequence

<220>
<223> BS-BDC

<400> 238

```
Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1               5                  10                  15

Ala Phe Leu Leu Ile Pro Asp Ile Val Met Thr Gln Ser Gln Lys Ile
            20                  25                  30

Met Ser Thr Thr Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser
        35                  40                  45

Gln Asn Val Asp Ala Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln
    50                  55                  60

Ser Pro Lys Leu Leu Ile Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val
65                  70                  75                  80

Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
                85                  90                  95

Ile Ser Asn Met Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln
            100                 105                 110

Tyr Asp Ile Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
        115                 120                 125

Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
    130                 135                 140

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala
145                 150                 155                 160

Ser Val Thr Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Asp Tyr
                165                 170                 175

Glu Met His Trp Val Ile Gln Thr Pro Val His Gly Leu Glu Trp Ile
            180                 185                 190

Gly Ala Ile Asp Pro Glu Thr Gly Gly Thr Ala Tyr Asn Gln Lys Phe
        195                 200                 205

Lys Gly Lys Ala Ile Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
    210                 215                 220

Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
```

```
225                 230                 235                 240

Thr Gly Tyr Tyr Asp Tyr Asp Ser Phe Thr Tyr Trp Gly Gln Gly Thr
                245                 250                 255

Leu Val Thr Val Ser Ala Gly Gly Gly Gly Ser Gln Val Gln Leu Val
            260                 265                 270

Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser
        275                 280                 285

Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Ile His Trp Val
    290                 295                 300

Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Cys Ile Tyr Pro
305                 310                 315                 320

Gly Asn Val Asn Thr Asn Tyr Asn Glu Lys Phe Lys Asp Arg Ala Thr
                325                 330                 335

Leu Thr Val Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg
            340                 345                 350

Leu Arg Ser Asp Asp Thr Ala Val Tyr Phe Cys Thr Arg Ser His Tyr
        355                 360                 365

Gly Leu Asp Trp Asn Phe Asp Val Trp Gly Gln Gly Thr Thr Val Thr
    370                 375                 380

Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
385                 390                 395                 400

Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
                405                 410                 415

Val Gly Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asn Ile Tyr
            420                 425                 430

Val Trp Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
        435                 440                 445

Leu Ile Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser Arg Phe
    450                 455                 460

Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
465                 470                 475                 480
```

Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Thr Tyr
485 490 495

Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Glu Gln Lys
500 505 510

Leu Ile Ser Glu Glu Asp Leu His His His His His His
515 520 525

<210> 239
<211> 520
<212> PRT
<213> Artificial Sequence

<220>
<223> BS-BDC

<400> 239

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Asp Ile Val Met Thr Gln Ser Gln Lys Ile
20 25 30

Met Ser Thr Thr Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser
35 40 45

Gln Asn Val Asp Ala Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln
50 55 60

Ser Pro Lys Leu Leu Ile Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val
65 70 75 80

Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
85 90 95

Ile Ser Asn Met Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln
100 105 110

Tyr Asp Ile Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
115 120 125

Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
130 135 140

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala
145 150 155 160

Ser Val Thr Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Asp Tyr

```
                165                 170                 175

Glu Met His Trp Val Ile Gln Thr Pro Val His Gly Leu Glu Trp Ile
            180                 185                 190

Gly Ala Ile Asp Pro Glu Thr Gly Gly Thr Ala Tyr Asn Gln Lys Phe
        195                 200                 205

Lys Gly Lys Ala Ile Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
    210                 215                 220

Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
225                 230                 235                 240

Thr Gly Tyr Tyr Asp Tyr Asp Ser Phe Thr Tyr Trp Gly Gln Gly Thr
                245                 250                 255

Leu Val Thr Val Ser Ala Gly Gly Gly Gly Ser Gln Val Gln Leu Leu
            260                 265                 270

Glu Ser Gly Pro Glu Leu Leu Lys Pro Gly Ala Ser Val Lys Met Ser
        275                 280                 285

Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met His Trp Val
    290                 295                 300

Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Tyr Ile Tyr Pro
305                 310                 315                 320

Tyr Thr Gly Gly Thr Gly Tyr Asn Gln Lys Phe Lys Asn Lys Ala Thr
                325                 330                 335

Leu Thr Val Asp Ser Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser
            340                 345                 350

Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asn Phe Arg
        355                 360                 365

Tyr Thr Tyr Trp Tyr Phe Asp Val Trp Gly Gln Gly Thr Thr Val Thr
    370                 375                 380

Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
385                 390                 395                 400

Gly Ser Asp Ile Val Met Thr Gln Ser Pro Ala Ser Leu Ala Val Ser
                405                 410                 415
```

```
Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp
            420                 425                 430

Ser Tyr Asp Asn Ser Leu Met His Trp Tyr Gln Gln Lys Pro Gly Gln
        435                 440                 445

Pro Pro Lys Val Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val
    450                 455                 460

Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr
465                 470                 475                 480

Ile Asp Pro Val Glu Ala Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gln
                485                 490                 495

Asn Asn Glu Asp Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
            500                 505                 510

Lys Arg His His His His His His
        515                 520
```

<210> 240
<211> 527
<212> PRT
<213> Artificial Sequence

<220>
<223> BS-BDC

<400> 240

```
Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1               5                   10                  15

Ala Phe Leu Leu Ile Pro Glu Leu Val Met Thr Gln Thr Pro Ser Ser
            20                  25                  30

Thr Ser Gly Ala Val Gly Gly Thr Val Thr Ile Asn Cys Gln Ala Ser
        35                  40                  45

Gln Ser Ile Asp Ser Asn Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln
    50                  55                  60

Pro Pro Thr Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val
65                  70                  75                  80

Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Glu Tyr Thr Leu Thr
                85                  90                  95

Ile Ser Gly Val Gln Arg Glu Asp Ala Ala Thr Tyr Tyr Cys Leu Gly
```

```
            100                 105                 110

Gly Val Gly Asn Val Ser Tyr Arg Thr Ser Phe Gly Gly Gly Thr Glu
        115                 120                 125

Val Val Val Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
    130                 135                 140

Gly Gly Ser Gln Ser Val Lys Glu Ser Glu Gly Asp Leu Val Thr Pro
145                 150                 155                 160

Ala Gly Asn Leu Thr Leu Thr Cys Thr Ala Ser Gly Ser Asp Ile Asn
                165                 170                 175

Asp Tyr Pro Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
            180                 185                 190

Trp Ile Gly Phe Ile Asn Ser Gly Gly Ser Thr Trp Tyr Ala Ser Trp
        195                 200                 205

Val Lys Gly Arg Phe Thr Ile Ser Arg Thr Ser Thr Thr Val Asp Leu
    210                 215                 220

Lys Met Thr Ser Leu Thr Thr Asp Asp Thr Ala Thr Tyr Phe Cys Ala
225                 230                 235                 240

Arg Gly Tyr Ser Thr Tyr Tyr Gly Asp Phe Asn Ile Trp Gly Pro Gly
                245                 250                 255

Thr Leu Val Thr Ile Ser Ser Gly Gly Gly Gly Ser Asp Ile Lys Leu
            260                 265                 270

Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala Ser Val Lys Met
        275                 280                 285

Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Arg Tyr Thr Met His Trp
    290                 295                 300

Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Asn
305                 310                 315                 320

Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe Lys Asp Lys Ala
                325                 330                 335

Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser
            340                 345                 350
```

Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr
355 360 365

Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr
370 375 380

Val Ser Ser Val Glu Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly
385 390 395 400

Ser Gly Gly Val Asp Asp Ile Gln Leu Thr Gln Ser Pro Ala Ile Met
405 410 415

Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser
420 425 430

Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro
435 440 445

Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val Ala Ser Gly Val Pro Tyr
450 455 460

Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser
465 470 475 480

Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser
485 490 495

Ser Asn Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Glu
500 505 510

Gln Lys Leu Ile Ser Glu Glu Asp Leu His His His His His His
515 520 525

<210> 241
<211> 515
<212> PRT
<213> Artificial Sequence

<220>
<223> BS-BDC

<400> 241

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15

Gly Ser Thr Gly Glu Leu Val Met Thr Gln Thr Pro Ser Ser Thr Ser
20 25 30

Gly Ala Val Gly Gly Thr Val Thr Ile Asn Cys Gln Ala Ser Gln Ser

35 40 45

Ile Asp Ser Asn Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro
50 55 60

Thr Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ser
65 70 75 80

Arg Phe Ser Gly Ser Arg Ser Gly Thr Glu Tyr Thr Leu Thr Ile Ser
85 90 95

Gly Val Gln Arg Glu Asp Ala Ala Thr Tyr Tyr Cys Leu Gly Gly Val
100 105 110

Gly Asn Val Ser Tyr Arg Thr Ser Phe Gly Gly Gly Thr Glu Val Val
115 120 125

Val Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
130 135 140

Ser Gln Ser Val Lys Glu Ser Glu Gly Asp Leu Val Thr Pro Ala Gly
145 150 155 160

Asn Leu Thr Leu Thr Cys Thr Ala Ser Gly Ser Asp Ile Asn Asp Tyr
165 170 175

Pro Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
180 185 190

Gly Phe Ile Asn Ser Gly Gly Ser Thr Trp Tyr Ala Ser Trp Val Lys
195 200 205

Gly Arg Phe Thr Ile Ser Arg Thr Ser Thr Thr Val Asp Leu Lys Met
210 215 220

Thr Ser Leu Thr Thr Asp Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly
225 230 235 240

Tyr Ser Thr Tyr Tyr Gly Asp Phe Asn Ile Trp Gly Pro Gly Thr Leu
245 250 255

Val Thr Ile Ser Ser Gly Gly Gly Gly Ser Asp Ile Lys Leu Gln Gln
260 265 270

Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala Ser Val Lys Met Ser Cys
275 280 285

```
Lys Thr Ser Gly Tyr Thr Phe Thr Arg Tyr Thr Met His Trp Val Lys
    290                 295                 300

Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser
305                 310                 315                 320

Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu
                325                 330                 335

Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu
            340                 345                 350

Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Asp Asp
        355                 360                 365

His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser
    370                 375                 380

Ser Val Glu Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly
385                 390                 395                 400

Gly Val Asp Asp Ile Gln Leu Thr Gln Ser Pro Ala Ile Met Ser Ala
                405                 410                 415

Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val
            420                 425                 430

Ser Tyr Met Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg
        435                 440                 445

Trp Ile Tyr Asp Thr Ser Lys Val Ala Ser Gly Val Pro Tyr Arg Phe
    450                 455                 460

Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met
465                 470                 475                 480

Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn
                485                 490                 495

Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys His His His
            500                 505                 510

His His His
        515
```

<210> 242
<211> 514
<212> PRT

<213> Artificial Sequence

<220>
<223> BS-BDC

<400> 242

```
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1               5                  10                  15

Gly Ser Thr Gly Glu Leu Val Met Thr Gln Thr Pro Ser Ser Thr Ser
            20                  25                  30

Gly Ala Val Gly Gly Thr Val Thr Ile Asn Cys Gln Ala Ser Gln Ser
        35                  40                  45

Ile Asp Ser Asn Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro
    50                  55                  60

Thr Leu Leu Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ser
65                  70                  75                  80

Arg Phe Ser Gly Ser Arg Ser Gly Thr Glu Tyr Thr Leu Thr Ile Ser
                85                  90                  95

Gly Val Gln Arg Glu Asp Ala Ala Thr Tyr Tyr Cys Leu Gly Gly Val
            100                 105                 110

Gly Asn Val Ser Tyr Arg Thr Ser Phe Gly Gly Gly Thr Glu Val Val
        115                 120                 125

Val Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
    130                 135                 140

Ser Gln Ser Val Lys Glu Ser Glu Gly Asp Leu Val Thr Pro Ala Gly
145                 150                 155                 160

Asn Leu Thr Leu Thr Cys Thr Ala Ser Gly Ser Asp Ile Asn Asp Tyr
                165                 170                 175

Pro Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
            180                 185                 190

Gly Phe Ile Asn Ser Gly Gly Ser Thr Trp Tyr Ala Ser Trp Val Lys
        195                 200                 205

Gly Arg Phe Thr Ile Ser Arg Thr Ser Thr Thr Val Asp Leu Lys Met
    210                 215                 220
```

```
Thr Ser Leu Thr Thr Asp Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly
225                 230                 235                 240

Tyr Ser Thr Tyr Tyr Gly Asp Phe Asn Ile Trp Gly Pro Gly Thr Leu
                245                 250                 255

Val Thr Ile Ser Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln
            260                 265                 270

Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys
        275                 280                 285

Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Ile His Trp Val Arg
    290                 295                 300

Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Cys Ile Tyr Pro Gly
305                 310                 315                 320

Asn Val Asn Thr Asn Tyr Asn Glu Lys Phe Lys Asp Arg Ala Thr Leu
                325                 330                 335

Thr Val Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu
            340                 345                 350

Arg Ser Asp Asp Thr Ala Val Tyr Phe Cys Thr Arg Ser His Tyr Gly
        355                 360                 365

Leu Asp Trp Asn Phe Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val
    370                 375                 380

Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
385                 390                 395                 400

Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val
                405                 410                 415

Gly Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asn Ile Tyr Val
            420                 425                 430

Trp Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu
        435                 440                 445

Ile Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser Arg Phe Ser
    450                 455                 460

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
465                 470                 475                 480
```

```
Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Thr Tyr Pro
                485                 490                 495

Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys His His His His
            500                 505                 510

His His
```

<210> 243
<211> 522
<212> PRT
<213> Artificial Sequence

<220>
<223> BS-BDC

<400> 243

```
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1               5                   10                  15

Gly Ser Thr Gly Glu Leu Val Leu Thr Gln Ser Pro Ser Val Ser Ala
            20                  25                  30

Ala Leu Gly Ser Pro Ala Lys Ile Thr Cys Thr Leu Ser Ser Ala His
        35                  40                  45

Lys Thr Asp Thr Ile Asp Trp Tyr Gln Gln Leu Gln Gly Glu Ala Pro
    50                  55                  60

Arg Tyr Leu Met Gln Val Gln Ser Asp Gly Ser Tyr Thr Lys Arg Pro
65                  70                  75                  80

Gly Val Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Ala Asp Arg Tyr
                85                  90                  95

Leu Ile Ile Pro Ser Val Gln Ala Asp Asp Glu Ala Asp Tyr Tyr Cys
            100                 105                 110

Gly Ala Asp Tyr Ile Gly Gly Tyr Val Phe Gly Gly Gly Thr Gln Leu
        115                 120                 125

Thr Val Thr Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
    130                 135                 140

Gly Gly Ser Gln Glu Gln Leu Val Glu Ser Gly Gly Arg Leu Val Thr
145                 150                 155                 160
```

```
Pro Gly Gly Ser Leu Thr Leu Ser Cys Lys Ala Ser Gly Phe Asp Phe
                165                 170                 175

Ser Ala Tyr Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
            180                 185                 190

Glu Trp Ile Ala Thr Ile Tyr Pro Ser Ser Gly Lys Thr Tyr Tyr Ala
        195                 200                 205

Thr Trp Val Asn Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Gln Asn
    210                 215                 220

Thr Val Asp Leu Gln Met Asn Ser Leu Thr Ala Ala Asp Arg Ala Thr
225                 230                 235                 240

Tyr Phe Cys Ala Arg Asp Ser Tyr Ala Asp Asp Gly Ala Leu Phe Asn
                245                 250                 255

Ile Trp Gly Pro Gly Thr Leu Val Thr Ile Ser Ser Gly Gly Gly Gly
            260                 265                 270

Ser Asp Ile Lys Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly
        275                 280                 285

Ala Ser Val Lys Met Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Arg
    290                 295                 300

Tyr Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp
305                 310                 315                 320

Ile Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys
                325                 330                 335

Phe Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala
            340                 345                 350

Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr
        355                 360                 365

Cys Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln
    370                 375                 380

Gly Thr Thr Leu Thr Val Ser Ser Val Glu Gly Gly Ser Gly Gly Ser
385                 390                 395                 400

Gly Gly Ser Gly Gly Ser Gly Gly Val Asp Asp Ile Gln Leu Thr Gln
                405                 410                 415
```

```
Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr
            420                 425                 430

Cys Arg Ala Ser Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys
        435                 440                 445

Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val Ala
    450                 455                 460

Ser Gly Val Pro Tyr Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr
465                 470                 475                 480

Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr
                485                 490                 495

Cys Gln Gln Trp Ser Ser Asn Pro Leu Thr Phe Gly Ala Gly Thr Lys
            500                 505                 510

Leu Glu Leu Lys His His His His His His
        515                 520
```

<210> 244
<211> 521
<212> PRT
<213> Artificial Sequence

<220>
<223> BS-BDC

<400> 244

```
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1               5                   10                  15

Gly Ser Thr Gly Glu Leu Val Leu Thr Gln Ser Pro Ser Val Ser Ala
            20                  25                  30

Ala Leu Gly Ser Pro Ala Lys Ile Thr Cys Thr Leu Ser Ser Ala His
        35                  40                  45

Lys Thr Asp Thr Ile Asp Trp Tyr Gln Gln Leu Gln Gly Glu Ala Pro
    50                  55                  60

Arg Tyr Leu Met Gln Val Gln Ser Asp Gly Ser Tyr Thr Lys Arg Pro
65                  70                  75                  80

Gly Val Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Ala Asp Arg Tyr
                85                  90                  95
```

```
Leu Ile Ile Pro Ser Val Gln Ala Asp Asp Glu Ala Asp Tyr Tyr Cys
            100                 105                 110

Gly Ala Asp Tyr Ile Gly Gly Tyr Val Phe Gly Gly Gly Thr Gln Leu
        115                 120                 125

Thr Val Thr Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
    130                 135                 140

Gly Gly Ser Gln Glu Gln Leu Val Glu Ser Gly Gly Arg Leu Val Thr
145                 150                 155                 160

Pro Gly Gly Ser Leu Thr Leu Ser Cys Lys Ala Ser Gly Phe Asp Phe
                165                 170                 175

Ser Ala Tyr Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
            180                 185                 190

Glu Trp Ile Ala Thr Ile Tyr Pro Ser Ser Gly Lys Thr Tyr Tyr Ala
        195                 200                 205

Thr Trp Val Asn Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Gln Asn
    210                 215                 220

Thr Val Asp Leu Gln Met Asn Ser Leu Thr Ala Ala Asp Arg Ala Thr
225                 230                 235                 240

Tyr Phe Cys Ala Arg Asp Ser Tyr Ala Asp Asp Gly Ala Leu Phe Asn
                245                 250                 255

Ile Trp Gly Pro Gly Thr Leu Val Thr Ile Ser Ser Gly Gly Gly Gly
            260                 265                 270

Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly
        275                 280                 285

Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser
    290                 295                 300

Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp
305                 310                 315                 320

Ile Gly Cys Ile Tyr Pro Gly Asn Val Asn Thr Asn Tyr Asn Glu Lys
                325                 330                 335

Phe Lys Asp Arg Ala Thr Leu Thr Val Asp Thr Ser Ile Ser Thr Ala
            340                 345                 350
```

```
Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Phe
        355                 360                 365

Cys Thr Arg Ser His Tyr Gly Leu Asp Trp Asn Phe Asp Val Trp Gly
    370                 375                 380

Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
385                 390                 395                 400

Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
                405                 410                 415

Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys His
            420                 425                 430

Ala Ser Gln Asn Ile Tyr Val Trp Leu Asn Trp Tyr Gln Gln Lys Pro
        435                 440                 445

Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Asn Leu His Thr
    450                 455                 460

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
465                 470                 475                 480

Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
                485                 490                 495

Gln Gln Gly Gln Thr Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val
            500                 505                 510

Glu Ile Lys His His His His His His
        515                 520


<210>  245
<211>  514
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BS-BDC

<400>  245

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1               5                   10                  15

Gly Ser Thr Gly Asp Ile Val Met Thr Gln Ser Gln Lys Ile Met Ser
            20                  25                  30
```

```
Thr Thr Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn
        35                  40                  45

Val Asp Ala Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro
    50                  55                  60

Lys Leu Leu Ile Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp
65                  70                  75                  80

Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
                85                  90                  95

Asn Met Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Asp
            100                 105                 110

Ile Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Gly
        115                 120                 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
    130                 135                 140

Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val
145                 150                 155                 160

Thr Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Asp Tyr Glu Met
                165                 170                 175

His Trp Val Ile Gln Thr Pro Val His Gly Leu Glu Trp Ile Gly Ala
            180                 185                 190

Ile Asp Pro Glu Thr Gly Gly Thr Ala Tyr Asn Gln Lys Phe Lys Gly
        195                 200                 205

Lys Ala Ile Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu
    210                 215                 220

Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Thr Gly
225                 230                 235                 240

Tyr Tyr Asp Tyr Asp Ser Phe Thr Tyr Trp Gly Gln Gly Thr Leu Val
                245                 250                 255

Thr Val Ser Ala Gly Gly Gly Gly Ser Asp Ile Lys Leu Gln Gln Ser
            260                 265                 270

Gly Ala Glu Leu Ala Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys
        275                 280                 285
```

```
Thr Ser Gly Tyr Thr Phe Thr Arg Tyr Thr Met His Trp Val Lys Gln
    290                 295                 300

Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser Arg
305                 310                 315                 320

Gly Tyr Thr Asn Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr
                325                 330                 335

Thr Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr
            340                 345                 350

Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Asp Asp His
        355                 360                 365

Tyr Cys Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
    370                 375                 380

Val Glu Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly
385                 390                 395                 400

Val Asp Asp Ile Gln Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser
                405                 410                 415

Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser
            420                 425                 430

Tyr Met Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp
        435                 440                 445

Ile Tyr Asp Thr Ser Lys Val Ala Ser Gly Val Pro Tyr Arg Phe Ser
    450                 455                 460

Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu
465                 470                 475                 480

Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro
                485                 490                 495

Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys His His His His
            500                 505                 510

His His
```

<210> 246
<211> 513

<212> PRT
<213> Artificial Sequence

<220>
<223> BS-BDC

<400> 246

```
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1               5                  10                  15

Gly Ser Thr Gly Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser
            20                  25                  30

Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp
        35                  40                  45

Val Ser Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
    50                  55                  60

Lys Leu Leu Ile Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser
65                  70                  75                  80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
                85                  90                  95

Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Leu
            100                 105                 110

Tyr His Pro Ala Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly
        115                 120                 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val
    130                 135                 140

Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
145                 150                 155                 160

Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ser Trp Ile
                165                 170                 175

His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp
            180                 185                 190

Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly
        195                 200                 205

Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln
    210                 215                 220
```

```
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
225                 230                 235                 240

Arg His Trp Pro Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
                245                 250                 255

Thr Val Ser Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser
            260                 265                 270

Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys
        275                 280                 285

Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Ile His Trp Val Arg Gln
    290                 295                 300

Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Cys Ile Tyr Pro Gly Asn
305                 310                 315                 320

Val Asn Thr Asn Tyr Asn Glu Lys Phe Lys Asp Arg Ala Thr Leu Thr
                325                 330                 335

Val Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg
            340                 345                 350

Ser Asp Asp Thr Ala Val Tyr Phe Cys Thr Arg Ser His Tyr Gly Leu
        355                 360                 365

Asp Trp Asn Phe Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser
    370                 375                 380

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
385                 390                 395                 400

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
                405                 410                 415

Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asn Ile Tyr Val Trp
            420                 425                 430

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
        435                 440                 445

Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly
    450                 455                 460

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
465                 470                 475                 480
```

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Thr Tyr Pro Tyr
485 490 495

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys His His His His His
500 505 510

His

<210> 247
<211> 268
<212> PRT
<213> Artificial Sequence

<220>
<223> BS-BDC

<400> 247

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15

Gly Ser Thr Gly Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser
20 25 30

Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asn
35 40 45

Ile Tyr Val Trp Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
50 55 60

Lys Leu Leu Ile Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser
65 70 75 80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
85 90 95

Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Gln
100 105 110

Thr Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Gly
115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
130 135 140

Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val
145 150 155 160

```
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Ile
                165                 170                 175

His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Cys
            180                 185                 190

Ile Tyr Pro Gly Asn Val Asn Thr Asn Tyr Asn Glu Lys Phe Lys Asp
        195                 200                 205

Arg Ala Thr Leu Thr Val Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu
    210                 215                 220

Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Phe Cys Thr Arg
225                 230                 235                 240

Ser His Tyr Gly Leu Asp Trp Asn Phe Asp Val Trp Gly Gln Gly Thr
                245                 250                 255

Thr Val Thr Val Ser Ser His His His His His His
            260                 265
```

<210> 248
<211> 266
<212> PRT
<213> Artificial Sequence

<220>
<223> BS-BDC

<400> 248

```
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1               5                   10                  15

Gly Ser Thr Gly Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser
            20                  25                  30

Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp
        35                  40                  45

Val Ser Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
    50                  55                  60

Lys Leu Leu Ile Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser
65                  70                  75                  80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
                85                  90                  95
```

Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Leu
100 105 110

Tyr His Pro Ala Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly
115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val
130 135 140

Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
145 150 155 160

Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ser Trp Ile
165 170 175

His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp
180 185 190

Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly
195 200 205

Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln
210 215 220

Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
225 230 235 240

Arg His Trp Pro Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
245 250 255

Thr Val Ser Ser His His His His His His
260 265

<210> 249
<211> 524
<212> PRT
<213> Artificial Sequence

<220>
<223> BS-BDC

<400> 249

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15

Gly Ser Thr Gly Asp Ile Gln Leu Thr Gln Ser Pro Ala Ser Leu Ala
20 25 30

Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser

```
        35                  40                  45

Val Asp Tyr Asp Gly Asp Ser Tyr Leu Asn Trp Tyr Gln Gln Ile Pro
    50                  55                  60

Gly Gln Pro Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Val Ser
65                  70                  75                  80

Gly Ile Pro Pro Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
                85                  90                  95

Leu Asn Ile His Pro Val Glu Lys Val Asp Ala Ala Thr Tyr His Cys
            100                 105                 110

Gln Gln Ser Thr Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu
        115                 120                 125

Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
    130                 135                 140

Gly Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro
145                 150                 155                 160

Gly Ser Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser
                165                 170                 175

Ser Tyr Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu
            180                 185                 190

Trp Ile Gly Gln Ile Trp Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly
        195                 200                 205

Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Glu Ser Ser Ser Thr
    210                 215                 220

Ala Tyr Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr
225                 230                 235                 240

Phe Cys Ala Arg Arg Glu Thr Thr Thr Val Gly Arg Tyr Tyr Tyr Ala
                245                 250                 255

Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly
            260                 265                 270

Gly Gly Ser Asp Ile Lys Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg
        275                 280                 285
```

Pro Gly Ala Ser Val Lys Met Ser Cys Lys Thr Ser Gly Tyr Thr Phe
290 295 300

Thr Arg Tyr Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu
305 310 315 320

Glu Trp Ile Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn
325 330 335

Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser
340 345 350

Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val
355 360 365

Tyr Tyr Cys Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp
370 375 380

Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Val Glu Gly Gly Ser Gly
385 390 395 400

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Val Asp Asp Ile Gln Leu
405 410 415

Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr
420 425 430

Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln
435 440 445

Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys
450 455 460

Val Ala Ser Gly Val Pro Tyr Arg Phe Ser Gly Ser Gly Ser Gly Thr
465 470 475 480

Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr
485 490 495

Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu Thr Phe Gly Ala Gly
500 505 510

Thr Lys Leu Glu Leu Lys His His His His His His
515 520

<210> 250
<211> 531
<212> PRT

<213> Artificial Sequence

<220>
<223> BS-BDC

<400> 250

```
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1               5                  10                  15

Gly Ser Thr Gly Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys
            20                  25                  30

Lys Pro Gly Glu Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr
        35                  40                  45

Phe Thr Asn Tyr Gly Met Asn Trp Val Lys Gln Ala Pro Gly Gln Gly
    50                  55                  60

Leu Glu Trp Met Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr
65                  70                  75                  80

Ala Asp Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr
                85                  90                  95

Ser Thr Ala Tyr Met Glu Ile Arg Asn Leu Gly Gly Asp Asp Thr Ala
            100                 105                 110

Val Tyr Tyr Cys Ala Arg Trp Ser Trp Ser Asp Gly Tyr Tyr Val Tyr
        115                 120                 125

Phe Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Gly Gly
    130                 135                 140

Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val
145                 150                 155                 160

Met Thr Gln Ser Pro Asp Ser Leu Thr Val Ser Leu Gly Glu Arg Thr
                165                 170                 175

Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Asp Ser Ser Thr Asn
            180                 185                 190

Lys Asn Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys
        195                 200                 205

Leu Leu Leu Ser Trp Ala Ser Thr Arg Glu Ser Gly Ile Pro Asp Arg
    210                 215                 220
```

```
Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asp Ser
225                 230                 235                 240

Pro Gln Pro Glu Asp Ser Ala Thr Tyr Tyr Cys Gln Gln Ser Ala His
                245                 250                 255

Phe Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Ser Gly
            260                 265                 270

Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
        275                 280                 285

Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr
    290                 295                 300

Phe Asn Lys Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly
305                 310                 315                 320

Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr
                325                 330                 335

Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp
            340                 345                 350

Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp
        355                 360                 365

Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr
    370                 375                 380

Ile Ser Tyr Trp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
385                 390                 395                 400

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
                405                 410                 415

Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly
            420                 425                 430

Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly
        435                 440                 445

Asn Tyr Pro Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly
    450                 455                 460

Leu Ile Gly Gly Thr Lys Phe Leu Ala Pro Gly Thr Pro Ala Arg Phe
465                 470                 475                 480
```

```
Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val
                485                 490                 495


Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Val Leu Trp Tyr Ser Asn
            500                 505                 510


Arg Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu His His His
        515                 520                 525


His His His
    530


<210>  251
<211>  523
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BS-BDC

<400>  251

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1               5                   10                  15


Gly Ser Thr Gly Asp Ile Gln Leu Thr Gln Ser Pro Ala Ser Leu Ala
            20                  25                  30


Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser
        35                  40                  45


Val Asp Tyr Asp Gly Asp Ser Tyr Leu Asn Trp Tyr Gln Gln Ile Pro
    50                  55                  60


Gly Gln Pro Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Val Ser
65                  70                  75                  80


Gly Ile Pro Pro Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
                85                  90                  95


Leu Asn Ile His Pro Val Glu Lys Val Asp Ala Ala Thr Tyr His Cys
            100                 105                 110


Gln Gln Ser Thr Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu
        115                 120                 125


Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
    130                 135                 140
```

```
Gly Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro
145                 150                 155                 160

Gly Ser Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser
                165                 170                 175

Ser Tyr Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu
            180                 185                 190

Trp Ile Gly Gln Ile Trp Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly
        195                 200                 205

Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Glu Ser Ser Ser Thr
    210                 215                 220

Ala Tyr Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr
225                 230                 235                 240

Phe Cys Ala Arg Arg Glu Thr Thr Thr Val Gly Arg Tyr Tyr Tyr Ala
                245                 250                 255

Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly
            260                 265                 270

Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
        275                 280                 285

Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
    290                 295                 300

Thr Ser Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
305                 310                 315                 320

Glu Trp Ile Gly Cys Ile Tyr Pro Gly Asn Val Asn Thr Asn Tyr Asn
                325                 330                 335

Glu Lys Phe Lys Asp Arg Ala Thr Leu Thr Val Asp Thr Ser Ile Ser
            340                 345                 350

Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val
        355                 360                 365

Tyr Phe Cys Thr Arg Ser His Tyr Gly Leu Asp Trp Asn Phe Asp Val
    370                 375                 380

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser
385                 390                 395                 400
```

```
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln
                405                 410                 415


Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr
            420                 425                 430


Cys His Ala Ser Gln Asn Ile Tyr Val Trp Leu Asn Trp Tyr Gln Gln
        435                 440                 445


Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Asn Leu
    450                 455                 460


His Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
465                 470                 475                 480


Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr
                485                 490                 495


Tyr Cys Gln Gln Gly Gln Thr Tyr Pro Tyr Thr Phe Gly Gly Gly Thr
            500                 505                 510


Lys Val Glu Ile Lys His His His His His His
        515                 520


<210>  252
<211>  518
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BS-BDC

<400>  252

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1               5                   10                  15


Gly Ser Thr Gly Glu Leu Val Leu Thr Gln Ser Pro Ser Val Ser Ala
            20                  25                  30


Ala Leu Gly Ser Pro Ala Lys Ile Thr Cys Thr Leu Ser Ser Ala His
        35                  40                  45


Lys Thr Asp Thr Ile Asp Trp Tyr Gln Gln Leu Gln Gly Glu Ala Pro
    50                  55                  60


Arg Tyr Leu Met Gln Val Gln Ser Asp Gly Ser Tyr Thr Lys Arg Pro
65                  70                  75                  80
```

```
Gly Val Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Ala Asp Arg Tyr
                85                  90                  95

Leu Ile Ile Pro Ser Val Gln Ala Asp Asp Glu Ala Asp Tyr Tyr Cys
            100                 105                 110

Gly Ala Asp Tyr Ile Gly Gly Tyr Val Phe Gly Gly Gly Thr Gln Leu
        115                 120                 125

Thr Val Thr Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
    130                 135                 140

Gly Gly Ser Gln Glu Gln Leu Val Glu Ser Gly Gly Arg Leu Val Thr
145                 150                 155                 160

Pro Gly Gly Ser Leu Thr Leu Ser Cys Lys Ala Ser Gly Phe Asp Phe
                165                 170                 175

Ser Ala Tyr Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
            180                 185                 190

Glu Trp Ile Ala Thr Ile Tyr Pro Ser Ser Gly Lys Thr Tyr Tyr Ala
        195                 200                 205

Thr Trp Val Asn Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Gln Asn
    210                 215                 220

Thr Val Asp Leu Gln Met Asn Ser Leu Thr Ala Ala Asp Arg Ala Thr
225                 230                 235                 240

Tyr Phe Cys Ala Arg Asp Ser Tyr Ala Asp Asp Gly Ala Leu Phe Asn
                245                 250                 255

Ile Trp Gly Pro Gly Thr Leu Val Thr Ile Ser Ser Gly Gly Gly Gly
            260                 265                 270

Ser Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly
        275                 280                 285

Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Thr
    290                 295                 300

Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp
305                 310                 315                 320

Met Gly Lys Ile Tyr Pro Gly Asp Ser Tyr Thr Asn Tyr Ser Pro Ser
                325                 330                 335
```

```
Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala
            340                 345                 350

Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr
        355                 360                 365

Cys Ala Arg Gly Tyr Gly Ile Phe Asp Tyr Trp Gly Gln Gly Thr Leu
    370                 375                 380

Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
385                 390                 395                 400

Gly Gly Gly Ser Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val
                405                 410                 415

Ser Pro Gly Gln Thr Ala Ser Ile Thr Cys Ser Gly Asp Asn Ile Gly
            420                 425                 430

Asp Gln Tyr Ala His Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val
        435                 440                 445

Leu Val Ile Tyr Gln Asp Lys Asn Arg Pro Ser Gly Ile Pro Glu Arg
    450                 455                 460

Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly
465                 470                 475                 480

Thr Gln Ala Met Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Tyr Thr Gly
                485                 490                 495

Phe Gly Ser Leu Ala Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
            500                 505                 510

His His His His His His
        515


<210>  253
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  1H7 CDR

<400>  253

Arg Ala Ser Gln Asp Ile Asn Tyr Tyr Leu Asn
1               5                   10
```

<210> 254
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> 1H7 CDR

<400> 254

Tyr Ser Ser Arg Leu His Ser Gly
1 5

<210> 255
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> 1H7 CDR

<400> 255

Gln Gln Asp Asp Ala Leu Pro Tyr Thr
1 5

<210> 256
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> 1H7 CDR

<400> 256

Gly Tyr Ala Phe Ser Asn Tyr Trp Met Asn
1 5 10

<210> 257
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> 1H7 CDR

<400> 257

Gln Ile Asn Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly
1 5 10

<210> 258
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> 1H7 CDR

<400> 258

Glu Asp Arg Asp Tyr Phe Asp Tyr
1   5

<210> 259
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR

<400> 259

Ile Lys Leu Gly Thr Val Thr Thr Val Asp Tyr
1   5   10

<210> 260
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> His tag

<400> 260

His His His His His His
1   5

<210> 261
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-4-1BB CDR

<400> 261

Ser Gly Asp Asn Ile Gly Asp Gln Tyr Ala His
1   5   10

<210> 262
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-4-1BB CDR

<400> 262

Gln Asp Lys Asn Arg Pro Ser
1   5

<210> 263
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-4-1BB CDR

<400> 263

Ala Thr Tyr Thr Gly Phe Gly Ser Leu Ala Val
1 5 10

<210> 264
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-4-1BB CDR

<400> 264

Gly Tyr Ser Phe Ser Thr Tyr Trp Ile Ser
1 5 10

<210> 265
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-4-1BB CDR

<400> 265

Lys Ile Tyr Pro Gly Asp Ser Tyr Thr Asn Tyr Ser Pro Ser
1 5 10

<210> 266
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-4-1BB CDR

<400> 266

Gly Tyr Gly Ile Phe Asp Tyr
1 5

<210> 267
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-L1 1 CDR

<400> 267

Arg Ala Ser Gln Asp Val Ser Thr Ala Val Ala
1   5   10

<210> 268
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-L1 1 CDR

<400> 268

Ser Ala Ser Phe Leu Tyr Ser
1   5

<210> 269
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-L1 1 CDR

<400> 269

Gln Gln Tyr Leu Tyr His Pro Ala Thr
1   5

<210> 270
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-L1 1 CDR

<400> 270

Ser Gly Phe Thr Phe Ser Asp Ser Trp Ile His
1   5   10

<210> 271
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-L1 1 CDR

<400> 271

Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
1   5   10   15

Gly

<210> 272
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-L1 1 CDR

<400> 272

Arg His Trp Pro Gly Gly Phe Asp Tyr
1 5

<210> 273
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-L1 2 CDR

<400> 273

Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10

<210> 274
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-L1 2 CDR

<400> 274

Asp Val Ser Asn Arg Pro Ser
1 5

<210> 275
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-L1 2 CDR

<400> 275

Ser Ser Tyr Thr Ser Ser Ser Thr Arg Val
1 5 10

<210> 276
<211> 11
<212> PRT

<213> Artificial Sequence

<220>
<223> anti-PD-L1 2 CDR

<400> 276

Ser Gly Phe Thr Phe Ser Ser Tyr Ile Met Met
1 5 10

<210> 277
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> anti-PD-L1 2 CDR

<400> 277

Ser Ile Tyr Pro Ser Gly Gly Ile Thr Phe Tyr Ala Asp Thr Val Lys
1 5 10 15

Gly